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ABSTRACT 
 
 
A New Class of Dirhodium Compounds with an Electron Acceptor Ligand: Enhancing  
 
Chemotherapeutic Properties with Light.  (May 2007) 
 
Alfredo Milton Angeles Boza, B.S., Pontificia Universidad Católica del Perú 
Chair of Advisory Committee: Dr. Kim R. Dunbar  
 
The syntheses and characterization of new dirhodium complexes based on the 
electron acceptor ligand dipyrido[3,2-a:2´,3´-c]phenazine (dppz) and its derivatives are 
reported. These complexes have been shown to photocleave pUC18 plasmid in vitro 
under irradiation with visible light which results in the nicked, circular form of DNA.  
Unlike typical DNA photocleavage agents, the new compounds are capable of 
photocleaving DNA in the absence of oxygen as well as in the presence of oxygen. The 
toxicity of the complexes which contain the electron acceptor dppz ligand toward human 
skin cells increases when the cell cultures are irradiated with visible light. In contrast, 
the photocytotoxicity of those complexes that do not contain the dppz do not differ from 
cytotoxicity in the dark. 
The chemistry of the newly synthesized dirhodium-dppz complexes with 
glutathione, which is considered to be an important molecule in the deactivation of 
metal-based drugs, has also been investigated. The results show that glutathione 
reversibly reduces [Rh2(µ-O2CCH3)2(dppz)2]2+ (6) and [Rh2(µ-O2CCH3)2(dppz)(bpy)]2+ 
(7), and that they are easily reoxidized to the original form in air. EPR measurements 
 
 iv
and DFT calculations indicate that the additional electron is delocalized in the ligand 
orbitals. 
The molecular characteristics that affect the in vitro activity of dirhodium 
complexes is discussed. The lability of the groups coordinated to the dirhodium 
complexes is a significant factor that influences the toxicity of the complexes. In 
addition, the presence of labile solvent molecules and monodentate acetate groups 
provide potential “open sites” accessible for nucleophilic substitution, as opposed to 
these sites being occupied by non-labile groups that reduce the reactivity of the 
complexes.  
Finally, the results also demonstrate that the carbonato-bridged complexes of the 
type [Rh2(µ-O2CO)2(diimine)2(H2O)2]2+ are useful precursors to access new dirhodium-
diimine compounds that are not accessible from the acetate precursors. These 
compounds react with trifluoroacetamide, 2-pyrrolidinone, and trifluoroacetic acid to 
form products in which the carbonato ligands are substituted in favor of the new 
bridging group. This work provides a foundation for the preparation of new series of 
dirhodium complexes that contain the dppz ligand and bridging ligands other than 
acetate. 
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CHAPTER I 
INTRODUCTION 
 
 
General Principles of Cancer Chemotherapy 
Cancer is the term that describes a group of genetic diseases that arise from an 
accumulation of mutations and causes uncontrolled proliferation of transformed cells.1 
There are approximately 200 documented types of cancer that correspond to different 
cellular systems in the body and differ from one other by their capacity to invade both 
neighboring or distant tissues and organs.1,2 Cancer alterations originate in special genes 
called proto-oncogenes, which when transformed into oncogenes become responsible for 
the transformation of normal cells into malignant cells.3 These transformed cells are then 
referred to as cancerous or tumoral in nature.1-3
The history of cancer chemotherapy harks back to the serendipitous discovery of 
the mustard family of agents in the first half of the twentieth century.1,4-8 The important 
observation that sulphur mustard, used at that time as toxic agent in warfare, lowered the 
white-blood-cell count in people exposed to it, led scientists to test it in humans as a 
treatment for leukemia. Unfortunately, the compound proved to be far too toxic for 
therapeutical purposes. It was hypothesized that the high toxicity associated with the use 
of sulphur mustard was related to the electrophilicity of the compound, which makes it 
very reactive towards highly nucleophilic groups found in living cells. The development 
of less electrophilic compounds quickly followed those early experiments, and the first  
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nitrogen mustards were introduced into clinic in 1946.8,9  
A more reliable way of obtaining molecules with interesting anticancer 
properties originated after the progress achieved with the nitrogen mustards. Screening 
programs have been developed using a diverse numbers of cancer cell lines, and 
compounds are evaluated against all the cell lines.10,11 The molecules tested in this way 
are either obtained from natural products, through synthetic methods, or a combination 
of both. An example of one of these programs is the National Cancer Institute’s 
Developmental Therapeutics Program that has been in operation for nearly 50 years and 
tests approximately 60 human tumor cell lines.10 Although the new approach did not 
entirely solve the problem of serendipity, it increased the chances of obtaining new 
anticancer-drug leads.12,13  
A third, and more recent, method of new anticancer active drugs is the so called 
“rational” approach.1 In this approach, thanks to the advances in molecular biology, the 
specific target is known;1,2 more importantly, its three-dimensional structure is known,1,2 
and this allows for the rational design of molecules that can specifically interact with the 
target.1,2,14,15 This method is currently combined with in silico screening resulting in a 
powerful method for obtaining possible lead molecules with high specificity.1,2
Anticancer drugs currently in use or in clinical trials target various important 
molecules involved in critical cellular processes.1,2 For instance, they can inhibit the 
synthesis of purines,16 or the conversion of ribonucleosides into deoxyribonucleotides.17 
They can also target DNA, as in the case of alkylating agents,6 or they can alter 
microtubules polymerization, as for example taxol and its derivatives.6  
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Among the carcinostatic agents, those with alkylating properties should be 
highlighted. Alkylating drugs, such as the nitrogen mustards, were the first to be 
developed, and are the main contributors to the medical arsenal against cancer. They 
target nucleophilic sites on DNA, RNA, enzymes, and other proteins, causing damage 
that can be potentially detrimental to cells; however, evidence suggests that these 
nucleophilic reactions form products that are repairable with one likely exception, 
namely the adducts formed with DNA.6 This DNA modification, along with the fact that 
rapidly proliferating tumors are more prone to suffer this deleterious effect, is one of the 
main reasons for the use of alkylating drugs, but there are numerous side-effects 
encountered in such cancer treatment.5  
Compounds that are usually classified as being part of the family of alkylating 
drugs are those containing metal ions. Although these molecules do not alkylate their 
target per se, since no alkyl unit is transferred to either DNA or any other nucleophile, 
they are usually included in this family because they are capable of acting as an 
electrophile and bind to their targets in a fashion similar to an organic alkylator. 
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Antitumor-Active Metallic Drugs 
The serendipitous discovery of the anticancer activity of cis-[PtCl2(NH3)2] (cis-
diamminedichloroplatinum(II), commonly known as cisplatin (Figure I.1), in 1965 by 
Rosenberg and his colleagues at Michigan State University resulted in the re-birth of the 
field of medicinal bioinorganic chemistry.18,19 In his famous experiment, Rosenberg and 
co-workers were studying the effect of an electric field on cell division. They observed 
that bacterial cell division was inhibited; however, the inhibition was not caused by the 
electric field generated, but by a compound that was being formed during the course of 
the experiment, namely cis-[PtCl2(NH3)2]. Cisplatin was eventually approved by the 
FDA as an anticancer drug, and it has been used since then in combination with other 
drugs in the chemotherapeutic treatment of testicular, ovarian, cervical, head and neck, 
and non-small-cell lung cancer. During the past three decades two additional platinum-
based compounds, diammine[1,1-cyclobutanedicarboxylato(2-)]-O,O'-platinum(II) 
(carboplatin) and (trans-L-diaminocyclohexane)oxalatoplatinum(II) (oxaliplatin), have 
been approved as anticancer drugs (Figure I.1).20,21 In spite of the considerable success  
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of these drugs, there is still a pressing need for developing new anticancer agents with 
fewer deleterious side effects, as well as improved efficacy against cancer cell lines that 
are resistant towards cisplatin and its derivatives.22
Despite the fact that the three platinum drugs approved for treatment have a cis 
geometry, and that the first quantitative structure-activity relationship (QSAR) studies on 
platinum compounds suggested that this geometry was vital for the anticancer activity of 
the complexes, several trans derivatives have been shown to exhibit promising antitumor 
properties. These non-classical platinum complexes typically contain planar amine 
ligands, bulky aliphatic amines, and cyclic amines, and are particularly effective in 
cisplatin-resistant cell lines.23,24 In addition, Farrell and coworkers have shown that 
multinuclear platinum compounds are also highly cytotoxic and exhibit outstanding 
anticancer properties. One member of this family of compounds, BBR3464 ([(trans-
PtCl(NH3)2-µ-(trans-Pt(NH3)2-(NH2(CH2)6NH2)2)](NO3)4), is currently in Phase II 
clinical trials (Figure I.1).25,26  
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Figure I.1. Schematic representations of Pt compounds that are anticancer active.  
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Platinum is not the only metal that can be used in the design of anticancer agents. 
Complexes containing metals such as ruthenium and titanium have been extensively 
investigated for antitumor properties.25-29 Early work by Clarke and coworkers showed 
that Ru(III) complexes containing two chloride substitutents in a cis disposition are 
cytotoxic to cancer cells. Later, independent work by Alessio and Keppler resulted in 
two octahedral Ru(III) complexes trans-[Him]-[RuCl4(DMSO)(Im)] (Im = imidazole; 
NAMI-A), and  trans-[HInd]-[RuCl4(DMSO)(Ind)] (Ind = indazole) entering clinical 
trials (Figure I.2).27-29 The former complex is particularly interesting because it exhibits 
anti-metastatic activity, while being nontoxic to primary cancer cells. Titanium 
complexes have also shown promising activity as anticancer agents, and [Cp2TiCl2] is 
currently in Phase II clinical trials (Figure I.2). A second generation of titanium 
complexes containing aryl and heteroaryl substitutents has been tested successfully and 
some of them are candidates for further studies.  
Understanding the mechanisms by which cells process metal-based drugs 
provides important insight for improving the design of these metallo-pharmaceuticals. In 
the case of platinum-based anticancer agents, the mechanism of action is believed to be 
formation of metal-DNA adducts that ultimately lead to cell death. In cisplatin, the 
platinum atom binds to the N7 positions of purine bases to form primarily 1,2- or 1,3-
intrastrand crosslinks (Figures I.3 and I.4).30,31 These modifications onto the DNA distort 
the structure of the DNA duplex and activate numerous cellular processes that mediate 
the cytotoxicity of these compounds.31 Ruthenium complexes such as NAMI also bind to 
the N7 position of guanine bases and form 1,2-intrastrand crosslinks, but, recent  
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Figure I.2. Schematic representations of Ru and Ti anticancer active compounds. 
 
 
Pt NH3
NH3
Pt NH3
NH3
(a)                                                 (b)
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studies support the view that, despite the ability of NAMI-A to bind DNA, its activity is 
based mainly on its ability to interfere with type IV collagenolytic activity reducing the 
metastatic potential of tumors.27,28  
The antitumor activity of titanium complexes is mainly related to its ability to 
bind proteins. Unlike the platinum- and ruthenium-based antitumor agents, budotitane 
and titanocene dichloride do not bind to the N7 purine site in DNA, but prefer the ribose 
hydroxyl groups (Figure I.4).32,33 Overall, they exhibit a strong preference for binding to 
proteins, in particular transferrin, and it is thought that budotitane and titanocene 
dichloride use this protein as a carrier to enter cells.32-34 In addition, it has been 
suggested that the anti-cancer activity of these complexes is related to their ability to 
inhibit topoisomerase II activity.32-34  
Metal-based drugs are among the most potent of anticancer compounds. They 
can effectively target DNA as well as proteins encountered in cells. Clearly, the use of 
metal centers other than those in the aforementioned text may also result in the discovery 
of potent chemotherapeutics with enhanced efficacy. One class of metal complexes that 
deserves particular attention is the family of compounds that contain a Rh2(II,II) unit.  A 
detailed discussion of previous anticancer activity studies and attempts to understand the 
mechanism of action of dirhodium complexes is presented in the following section.  
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Dirhodium Complexes 
Dirhodium complexes as anticancer agents  
Dinuclear metal-metal bonded compounds of rhodium have attracted attention 
since the 1970’s for their cytostatic properties and are among the most promising non-
platinum anticancer complexes.35 It was first shown by Bear and his collaborators that 
dirhodium tetraacetate exhibits appreciable cytostatic activity against a variety of cell 
lines including sarcoma 180, Ehrlich ascites tumor, and P388 lymphocytic leukemia.36,37 
Since this time, the antitumor activities of other dirhodium complexes have also been 
reported. Following Bear’s studies, Piraino and co-workers reported that Rh2(µ-
O2CCH3)2(DTolF)2L2 (DTolF = N,N'-ditolylformamidinate and L = solvent molecules) 
exhibits antitumor activity against sarcoma cells.38 Some years later, Pruchnik et al. 
showed that cationic diimine complexes of dirhodium(II,II), namely Rh2(µ-
O2CCH3)2(diimine)22+ (diimine = 2,2'-bipyridine (bpy), and 1,10-phenanthroline (phen)), 
also exhibit antitumor activity, in some cases higher than that of cisplatin.39 More 
recently, Esposito and collaborators demonstrated that another member of the dirhodium 
family, namely Rh2(µ-ONHCCF3)4, is active against U937 and K562 human leukemia 
cells as well as Ehrlich ascites tumor cells both in vitro and in vivo.40,41 Schematic 
representations of some the dirhodium compounds mentioned above are illustrated in 
Figure I.5.  
Systematic studies of structure-activity relationships among dirhodium 
complexes have shed some light on their antineoplastic activity. A study performed on 
the dirhodium tetracarboxylate complexes, Rh2(µ-O2CR)4 (R = CH3, C2H5, C3H7), which   
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exhibit cytostatic activity against Ehrlich ascites tumor, Leukemia L1210, and Sarcoma 
180 cells,  revealed that the activity in the series Rh2(µ-O2CR)4 (R = CH3, C2H5, C3H7) 
increases with the hydrophobicity of the R group, but that a further lengthening of the 
carboxylate group beyond the pentanoate group reduces the therapeutic efficacy (Table 
I.1).42 A plausible explanation for the increased activity of the compounds is that they 
become more lipid-soluble, therefore, a larger amount of compound can be more readily 
transported into the interior of the cell.42 This reasoning is confirmed by the observation 
that the partition coefficient correlates with the amount of rhodium absorbed by cells.42 In 
the case of the pentanoate and hexanoate derivatives, the activity could not be measured 
because of the extremely low solubility in water of the compounds.42 In another study, 
involving the dirhodium(II,II) formamidinato class, an additional fact was revealed. 
The tetra-substituted compound Rh2(µ-DTolF)4 exhibits no appreciable cytotoxicity,38
 
 
 
 
 Table I.1. Cytotoxicity (LD10) and hydrophobicity of dirhodium tetracarboxylate 
compounds (modified from ref. 42). Complex LD10 (mol/kg) Partition Coefficient 
(1-octanol) 
Rh2(µ-O2CCH3)4 2.6 × 10-4 6.54 × 10-2
Rh2(µ-O2CCH2CH3)4 1.9 × 10-5 8.17 
Rh2(µ-O2C(CH2)2CH3)4 6.0 × 10-6 898 
Rh2(µ-O2C(CH2)3CH3)4 Insoluble > 3000 
Rh2(µ-O2C(CH2)4CH3)4 Insoluble > 3000 
 
 14
however, the heteroleptic Rh2(µ-DTolF)2(µ-O2CCF3)2, with two labile trifluoroacetato 
bridging groups, shows comparable antitumor activity to cisplatin.38 The authors 
suggested that this behavior was due to the higher reactivity of the latter compound with 
two labile trifluoroacetate ligands as compared to the former complex. 
The antitumor activity of dirhodium complexes is thought to be analogous to that 
of cisplatin, i.e. binding of DNA nucleobases, although activity due to direct binding to 
enzymes is also a possibility.42 Early, it was postulated that the activity of dirhodium 
tetraacetate was due to the binding of this complex to DNA through its axial positions, 
but, since it was known that this binding mode is weak, due to the strong trans-effect of 
the dirhodium unit, it was obvious that the activity of this complex could not originate 
solely from this DNA binding mode. The use of bidentate nitrogen chelating ligands 
helped to prove that dirhodium complexes can bind to two adjacent nucleobases in a 
manner akin to cisplatin, and that the binding mode of dirhodium complexes to DNA may 
involve not only the axial positions, but also the equatorial sites (Scheme I.1).43-45 It is 
also important to point out that reactions of Rh2(µ-O2CCH3)4 with bpy and phen reveal 
that two adjacent nucleobases are capable of displacing two of the bridging acetate 
ligands, a fact that is counterintuitive to the original assumption that the only reasonable 
binding mode was at the axial positions.43-45 
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Scheme I.1. Possible mechanism for the reaction of adjacent nucleobases and
dirhodium tetraacetate (modified from ref. 43).  
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Interaction of dirhodium complexes and nucleobases  
Several model systems of nucleic acid binding to the Rh2(µ-O2CCH3)4 core have 
been structurally characterized;46-50 these constitute excellent illustrations of the diverse 
nucleobase chemistry of dirhodium(II,II) complexes. Adenine and guanine binding to 
dirhodium(II,II) carboxylate complexes has been found to occur either through the axial 
position or in a bridging fashion through the equatorial sites.46-50 Adenine is known to 
strongly bind to Rh2(µ-O2CCH3)4 through the axial position due to the hydrogen-
bonding interactions between the exocyclic amine group and an oxygen atom from the 
carboxylato bridge as observed in a crystallographic study of the bis(1-methyladenosine) 
adduct of Rh2(µ-O2CCH3)4 (Figure I.6).46 In the case of guanine, there is no direct 
evidence of binding to Rh2(µ-O2CCH3)4 through the axial position. It has been proposed 
that the oxygen atom at position 6 of the purine is involved in a repulsive interaction with 
the carboxylate oxygen atoms. Guanine, however, axially binds to Rh2(µ-O2CCH3)2(µ-
HNOCCF3)2, forming a hydrogen bond between the O6 and the NH group of the 
trifluoroacetamide bridge (Figure I.7).46
Early reports concerning the antitumor activity of dirhodium tetraacetate 
erroneously established that this compound did not react with guanine, since no color 
change was observed upon addition of either guanine or guanosine to a solution of the 
metal complex.47 It was later discovered, however, that Rh2(µ-O2CCH3)4 reacts with 9-
ethylguanine, a model compound for guanine and guanosine, in H2O forming a dimetal 
complex that contains either protonated or  deprotonated 9-ethylguanine that bridge the 
two rhodium atoms via N7/O6 in a cis disposition with head-to-head (H-H) or head-to-tail  
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Figure I.6. Schematic representation of the adduct formed between Rh2(µ-O2CCH3)4
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Figure I.7. Schematic representation of the adduct formed between Rh2(µ-
O2CCH3)2(µ-HNOCCF3)2 and 9-ethylguanine (R = Et). 
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(a) 
 
 
 
 
 
 
 
 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
Figure I.8. Molecular structure of (a) H-T cis-[ Rh2(µ-O2CCH3)2(9-EtGua)2(CH3OH)2]  
and (b) H-H cis-[ Rh2(µ-O2CCH3)2(9-EtGua)2((CH3)2CO)(H2O)]2+. 
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(H- T) orientations (Figure I.8).48 Likewise, Rh2(µ-O2CCF3)4 reacts with two equivalents 
of 9-ethylguanine to form a dirhodium complex that contains two bridging protonated 9-
ethylguanine molecules in only the H-T arrangement. In these reactions, the N1 position 
is either protonated or deprotonated, depending on the pKb of the leaving group. In the 
acetato-bridged compound, the purine is deprotonated at N1, whereas in the 
trifluoroacetate analogue, the N1 site is protonated, in accord with the lower basicity of 
CF3CO2- (pKb ≈ 13.5) compared to CH3CO2- (pKb ≈ 9.2).48
In a similar fashion, adenine can also bind equatorially to the dirhodium unit, 
however, reactions of [Rh2(DTolF)2(CH3CN)6](BF4)2 with 9-EtAdeH afford only the H-T 
isomer of cis-[Rh2(DTolF)2(9-EtAdeH)2(CH3CN)](BF4)2 with two 9-EtAdeH molecules 
bridging at eq sites via N7/N6 (Figure I.9).49,50 Additionally, binding of adenine in a  
 
 
 
 
 
 
 
 
 
 
Figure I.9. Molecular structure of H-T cis-[Rh2(DTolF)2(9-EtAdeH)2(CH3CN)]2+.  
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bridging fashion to a dinuclear center has also been observed in the complex cis-[Mo2(µ-
O2CCF3)2(9-EtAdeH)2](BF4)2, which was isolated as the H-T isomer. Variable 
temperature 1H NMR studies indicate that in the case of cis-[Rh2(DTolF)2(9-
EtAdeH)2(CH3CN)](BF4)2, 9-EtAdeH is present in its rare imino form. The stabilization 
of the imino form, as a result of the presence of the dirhodium complex, will alter the 
hydrogen bonding scheme of the nucleobase, a fact that might be related to the deleterious 
effect of this family of dimetal complexes on cells since it can ultimately result in 
nucleobase mispairing and cell mutations (Scheme I.2). 
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Dirhodium complexes and their interactions with dinucleotides  
1H-NMR studies of the reactions of Rh2(µ-O2CCH3)4 and 
[Rh2(DTolF)2(CH3CN)6](BF4)2 with the dinucleotides d(GpG) and d(pGpG) reveal that 
the bidentate N7/O6 binding observed previously for 9-ethylguanine is also possible when 
the two guanine bases are joined by a phosphodiester bond.51-53 In the case of Rh2(µ-
O2CCH3)4, these studies indicate that, for both dinucleotide adducts, the guanine bases are 
arranged in a H-H arrangement and, as in the case of 9-EtGuaH, there is an increase in the 
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acidity of the purine sites N1-H (pKa ≈ 5.7) (Figure I.10). As in the case of the cisplatin 
adduct of d(pGpG), cis-[Pt(NH3)2(pGpG)], the Rh2(µ-O2CCH3)2(pGpG) adduct is 
observed to exist as a left-handed conformer HH1L, whereas the Rh2(µ-O2CCH3)2(GpG) 
adduct exhibits two major right handed conformers HH1R (~75%) and HH2R (~25%), 
which differ in the relative canting of the two bases.51,52 In the case of 
[Rh2(DTolF)2(CH3CN)6](BF4)2, the formation of the H-H isomer of Rh2(DTolF)2(GpG) 
was observed, but unlike the Rh2(µ-O2CCH3)2(GpG) product, only the right-handed 
HH1R conformer was observed in solution (Figure I.11).53 This difference is attributed to 
the presence of the bulkier and more electron donating formamidinato bridging group 
which induces conformational changes to the dirhodium d(GpG) adduct. The acidity of 
the N1-H purine site is also affected, and as, in the previous case, it increases (pKa ≈ 7.5), 
although to a lesser degree. This difference may also originate in the higher Lewis 
basicity of the formamidinato ligand as compared to the acetate ion.  It is clear from these 
collective results that the DNA adducts formed by the dirhodium core are intimately 
related to the nature of the bridging groups that are not substituted in these reactions.53  
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 Figure I.10. Structures of Rh2(µ-O2CCH3)2(GpG) and Rh2(µ-O2CCH3)2(pGpG) 
(ref. 51, 52). Figure I.11. Structure of Rh2(DTolF)2(GpG) (ref. 53). 
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Dirhodium complexes and their interactions with double-stranded DNA  
Reactions of Rh2(µ-O2CCH3)4, [Rh2(µ-O2CCH3)2(CH3CN)6]2+, and Rh2(µ-
O2CCF3)4 with single-stranded oligonucleotide tetramers, octamers, and dodecamers were 
studied by matrix-assisted laser desorption ionization (MALDI) and nanoelectrospray 
(nanoESI) coupled to time-of-flight mass spectrometry (TOF MS).54 In order to obtain 
important information regarding the binding preference of these complexes with key 
dinucleotide sequences, the oligomers that were investigated were designed to contain 
AA, GG, GA, and AG dipurine sites. The study revealed that the dimetal unit remains 
intact and that the dirhodium bis-acetate oligonucleotide adducts are the main products of 
the reactions.54 In addition, adducts containing less than two bridging acetates were also 
observed for longer oligonucleotides. From the MALDI experiments, it was also possible 
to establish a relative order of reactivity of the dirhodium complexes studied as well as 
cisplatin and cis-[Pt(NH3)2(OH2)2]2+ (activated cisplatin): cis-[Pt(NH3)2(OH2)2]2+ ~  
Rh2(µ-O2CCF3)4 > cis-[Pt(NH3)2Cl2] (cisplatin) >> [Rh2(µ-O2CCH3)2(CH3CN)6]2+ > 
Rh2(µ-O2CCH3)4.55 This order of reactivity is in accord with the known relative lability of 
the leaving group(s) for each complex. The enhanced reactivity of Rh2(µ-O2CCF3)4 as 
compared to that of Rh2(µ-O2CCH3)4 correlates with the increased basicity of CH3CO2- 
(pKb 9.2) compared to that of CF3CO2- (pKb 13.5), which makes CF3CO2- a better leaving 
group. The higher reactivity of [Rh2(µ-O2CCH3)2(CH3CN)6]2+ as compared to that of 
Rh2(µ-O2CCH3)4 can be explained on the basis of the presence of the more labile 
monodentate equatorial acetonitrile groups in the former compound. Finally, the study 
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also established that both GG, as well as AA sites are the targeted residues in these 
oligomers.55
Despite earlier claims that Rh2(µ-O2CCH3)4 was not able to react with double-
stranded DNA (dsDNA), work in our laboratories established that dirhodium tetraacetate, 
and its derivatives do indeed bind to dsDNA. A study aimed at investigating the 
interactions of dsDNA and dirhodium carboxylate compounds revealed that Rh2(µ-
O2CCH3)4, Rh2(µ-O2CCF3)4, and [Rh2(µ-O2CCH3)2(CH3CN)6]2+ are capable of forming 
DNA interstrand crosslinks (Figure I.12).56 Additionally, it was observed that other 
adducts, namely monofunctional and intrastrand adducts, are also formed during the 
reaction. The adducts formed between DNA and the dirhodium core most likely involve 
all the variety of coordination modes observed in model complexes including ax/ax, 
ax/eq, and eq/eq.56
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Figure I.12. Denaturating PAGE (5%) of reactions between cisplatin (cis-DDP), 
Rh2(µ-O2CCH3)4 (Rh1), [Rh2(µ-O2CCH3)2(CH3CN)6]2+ (Rh2), and  Rh2(µ-O2CCF3)4 
(Rh3) (taken from ref. 56). 
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Inhibition of transcription by dirhodium complexes  
  It has also been reported that several dirhodium compounds inhibit transcription, a 
process by which cells copy DNA into RNA.57-58 Interestingly, it was found that 
Rh2(µ-O2CCH3)4  and cis-[Rh2(µ-O2CCH3)2(phen)2]2+ (phen = 1,10-phenanthroline) were 
more active than cis-[Pt(NH3)2(H2O)2]2+, commonly referred to as “activated cisplatin”. 
The relative concentrations, [complex]/[DNA], of Rh2(µ-O2CCH3)4 and cis-[Rh2(µ-
O2CCH3)2(phen)2]2+at which 50% of the transcription is inhibited (Rinh50), are 0.0031 and 
0.0011, respectively; while the Rinh50 value found for activated cisplatin is 0.0085 (Figure 
I.13). It was also observed that, unlike cisplatin, the mechanism of the inhibition of 
transcription by Rh2(µ-O2CCH3)4 and cis-[Rh2(µ-O2CCH3)2(phen)2]2+ is the binding of the 
complexes to the enzyme T7-RNA polymerase (T7-RNAP).57 More recently, the ability 
to inhibit transcription of four other dirhodium complexes, namely Rh2(µ-O2CCF3)4, 
Rh2(µ-HNOCCH3)4, Rh2(µ-HNOCCF3)4, and cis-[Rh2(µ-O2CCH3)2(CH3CN)6]2+ was also 
reported.58 In these studies, it was shown that the nature of the bridging ligand affects the 
ability and the mechanism of the complexes to inhibit transcription. As for Rh2(µ-
O2CCF3)4, Rh2(µ-HNOCCF3)4, and cis-[Rh2(µ-O2CCH3)2(CH3CN)6]2+ the mechanism of 
inhibition was found to be the same as the one reported for Rh2(µ-O2CCH3)4 and cis-
[Rh2(µ-O2CCH3)2(phen)2]2+ , namely binding to T7-RNAP; conversely Rh2(µ-
HNOCCH3)4 does not appear to bind T7-RNAP.58 The differences in the reactivity and 
the mechanism of transcription inhibition among dirhodium complexes with different 
bridging ligands is explained by the changes in the Lewis basicity of the axial site due to 
the presence of different atoms, nitrogen and/or oxygen, binding the metal center.58
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Figure I.13. Agarose gel of transcribed mRNA in the presence of cis-[Rh2(µ-
O2CCH3)2(phen)2]2+at various complex/[template DNA base] ratios, R. Lanes 1-6, R = 
0.0000, 0.0005, 0.0010, 0.0015, 0.0020, 0.0025 (taken from ref. 57). 
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Excited state properties of Rh2(µ-O2CCH3)4
Turro and coworkers have recently reported the observation of a transient species 
formed upon excitation of Rh2(µ-O2CCH3)4(L)2 (L = CH3OH, tetrahydrofuran, PPh3, 
pyridine) with a short laser pulse.59 The transient species are long-lived, and depending 
on the axial ligands have a lifetime that ranges from 3.5 µs (L = THF) to 5.0 µs (L = 
PPh3). Although many of the transient species formed from metal complexes are due to 
the loss of a ligand, this is not case for Rh2(µ-O2CCH3)4, in which case no lost of ligands 
was observed. Additionally, no emission from any of the transient complexes was 
observed, however, energy transfer from the excited state to the 3ππ* excited state of 
perylene was observed. The authors also demonstrated that the excited-state energy, E00, 
of the transient species formed from Rh2(µ-O2CCH3)4(PPh3)2 was between 1.34 and 1.77 
eV.59
Investigation of the reactivity with DNA of the species formed upon excitation 
was later reported by the same group.60 Excitation of Rh2(µ-O2CCH3)4(H2O)2 with 
visible light in the presence of either 3-cyano-1-methylpyridinium tetrafluoroborate or 
1,8-anthraquinone disulfonate results in the formation of the one-electron-oxidized 
complex, [Rh2(µ-O2CCH3)4(H2O)2]+, which efficiently cleaves dsDNA.60 The photo-
induced DNA cleavage of Rh2(µ-O2CCH3)4(H2O)2 is more effective under N2 
atmosphere than in air, consistent with the quenching of the excited state of the rhodium 
complex by O2 resulting in a decreased production of the active species, [Rh2(µ-
O2CCH3)4(H2O)2]+. The presence of PPh3 or pyridine in the axial positions inhibits the 
photocleavage ability of the complex, underlining the importance of the aquo-adduct, 
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Rh2(µ-O2CCH3)4(H2O)2.60 DFT calculations have shown that the one-electron-oxidized 
complex, [Rh2(µ-O2CCH3)4(H2O)2]+, can generate hydroxyl radicals, species that might 
be involved in the DNA-cleavage mechanism.61
It is obvious from the research conducted to date, that dirhodium(II,II) complexes 
are a diverse and promising class of cytotoxic compounds. My research project involved 
the syntheses of a series of Rh2(II,II) complexes with the electron acceptor dipyrido[3,2-
a:2´,3´-c]phenazine (dppz) ligand in order to study the ability of these complexes to 
increase their cytotoxicity upon irradiation. In addition, studies on the molecular 
characteristics that affect the in vitro activity of these compounds were performed. 
Finally, dirhodium complexes containing naturally occurring polyamines were also 
synthesized and investigated. All of these topics will be covered in the following 
chapters. The last chapter will discuss the conclusions of the studies presented and 
continuing studies for future work.  
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CHAPTER II 
SYNTHESIS, DNA BINDING AND PHOTOCLEAVAGE OF   
DIRHODIUM(II,II) DPPZ COMPLEXES* 
Introduction 
The success of the platinum-based compounds as antitumor agents and the 
emerging practical uses of photodynamic therapy have led to the exploration of various 
new transition metal complexes for potential use in photochemotherapy.62-65 Crucial 
challenges involving the use of cisplatin and its analogues include their effectiveness 
towards some cancers and not others and the resistance developed by tumor cells to the 
drugs.62,66 The severe toxic side-effects of these drugs as well as other antitumor drugs is 
also a major concern.62,67 An alternative approach to localize the action of compounds to 
the target cells, and in this way eliminate or hamper the side-effects, is the activation of 
otherwise nontoxic drugs through irradiation of tumors with visible or near-IR light, a 
field generally known as photodynamic therapy (PDT).68-71 Many compounds are 
currently being investigated for potential use in PDT; these are typically based on 
derivatives of porphyrins and phthalocyanins.72-75 The photoactive drug Photofrin® 
 
* Reprinted in part from “Direct DNA Photocleavage by a New Intercalating 
Dirhodium(II,II) Complex: Comparison to Rh2(µ-O2CCH3)4” Bradley, P. M.; Angeles-
Boza, A. M., Dunbar, K. R., Turro, C. Inorg. Chem. 2004, 43(8), 2450-2452; “DNA 
Binding and Photocleavage in vitro by New Dppz Dirhodium(II,II) Complexes: 
Correlation to Cytotoxicity and Photocytotoxicity” Angeles-Boza, A. M.; Bradley, P. 
M.; Fu, P. K.-L.; Wicke, S. E.; Bacsa, J.; Dunbar, K. R., Turro, C. Inorg. Chem. 2004, 
43(26), 8510-8519; and “Photocytotoxicity of a New Rh2(II,II) Complex: Increase in 
Cytotoxicity upon Irradiation Similar to Hematoporphyrin” Angeles-Boza, A. M.; 
Bradley, P. M.; Fu, P. K.-L.; Shatruk, M.; Hilfiger, M.G.; Dunbar, K. R.; Turro, C. 
Inorg. Chem. 2005, 44(21), 7262-7264. Copyright 2004, 2005, with permission from the 
American Chemical Society. 
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which is in use for the photodynamic treatment of lung and esophageal cancers is 
composed of a mixture of hematoporphyrin and its derivatives.76 Typically, 1O2 
produced through energy transfer from the drug’s long-lived 3ππ* excited state is the 
reactive species that results in damage to biomolecules. Drawbacks of current PDT 
agents are their prolonged cutaneous sensitivity and the requirement of O2 for their 
function, since once consumed, O2 must diffuse to the proximity of the agent.69,71,77,78 In 
addition, some of the most malignant and drug resistant cancer cells are hypoxic (they 
lack oxygen).71,78 New classes of transition metal PDT agents may prove to be useful in 
circumventing the problems associated with the current drugs. 
Metal complexes containing the dipyrido[3,2-a:2´,3´-c]phenazine (dppz) ligand, 
for example [Ru(L)2(dppz)]2+ (L = bpy (2,2´-bipyridine), phen (1,10-phenanthroline)), 
have been explored extensively as reporters of structure,79-85 sequence,81 crosslinking,86 
drug binding,87 electron transfer,88-90 and nucleic acid solvation environment and 
dynamics in DNA duplexes.91-94 The DNA photocleavage by [Ru(bpy)3]2+ and related 
Ru(II) complexes, including intercalated [Ru(bpy)2(dppz)]2+, is observed only in the 
presence of O2, and it likely proceeds via the formation of 1O2 through energy transfer 
from the excited state of the complex.95 Since the first reports of the “light switch” 
effect, numerous mononuclear and bimetallic dppz complexes containing a wide variety 
of metal centers were reported and typically exhibit strong binding to DNA owing to the 
intercalation of the dppz ligand (Kb values range from ~104 to ~108 M–1).96-99 It was 
shown that bimetallic complexes of dppz also bind strongly to DNA, but the two metal 
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centers in the systems reported to date are not in close proximity, and their 
photoreactivity towards nucleic acids has not been explored.100,101   
Bimetallic complexes that exhibit strong metal-metal interactions often afford 
reactive excited states that are not available in mononuclear complexes.  For example, 
hydrogen abstraction from the DNA backbone upon photoexcitation of [Pt2(pop)4]4- 
(pop2- = HO2POPO2H2-) was reported, which results in DNA cleavage.102,103 The 
cleavage of duplex DNA by the triplet excited state of [Pt2(pop)4]4- is not enhanced by 
piperidine treatment, consistent with hydrogen abstraction rather than with a mechanism 
involving guanine oxidation.104 In model systems, it was shown that [Pt2(pop)4]4- reacts 
with  nucleic acids and nucleotides through 4´- and 5´-hydrogen abstraction from the 
deoxyribose backbone.102,103 The overall negative charge of the complex, however, 
precludes it from binding to the double helix, thereby slowing the bimolecular rate of 
photocleavage which renders the process inefficient.  In order to circumvent electrostatic 
repulsion between anionic complexes and DNA, neutral and cationic dirhodium 
complexes were explored as agents for DNA photocleavage.60  Complexes of the type 
Rh2(µ-O2CCH3)4(L)2  (L = alcohols, PPh3, py, THF, H2O) possess long-lived excited 
states (τ = 3.5 to 5.0 ms) that can be accessed with visible light (500 to 700 nm).59 The 
compound Rh2(µ-O2CCH3)4(OH2)2 exhibits weak  DNA binding (Kb = 4.6 × 102 M–1), 
and has been shown to photocleave DNA, but only in the presence of electron 
acceptors.60  
In order to increase the DNA binding of dirhodium complexes and achieve direct 
DNA photocleavage, the photoreactive dirhodium(II,II) core was combined with 
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intercalating dppz ligands.  This chapter describes the synthesis and characterization of 
dirhodium(II,II) complexes containing the dppz ligand. The DNA binding and 
photocleavage properties of some of the complexes were measured in vitro, and the 
results were correlated to the differences in the cytotoxicity and photo-cytotoxicity of 
these complexes towards human skin cells.   
 
Experimental Section 
Materials   
Sodium chloride, sodium phosphate, gel loading buffer (0.05% (w/v) 
bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH = 8.0), 0.5% (w/v) sodium 
lauryl sulfate), Tris base, Tris/HCl, and ethidium bromide were purchased from Sigma 
and used as received.  Calf thymus DNA was purchased from Sigma and was dialyzed 
against 5 mM Tris, 50 mM NaCl (pH = 7.5) buffer three times during a 48 hour period 
prior to use.  The pUC18 plasmid was purchased from Bayou Biolabs and purified using 
the Concert Miniprep System from Life Technology.  SmaI was purchased from 
Invitrogen and used as received.  Acetonitrile and dichloromethane were dried over 3 
and 4 Å molecular sieves, respectively, and distilled under a nitrogen atmosphere prior 
to use. All reactions were carried out under nitrogen using standard Schlenk-line 
techniques. The reagents RhCl3, sodium acetate, NaBF4, and polystyrene sulfonate 
(PSS) were purchased from Aldrich and used without further purification. The 
compounds Rh2(µ-O2CCH3)4 (1),105 Rh2(µ-O2CCF3)4 (2),105 [Rh2(µ-
O2CCH3)2(phen)2](O2CCH3)2 (3),44 [Rh2(µ-O2CCF3)2(phen)2](O2CCF3)2 (4),44 and dppz  
 34
were synthesized by previously reported methods.106 The compound cis-[Rh2(µ-
O2CCF3)2(dppz)2](O2CCF3)2 (8) was synthesized as reported in Chapter IV. 
cis-[Rh2(µ-O2CCH3)2(dppz)(η1-O2CCH3)(CH3OH)](O2CCH3) (5)  
A suspension of dppz (53.8 mg, 0.19 mmol) in CH2Cl2 was added to a slurry of 1 
(100 mg, 0.19 mmol) in CH2Cl2. The mixture was stirred for 36 h under refluxing 
conditions and the resulting green precipitate was filtered and washed with CH2Cl2. The 
product was suspended into methanol and stirred for 24 h at room temperature. The 
solution was concentrated and diethyl ether was added to precipitate a green solid which 
was collected by filtration (91% yield). ESI-MS ([Rh2(µ-O2CCH3)2(dppz)(η1-
O2CCH3)+): calc. m/z =  664.941, obsd. m/z = 664.88.  1H NMR (300 MHz) in CD3OD, 
δ / ppm (mult., int., assignment):  1.11 (s, 3H, CH3CO2), 1.88 (s, 3H, CH3CO2), 2.35 (s, 
3H, CH3CO2), 2.41 (s, 3H, CH3CO2), 8.15 (m, 4H, dppz), 8.51 (m, 2H, dppz), 8.88 (dd, 
2H, dppz), 9.79 (dd, 2H, dppz).  UV-vis in H2O, λ / nm (ε / M–1cm–1): 278 (57,870), 
360 (11,730), 428 (3,177), 590 (354).  
cis-[Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6)   
A solution of 1 (100 mg, 0.19 mmol) in acetonitrile was treated with solid dppz 
(107.7 mg, 0.38 mmol) and the suspension was heated to reflux for 24 h. After this time 
period, the red mixture was cooled to room temperature, filtered and washed with 
acetonitrile to afford a red solid (93% yield). Subsequent crystallization from a 
methanol/benzene/diethyl ether solution in an excess of NaBF4 produced crystals 
suitable for X-ray characterization.  ESI-MS ([Rh2(µ-O2CCH3)2(dppz)2]2+): calcd. m/z = 
444.513, obsd. m/z = 443.98. 1H NMR of the diacetate salt (300 MHz) in 
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CDCl3/CD3OD (1:1 v:v), δ / ppm (mult., int., assignment):  1.75 (s, 6H, CH3CO2), 2.67 
(s, 6H, CH3CO2), 7.73 (m, 4H, dppz), 7.81 (m, 4H, dppz), 7.90 (m, 4H, dppz), 8.64 (d, 
4H, dppz), 9.05 (d, 4H, dppz).  UV-vis in H2O, λ / nm (ε / M–1cm–1): 203 (69,390), 276 
(86,430), 363 (15,170), 434 (5,459). 
cis-[Rh2(µ-O2CCH3)2(bpy)(dppz)](O2CCH3)2 (7)  
A solution of cis-[Rh2(µ-O2CCH3)2(bpy)(η1-O2CCH3)(CH3OH)](O2CCH3) (5; 
403.3 mg, 0.64 mmol) in CH3CN (30 mL) was treated with dppz (183.5 mg, 0.65 mmol) 
in CH3CN (30 mL) and refluxed for 24 h under N2. After this time period, the red-brown 
product was collected by vacuum filtration and washed with diethyl ether (2 × 15 mL) 
and recrystallized from CH3OH/CH2Cl2 (63% yield).  ESI-MS ([Rh2(µ-
O2CCH3)2(bpy)(dppz)](O2CCH3)]+): calcd. m/z = 821.426, obsd. m/z = 821.00.  1H 
NMR: (CDCl3) δ (ppm) 1.88 (s, 6H, CH3CO2-axial), 2.59 (s, 6H, CH3CO2-bridge), 7.32 
(d, 2H, bpy), 7.45 (t, 2H, bpy), 7.61 (t, 2H, bpy), 7.92 (m, 2H, dppz), 8.16 (m, 2H, dppz), 
8.47 (d, 2H, bpy), 8.50 (m, 2H, dppz), 8.78 (d, 2H, dppz), 9.51 (d, 2H, dppz). UV-Vis 
(MeOH): λ, nm (ε, M-1cm-1): 530 (sh,350), 432 (3100), 366 (12000), 282 (61000). 
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Methods 
X-ray Crystallographic Studies 
X-ray Structural Study of cis-[Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6).  For the 
X-ray crystallographic analysis, two red prismatic crystals of 6, 6a (approximate 
dimensions:  0.17 x 0.08 x 0.22 mm3) and 6b (approximate dimensions:  0.37 x 0.25 x 
0.19 mm3) were selected. The crystals were grown under different conditions. 
Compound 6a was grown from a solution of 6 in CH3CN/CH3CH2OH in the presence of 
two equivalents of NaBF4, whereas 6b was grown form a solution of CH3OH/benzene 
layered with diethyl ether in the presence of excess NaBF4. The crystals were coated 
with Paratone oil, transferred to a nylon loop, and placed in a cold N2 stream at 110(2) 
K.  An indexing of the preliminary diffraction patterns indicated that both crystals were 
monoclinic. For 6a, a total of 17,935 reflections were collected in the range 2.40 ≤ θ  ≤ 
27.49°, and in the case of 6b, 11,775 total reflections were collected in the range 1.73 ≤ 
θ  ≤ 27.21°. The data collection covered approximately a hemisphere of reciprocal space, 
by a combination of three or four sets of exposures; each set had a different φ  angle for 
the crystal and each exposure covered 0.3° in Ω.  Crystal decay, which was monitored 
by analyzing duplicate reflections, was found to be less than 1%, therefore, no decay 
corrections were applied.  During the final cycles of refinement, all atoms with the 
exception of hydrogen atoms were refined anisotropically.  Hydrogen atoms belonging 
to hydroxo groups were placed in suitable positions with idealized tetrahedral X-O-H 
geometries.  Hydrogen atoms belonging to methyl groups were placed in regions of 
maximum electron density around the methyl C atoms, and the torsional angles were 
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refined with idealized C-H distances and tetrahedral angles.  The structure of 6a was 
solved and refined in the chiral space group P21, whereas 6b was solved in the P21/n 
space group.  
X-ray Structural Study of cis-[Rh2(µ-O2CCH3)2(bpy)(dppz)](O2CCH3)2 (7).  For 
the X-ray crystallographic analysis, a red prismatic crystal of 8 (approximate 
dimensions:  0.24 x 0.16 x 0.18 mm3) was selected.  The crystal was coated with 
Paratone oil, transferred to a nylon loop, and placed in a cold N2 stream at 110(2) K.  An 
indexing of the preliminary diffraction patterns indicated that the crystal was 
monoclinic. A total of 46,469 reflections were collected in the range 1.58 ≤ θ  ≤ 27.48o.  
Hydrogen atoms belonging to methyl groups were placed in regions of maximum 
electron density around the methyl C atoms. The structure was solved and refined in the 
space group P21/n. The final refinement cycle was based on 9,275 unique reflections 
(6,225 with Fσ2 > 2σ( Fσ2)), 583 parameters, and 33 restraints (R1 = 0.0871, wR2 = 
0.2534).  The maximum and minimum peaks in the final difference Fourier map 
corresponded to 1.90 and –1.083 e/Å3, respectively, with a goodness-of-fit value of 
1.087. 
Melting Point Experiments  
Solutions containing 100 µM calf-thymus DNA and 20 µM of either 5 or 6 (1 
mM phosphate buffer, 2 mM NaCl, pH = 7.2) were used to determine the melting 
temperatures.   
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DNA Photocleavage Experiments 
The DNA photocleavage experiments were carried out using 20 µL of total 
sample volume in 0.5 mL transparent eppendorf tubes containing 100 µM pUC18 
plasmid and various concentrations of each metal complex.  Irradiation of the solutions 
was performed either in air, under a positive pressure of argon or nitrogen following 
bubbling for ~15 minutes, or after 5 freeze-pump-thaw cycles in quartz tubes equipped 
with a Kontes stopcock (using ~3-fold greater solution volume).  Following irradiation, 
4 µL of the DNA gel loading buffer was added to each 20 µL sample.  The 
electrophoresis was carried out using either 1% or 2% agarose gel stained with 0.5 mg/L 
eithidium bromide in 1X TAE buffer (40 mM tris-acetate, 1 mM EDTA, pH ~ 8.2); other 
conditions are specified as needed. 
DNA Binding Constants Determination 
The binding constants of the metal complexes to calf-thymus DNA determined 
by optical titrations at room temperature were measured with 5 µM  metal complex and 
the calf thymus DNA concentration was varied from 0 to 100 µM (5 mM Tris/HCl, pH 
7.5).  The dilution of metal complex concentration at the end of each titration was 
negligible.  The DNA binding constant, Kb, was obtained from fits of the titration data to 
eq 1,107,108
 εa – εf          b – (b
2 – 2 Kb
2Ct [DNA]t / s)1/2
 
(1) 
 εb – εf 2 KbCt                                   
= 
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where b = 1 + Kb Ct + Kb [DNA]t / 2s, Ct and [DNA]t represent the total complex and 
DNA concentrations, respectively, s is base pair binding site size, and εa, εf, and εb 
represent the apparent, free complex, and bound complex molar extinction coefficients, 
respectively.  The value of εb was determined from the plateau of the DNA titration, 
where addition of DNA did not result in further changes to the absorption spectrum. 
Cytotoxicity and Photocytotoxicity  
Human skin fibroblasts (Hs-27) were obtained from the American Type Culture 
Collection, cell line CRL-1634 (Manassas). Cells were cultured in Dulbecco’s modified 
Eagle medium, containing 10% fetal bovine serum (Life Technologies), 50 µg/mL 
gentamicin, 4.5 mg/ml glucose, and 4 mM L-glutamine (Invitrogen Life Technology).  
Cell cultures were incubated in a humidified atmosphere containing 5% CO2 at 37 
oC.  
For assessing the cytotoxicity and photocytotoxicity of different compounds, 
subconfluent (50% - 80% confluent) monolayers of Hs-27 in 60 mm culture dishes were 
used.  The monolayers were washed twice with phosphate-buffered saline (PBS) to 
ensure that the culture dishes were free of any culture medium, and then fresh medium 
containing different concentrations of each compound was added to cover the 
fibroblasts.  The cells were irradiated through the PBS buffer, which does not absorb 
light in the visible region.   After irradiation, the cells were removed from the dishes 
by trypsinization, seeded into 24-well culture dishes, and incubated for 2 to 4 days or 
until the untreated control group reached confluence.  N-lauroyl sarcosine (200 µL, 40 
mM) was then added to each well and the cells were allowed to lyse for at least 15 min.  
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Quantitative determination of the protein content in each well was undertaken using 
Peterson's Modification of the Micro-Lowry Method (Sigma reagent kit),109 where the 
lysate was treated with 200 µL Lowry reagent for 20 min and then with 100 µL Folin-
Ciocalteau phenol reagent for 30 min or until color developed.  A portion of the contents 
(200 µL) of each well was transferred to a 96-well plate for absorbance determination 
using a multiwell plate reader (Dynatech Laboratory).  The absorbance at 630 nm was 
monitored, which is proportional to the total protein content and the number of cells in 
each well.109      
Instrumentation 
The 1H NMR spectra of 5, 6, and 7 were recorded on a Unity-300 NMR 
spectrometer.  Absorption measurements were performed either on a Shimadzu UVPC-
3001 spectrophotometer or on a Hewlett-Packard diode array spectrometer (HP 8453) 
with HP8453 Win System software equipped with a Peltier temperature controlled 
sample cell and driver (HP89090A) for thermal denaturation studies.  The relative 
changes in viscosity were measured on a Cannon-Manning Semi-Micro viscometer for 
transparent liquids.  The viscometer was immersed in a constant temperature water bath 
(24 oC) controlled by a Neslab (Model RGE-100) circulator.  The ethidium bromide 
stained agarose gels were imaged using a GelDoc 2000 transilluminator (BioRad) 
equipped with Quality One (v. 4.0.3) software.   
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X-ray diffraction data were collected either on a Bruker APEX CCD or a Bruker 
SMART CCD diffractometer with graphite monochromated Mo-Kα radiation (λ = 
0.71073 Å).  The frames were integrated with the Bruker SAINT software,110 and a 
semi-empirical absorption correction using multiple-measured reflections was applied 
using SADABS.111 The structures were solved and refined using X-SEED,112 a graphical 
interface to SHELX97.113  
The DNA photocleavage experiments were conducted using a 150 W Xe arc 
lamp in a PTI housing (Milliarc Compact Lamp Housing) as the light source powered by 
an LPS-220 power supply (PTI) with an LPS-221 igniter (PTI).  The wavelength of the 
light reaching the samples was controlled by placing high-pass colored glass filters 
(Melles Griot) and a 10 cm water cell in the light path.  Irradiation of cell cultures was 
accomplished through the use of two 40 W GE watt-miser bulbs (General Electric) with 
an Acrylite OP-3 high-pass filter, keeping the total irradiation below 5 J/cm2 and 
providing a broadband source of irradiation (400 – 700 nm).  It should be noted that cell 
irradiation intensities greater than 5 J/cm2 have been shown to result in concomitant cell 
death in the absence of any external agents, and should therefore be avoided when 
testing compounds with potential applications to live tissue.114
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Results and Discussion 
Synthesis and structural characterization 
Synthesis and Structural Characterization of cis-[Rh2(µ-O2CCH3)2(dppz)(η1-
O2CCH3)(CH3OH)](O2CCH3) (5) 
The synthesis of 5 was performed in a similar fashion to the preparation of other 
mono-diimine complexes of dirhodium. A slurry of  Rh2(µ-O2CCH3)4 (1) in CH2Cl2 
reacts with one equivalent of dppz (dppz = dipyrido[3,2-a:2´,3´-c]phenazine) to yield an 
intermediate that is converted to cis-[Rh2(µ-O2CCH3)2(dppz)(η1-O2CCH3)(CH3OH)]+ 
(5) (Scheme II.1) by stirring the product of the reaction in CH3OH until a green solution 
is obtained.  Characterization of 5 was achieved by 1H NMR spectroscopy in CD3OD 
and ESI mass spectrometry.  Four separate acetate resonances were observed in the 
structure of C1 symmetry, corresponding to two in bridging positions (2.35, and 2.41 
ppm), one coordinated to a single rhodium atom in a terminal fashion (1.11 ppm), and 
the third as an unbound counterion (1.88 ppm).  The aromatic dppz resonances of 5 
appear at 8.15, 8.51, 8.88, 8.64 and 9.79 ppm, and are typical for a coordinated dppz 
ligand (Figure II.1).115,116 The ESI-MS shows a parent peak at m/z = 664.88 
corresponding to the species [Rh2(µ-O2CCH3)2(dppz)(η1-O2CCH3)]+.   
Synthesis and Structural Characterization of [Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6) 
The complex Rh2(µ-O2CCH3)4 (1) in CH3CN reacts with two equivalents of dppz 
(dppz = dipyrido[3,2-a:2´,3´-c]phenazine) to yield cis-[Rh2(µ-
O2CCH3)2(dppz)2](O2CCH3)2 (6) after heating to reflux for 24 hours (Scheme II.1). The 
molecular structure of 6, was determined by X-ray crystallographic methods.  
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 Scheme II.1. Synthetic scheme depicting the synthesis of compounds 5, 6, and 7. 
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 Figure II.1. 1H-NMR spectrum of the aromatic region of cis-[Rh2(µ-O2CCH3)2(dppz) 
(η1-O2CCH3)(CH3OH)](O2CCH3) (5).  
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The molecular structures of 6a and 6b consist of a dinuclear Rh2(II,II) core with a pair 
of chelating dppz ligands coordinated to each Rh atom in a syn disposition, and two 
bridging acetates occupying the remaining equatorial sites.  An acetate ion and a 
CH3CH2OH group coordinated at the axial positions complete an irregular octahedral 
coordination sphere about each Rh atom in 6a, whereas 6b contains a methanol molecule 
coordinated to each axial position.  The structure of the dinuclear cation in 6a and 6b are 
depicted in Figures II.2 and II.3 and are similar to those reported for related dirhodium 
complexes.45,117 The Rh-Rh internuclear distances in 6a and 6b, 2.5519(6) and 2.533(1) 
Å, respectively, are similar to those reported for [Rh2(µ-O2CCH3)4(L)2]2+ (L = bpy, 
phen, 4,7-dimethyl-phen, 3,4,7,8-tetramethyl-phen), 2.548(4), 2.5557(4), 2.565(1), and 
2.564(1) Å, respectively.45,117 Similarly, in cis-[ Rh2(µ-O2CCF3)4(bpy)2]2+ a Rh-Rh 
distance of 2.570(6) Å was reported.45 The lengths of the Rh-N bonds in 6, which range 
from 2.005(4) to 2.016(4) Å, are also comparable to those observed in the analogous 
bpy, phen, and substituted phen complexes.45
A striking feature of 6a and 6b is the close proximity of the two dppz ligands, 
with a nearly eclipsed conformation across the metal-metal bond dictated by the rigid 
bridging acetate groups. In the absence of bridging ligands, a staggered conformation 
about a Rh-Rh single bond is expected, since no electronic barrier to rotation is present.  
The internal twist angle away from the eclipsed geometry of ~ 13° in 6a and 6b is 
significantly greater than that observed for the bis-bpy analogue (6.2°), but similar to 
those in the corresponding phen and substituted phen complexes (16-20°).45,117 The  
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 Figure II.2. Thermal ellipsoid plot at the 50% probability level of the cation in 6a. 
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 Figure II.3. Thermal ellipsoid plot at the 50% probability level of the cation in 6b. 
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dihedral torsional angle defined by the two planes normal to the three aromatic rings of 
both dppz ligands closest to the metal is 15.1(2)° and 13.7(3)° for 6a and 6b, 
respectively. Similar values were observed in [Rh2(µ-O2CCH3)2(bpy)2]2+ (15.8°) and 
[Rh2(µ-O2CCH3)4(L)2]2+ (L = bpy, phen, 4,7-dimethyl-phen, 3,4,7,8-tetramethyl-phen), 
with deviations that range from 9.0° to 10.4°.45   
The splaying of the dppz ligands from a parallel orientation and the twisting from 
an eclipsed geometry serve to reduce steric interactions between the ligands, since the 
short Rh-Rh bond distance would otherwise bring them closer than is favorable for π-π 
stacking interactions.118 Since the dppz ligands are distorted, and their best least squares 
planes are not exactly parallel to each other, a unique interplanar distance cannot be 
defined for these ligands.  The shortest non-bonded atomic contacts, however, provide 
an indication of the separation of the two dppz ligands in these molecules, with 3.494(7) 
Å and 3.503(6) Å being the shortest distance between the outermost rings for 6a and 6b, 
respectively.  The shortest atomic contacts between dppz ligands occurs closest to the 
metal-metal bond, for example, in 6a the atomic distances for N1a···N1b, C7a···C7b, 
N2a···N2b, and C1a···C1b are 3.050(5) Å, 3.289(5) Å, 3.058(5) Å, and 3.242(5) Å, 
respectively. Selected crystal parameters for compounds 6a and 6b are listed in Tables 
II.1 and II.2. Selected bond lengths and angles for compounds 6a and 6b are listed in 
Tables II.3, II.4, II.5 and II.6, respectively. 
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Table II.1. Crystal data and structural refinement parameters for compound 6a. 
 
Empirical formula  C46H41BF4N8O8Rh2
Formula weight  1126.50 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
a  9.5905(19) Å 
b  23.870(5) Å 
c 10.132(2) Å 
α 90° 
β 108.44(3)° 
γ 90° 
Volume 2200.3(8) Å3
Z 2 
Density (calculated) 1.700 Mg/m3
Crystal size 0.22 x 0.17 x 0.08 mm3
Theta range for data collection 2.40 to 27.49°. 
Reflections collected 17935 
Independent reflections 6822 [R(int) = 0.0500] 
Data / restraints / parameters 6822 / 85 / 627 
Goodness-of-fit on F2 1.022 
Final R indices [I>2sigma(I)] R1 = 0.0389, wR2 = 0.0668 
R indices (all data) R1 = 0.0456, wR2 = 0.0688 
 
R1 = Σ⎪⎪Fo⎪ - ⎪Fc⎪⎪/Σ⎪Fo⎪; wR2 = [Σ[w(F02-Fc2)2]/Σ[w(F02)2]]1/2
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Table II.2. Crystal data and structural refinement parameters for compound 6b. 
 
Empirical formula  C55H51B2F8N8O7Rh2
Formula weight  1315.48 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
a  13.698(3) Å 
b  23.472(5) Å 
c 17.318(4) Å 
α 90° 
β 102.47(3)° 
γ 90° 
Volume 5436.7(19) Å3
Z 4 
Density (calculated) 1.607 Mg/m3
Crystal size 0.37 x 0.25 x 0.19 mm3
Reflections collected 43341 
Independent reflections 11775 [R(int) = 0.0785] 
Data / restraints / parameters 11775 /100 / 681 
Goodness-of-fit on F2 1.110 
Final R indices [I>2sigma(I)] R1 = 0.0968, wR2 = 0.2020 
R indices (all data) R1 = 0.1570, wR2 = 0.2332 
 
R1 = Σ⎪⎪Fo⎪ - ⎪Fc⎪⎪/Σ⎪Fo⎪; wR2 = [Σ[w(F02-Fc2)2]/Σ[w(F02)2]]1/2
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Table II.3.   Selected bond distances (Å) for  compound 6a. 
 
 Bond Distances (Å)
Rh(1)-N(1B)  2.005(4)
Rh(1)-N(2B)  2.007(4)
Rh(1)-O(3)  2.040(3)
Rh(1)-O(1)  2.044(3)
Rh(1)-O(5)  2.187(3)
Rh(1)-Rh(2)  2.5519(6)
Rh(2)-N(2A)  2.009(4)
Rh(2)-N(1A)  2.016(4)
Rh(2)-O(4)  2.048(3)
Rh(2)-O(2)  2.051(3)
Rh(2)-O(7)  2.334(3)
 
 
  
Table II.4.   Selected bond angles (°) for  compound 6a. 
 
 Bond Angles (°)
O(7)-Rh(2)-Rh(1) 171.10(9)
O(5)-Rh(1)-Rh(2) 167.10(8)
N(2B)-Rh(1)-O(5) 94.34(14)
O(3)-Rh(1)-O(5) 84.77(13)
O(1)-Rh(1)-O(5) 87.18(13)
O(4)-Rh(2)-O(7) 86.97(13)
O(2)-Rh(2)-O(7) 90.75(13)
N(1B)-Rh(1)-Rh(2) 96.61(11)
N(1B)-Rh(1)-O(5) 91.38(14)
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Table II.5.   Selected bond distances (Å) for  compound 6b. 
 
 Bond Distances (Å)
Rh(1)-N(1A)  2.009(7)
Rh(1)-N(2A)  2.018(7) 
Rh(1)-O(4)  2.033(6) 
Rh(1)-O(2)  2.046(6) 
Rh(1)-O(1)  2.284(5) 
Rh(1)-Rh(2)  2.533 (1) 
Rh(2)-N(1B)  1.995(7) 
Rh(2)-N(2B)  2.004(7) 
Rh(2)-O(3)  2.024(6) 
Rh(2)-O(5)  2.039(6) 
Rh(2)-O(6)  2.300(6) 
 
 
 
Table II.6.   Selected bond angles (°) for  compound 6b. 
 
 Bond Angles (°)
O(1)-Rh(1)-Rh(2) 171.4(2)
O(6)-Rh(2)-Rh(1) 172.5 (2) 
N(1A)-Rh(1)-O(1) 89.1(2) 
N(2A)-Rh(1)-O(1) 90.3(2) 
N(1B)-Rh(2)-O(6) 89.0(2) 
N(2B)-Rh(2)-O(6) 87.8(3) 
O(4)-Rh(1)-O(2) 88.7(2) 
O(3)-Rh(2)-O(5) 88.9(3) 
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The 1H NMR spectrum in CDCl3/CD3OD (1:1, v:v) is consistent with retention 
of the solid-state structure of 6 dissolved in this mixture.  Two acetate resonances are 
observed at 1.75 and 2.67 ppm corresponding to two free and two bridging acetates, 
respectively. The aromatic dppz protons appear at 7.73, 7.81, 7.90, 8.64 and 9.05 ppm, 
and are shifted upfield as compared to those of 5.  This shift is attributed to additional 
shielding of the dppz protons due to the close proximity of the second dppz ligand.  
Similar shifts of the aromatic protons were observed for cis-[Rh2(µ-O2CCH3)4(L)2]2+ (L 
= bpy, phen),  whose structures are similar to that of 6.45 The 1H NMR spectrum of 6 in 
solution is consistent with an eclipsed C2v symmetry of the ligands, indicating that a 
dynamic process is ocurring involving rotational oscillation about the Rh-Rh bond.45
Synthesis and Structural Characterization of cis-[Rh2(µ-O2CCH3)2(bpy)(dppz)] 
(O2CCH3)2 (7) 
The complex cis-[Rh2(µ-O2CCH3)2(bpy)(dppz)](O2CCH3)2 (7) was prepared by 
refluxing cis-[Rh2(µ-O2CCH3)2(bpy)(η1-O2CCH3)(CH3OH)](O2CCH3) (5; 0.64 mmol) 
and dppz (0.65 mmol) in CH3CN (30 mL) for 24 h under N2 (Scheme II.1). Crystals 
suitable for X-ray crystallography were grown from a solution of 7 in CH3OH in the 
presence of NaBF4 and NaCl. The molecular structure of the complex cation consists of 
a dinuclear Rh2(II,II) core with two acetato bridging ligands in cis disposition and 
chelating bpy and dppz ligands coordinated to each Rh atom. The axial positions are 
occupied by a chloride anion and a methanol molecule (Figure II.4). The Rh-Rh distance 
in 7, 2.5529(5) Å, is similar to those found for 6 and 7, 2.5519(6) and 2.567(1) Å,  
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 Figure II.4. Thermal ellipsoid plot at the 50% probability level of the cation in 7. 
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respectively. The internal twist angle across the metal-metal bond of 9.0(5)° in 7 is 
smaller than the one observed for the bis-dppz analogue (13°) but larger than that of the 
corresponding bis-bpy complex (6.2°). The Rh-Oeq bond lengths in 7, which range from 
2.041(6) to 2.055(6) Å, are longer than those in the analogous bis-dppz complex 
(2.009(2)-2.056(2) Å). The Rh-Ndppz bonds, 2.006(3) to 2.011(3) Å, are similar to those 
found for 6a, (2.005(4) to 2.016(4) Å), and 6b, (1.995(7) to 2.018(7) Å). The Rh-Nbpy 
bonds, 1.987(3) to 2.007(3) Å, are similar to those found for cis-[Rh2(µ-
O2CCH3)2(bpy)2(CH3CN)2](PF6)2 (1.984(11) to 2.003(10) Å). Selected crystal crystal 
data parameters for compounds 7 are listed in Table II.7. A summary of selected bond 
distances and angles for compound 7 is listed in Tables II.8 and II.9, respectively. 
 The 1H NMR spectrum of complex 7 in CDCl3/CD3OD (1:1, v:v) is similar to 
those observed for 6 and cis-[Rh2(µ-O2CCH3)2(bpy)2](O2CCH3)2. The heteroleptic 
compound 7 exhibits peaks at 7.32 (d, 2H, bpy), 7.45 (t, 2H, bpy), 7.61 (t, 2H, bpy) 7.92 
(m, 2H, dppz), 8.16 (m, 2H, dppz), 8.47 (d, 2H, bpy), 8.50 (m, 2H, dppz), 8.78 (d, 2H, 
dppz), and 9.51 (d, 2H, dppz) ppm. A greater shielding of the aromatic protons engaged 
in π-stacking interactions typically results in upfield shifts of the 1H NMR resonances. 
Such shifts are observed in the bpy ligand of 7, which exhibits larger upfield shifts than 
those reported for the bis-bpy complex, as a consequence of increased shielding of the 
bpy ligand in 7. 
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Table II.7. Crystal data and structural refinement parameters for compound 7. 
 
Empirical formula  C36H39BF4ClN6O8Rh2
Formula weight  1011.81 
Temperature  110(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/n 
a  11.855(2) Å 
b  20.514(4) Å 
c 16.602(2) Å 
α 90° 
β 90.368(11)° 
γ 90° 
Volume 4037.5(12) Å3
Z 4 
Density (calculated) 1.665 g/cm3  
Crystal size 0.33 x 0.09 x 0.02 mm3
Reflections collected 46469 
Independent reflections 9275 [R(int) = 0.0795] 
Data / restraints / parameters 9275 / 33 / 583 
Goodness-of-fit on F2 1.087 
Final R indices [I>2sigma(I)] R1 = 0.0473, wR2 = 0.0974 
R indices (all data) R1 = 0.0975, wR2 = 0.1270 
 
R1 = Σ⎪⎪Fo⎪ - ⎪Fc⎪⎪/Σ⎪Fo⎪; wR2 = [Σ[w(F02-Fc2)2]/Σ[w(F02)2]]1/2
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Table II.8.   Selected bond distances (Å) for  compound 7. 
 
 Bond Distances (Å)
Rh(1)-Rh(2) 2.5529(5)
Rh(1)-N(1)  1.987(3)
Rh(1)-N(2) 2.007(3)
Rh(1)-O(1)   2.041(2)
Rh(1)-O(3)  2.055(2)
Rh(1)-O(5) 2.273(3)
Rh(2)-N(4) 2.006(3)
Rh(2)-N(3) 2.011(3)
Rh(2)-O(4) 2.051(2)
Rh(2)-O(2) 2.056(2)
Rh(2)-Cl(1) 2.4983(9)
 
 
 
Table II.9.   Selected bond angles (°) for  compound 7. 
 
 Bond Angles (°)
O5 Rh1 Rh2 169.21(7)
Cl1 Rh2 Rh1 171.19(2)
N1 Rh1 N2 80.7(1)
N4 Rh2 N3 81.6(1)
O1 Rh1 O3 88.13(9)
O4 Rh2 O2 88.98(9)
N1 Rh1 O5 90.4(1)
N2 Rh1 O5 91.5(1)
N4 Rh2 O4 95.4(1)
N3 Rh2 O4 176.1(1)
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Electronic absorption and DNA binding 
The electronic absorption spectra of 5 and 6 in 5 mM Tris, 50 mM NaCl (pH = 
7.0) are shown in Figure II.5, which are similar to those recorded in water, and in 
CH3OH.  The absorption at 360 nm (ε = 11,700 M-1cm-1), 363 nm (ε = 15,200 M-1cm-1), 
363 (ε = 15,170 M-1cm-1), and 360 (ε = 16,400 M-1cm-1) observed in 5, 6, and 7, 
respectively, can be assigned as arising from a dppz ππ* ligand-centered (LC) transition.  
This LC transition at ~360 nm has also been observed in various dppz transition metal 
complexes.107,119 In all complexes the absorption tails off into the visible region, with a 
maximum at 428 nm (ε = 3,180 M-1cm-1) in 5, at 434 nm (ε = 5,460 M-1cm-1) in 6, and at 
378 nm (ε = 2,710 M-1cm-1) in 7. Similar transitions are also observed in the 
corresponding complexes of bpy at 424 nm (ε = 2,010 M-1cm-1) in cis-[Rh2(µ-
O2CCH3)2(bpy)(η1-O2CCH3)(CH3OH)]+ and 432 nm (ε = 2,080 M-1cm-1) in cis-[Rh2(µ-
O2CCH3)2(bpy)2]2+,45,117 as well as in [Rh2(µ-O2CCH3)2(L)2]2+ (L = substituted 2,2´-
bipyrine, 1,10-phenanthroline).45 A weaker transition is observed for Rh2(O2CCH3)4 at 
443 nm (ε = 112 M-1cm-1) in water, which was previously assigned to Rh–Rh(π*) →Rh–
O(σ*).  Since the intensity of the absorption at similar energies for 5, 6, and 7 are ~30 
and ~50-fold more intense than that for Rh2(µ-O2CCH3)4, it is likely that these 
transitions in the Rh2-dppz family of complexes are charge transfer in nature and involve 
the dppz ligands.  The weak absorption at λ > 500 nm in each complex is believed to 
arise from metal-centered (MC) transitions associated with the bimetallic core, since 
they are also observed in Rh2(µ-O2CCH3)4 and cis-[Rh2(µ-O2CCH3)2(L)2]2+  
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 Figure II.5.  Electronic absorption spectra of 5 µM (a) 5 and (b) 6 in 5 mM Tris (pH 
= 7.5) in water (––––) and in the presence of 100 mM calf-thymus DNA (- - - ) and 
100 mM PSS (–– –– ).  Insets:  fits of the absorption to eq 1 for (a) 6.2 µM 5 and (b) 
3.2 µM 6 (see text). 
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(L = bpy, phen).45,120,121 In Rh2(µ-O2CCH3)4, the transition at 585 nm (ε = 235 M-1cm-1) 
has been assigned to Rh–Rh(π*) →Rh–Rh(σ*). 
Negative deviations from Beer’s law are observed for 5 and 6 in water at 
concentrations greater than 20 µM (360 nm) and 5 µM (363 nm), respectively. These 
deviations are likely due to hydrophobic interactions or intermolecular π-stacking of the 
dppz ligands, which are commonly observed for organic aromatic compounds and metal 
complexes with hydrophobic ligands in water.122,123 The aggregation appears to be more 
pronounced for the bis-dppz complex, 6, than for 5, consistent with the more 
hydrophobic nature of the former arising from the presence of a second dppz ligand in 
the coordination sphere.   
The spectral changes of 5 µM solutions (5 mM tris, 50 mM NaCl, pH = 7) of 5 
and 6 upon addition of 100 µM DNA are shown in Figure II.5.  Complexes 5, 6, and 7 
exhibit pronounced hypochromism of the dppz ππ* transition, but only 5 and 6 exhibit a 
bathochromic shift. Binding of a 5 µM concentration of the complex to DNA results in 
18% hypochromicity in 5 at 360 nm, 22% in 6 at 363 nm, and 27% in 7 at 366.  Similar 
hypochromicity was reported for [Ru(NH3)4(dppz)]2+ and [Ru(phen)2(dppz)]2+, which 
are believed to bind to DNA through intercalation of the dppz ligand with binding 
constants, Kb, of 1.24×105 M-1 (s = 0.02) and 5.1×106 M-1 (s = 0.6), respectively.119 Fits 
of eq 1 using the decrease in the dppz ππ* absorption as a function of increasing DNA 
concentration for various concentrations of 5 and 6 in 5 mM Tris (pH = 7.0) results in Kb 
= 4.4(7)×105 M-1, s = 2.1(3) and Kb = 7.0(9)×106 M-1, s = 0.9(1), respectively.  Typical 
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fits are shown in the insets of Figure II.5 for 6.2 µM 5 and 3.2 µM 6 in 5 mM Tris (pH = 
7.0).  Addition of 50 mM NaCl (5 mM Tris, pH = 7.0) leads to a small decrease in the 
apparent binding constant of 5, with Kb = 2.4(9)×105 M-1, s = 1.4(3), and a greater 
decrease in that of 6, Kb = 1.3(6)×106 M-1, s = 1.0(3). 
Hypochromic and bathochromic shifts of LC transitions in aromatic ligands 
typically arise from π-stacking interactions in polar solvents, which, in this case, may 
result from intercalation between the DNA bases or from the formation of aggregates of 
the hydrophobic molecules in water.120-123 It had been shown previously that polyanions 
facilitate the aggregation of cationic hydrophobic molecules on their surface in aqueous 
media,65,124-126 including those which use DNA as a template.127 The structure of 5 
(Scheme II.1), with a single dppz ligand protruding from the dirhodium core, suggests 
that the complex should be able to intercalate between the DNA bases without 
significant steric constraints. A similar complex, [Rh2(µ-O2CCH3)2(dap)(η1-
O2CCH3)(CH3OH)]+ (dap = 1,2-diazaperylene), has been shown by 2D NMR 
spectroscopy studies to bind through a intercalative as well as an coordinative mode to 
DNA.128 As observed in Figure II.6, the proposed model contains the perylene unit 
intercalated between the DNA bases, whereas one of the rhodium atoms is bound to 
N7 of one of the adenine bases. In contrast, from the distance between the 
outermost rings of the two dppz ligands in the crystal structures of 6a and 6b 
(3.494(7) Å and 3.503(6) Å, respectively), one would not expect that the complex 
could intercalate between the DNA bases, which are ~3.4 Å apart in B-DNA. In the 
case of compound 7, partial intercalation could be possible since a section of the  
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Figure II.6. Proposed binding model for [Rh2(µ-O2CCH3)2(dap)(η1-O2CCH3) 
(CH3OH)]+ (taken from ref. 128). 
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dppz ligand extends beyond the volume occupied by the bpy ligand. In spite of these 
logical predictions, the apparent DNA binding constant obtained from the 
hypochromicity of the dppz-centered transition (eq 1) of 6 is 16 times higher than that of 
5.  The greater ionic strength effect on the binding constant of 6 compared to 5 may be 
due to greater aggregation of the former on the anionic DNA backbone.  Such templated 
aggregation may be explained by electrostatic binding of the cationic complexes to the 
phosphate backbone of the host DNA polyanion, coupled to cooperative intermolecular 
hydrophobic interactions between the dppz ligands.  The fitted value of s, the number of 
DNA bases associated with the complex, also provides information on surface 
aggregation.  The values of s obtained from the fits range from 1.4 to 2.0 for complex 5, 
but values of s ≤ 1 are obtained for 6.  Aggregation of hydrophobic molecules on the 
DNA surface result in low values of the binding site size, with s < 1.119  Therefore, both 
the ionic strength dependence and value of s are consistent with greater surface 
aggregation (π-stacking) of 6 relative to 5 aided by the anionic DNA backbone.   
Additional experiments aimed at the elucidation of the possible intercalation and 
surface aggregation of 5 and 6 were performed.  These include optical titrations with 
PSS (PSS = polystyrene sulfonate), a polyanion that does not support intercalation, shifts 
in the DNA melting temperature, and changes in viscosity of the DNA solutions in the 
presence of 5 and 6.   
The spectral changes to solutions of 6 that result from titrations with PSS are 
nearly superimposable with those observed in the presence of similar concentrations of 
DNA (Figure II.5).  Figure II.5b shows the absorption changes to a 5 µM solution of 6 (5 
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mM Tris, pH = 7.0) upon addition of 100 µM PSS and 100 µM DNA, where similar 
hypochromicity is observed in the presence of both polyanions.  Although some spectral 
changes are evident when a comparable experiment is performed with 5 (Figure II.5a), 
the addition of 100 µM DNA results in greater hypochromicity (18%) than PSS (11%).  
The changes in absorption for both complexes in the presence of PSS can be attributed to 
enhanced aggregation of 5 and 6 induced by the polyanion; the hypochromicity observed 
in 6 in the presence of DNA is solely due to surface aggregation driven by electrostatic 
and hydrophobic interactions, whereas 5 exhibits both surface aggregation and 
intercalation.  This type of aggregation has been shown to take place in aqueous media 
for cationic hydrophobic molecules and metal complexes with a variety of polyanions, 
including dendrimers, PSS, and DNA.120-124
As shown in Figure II.7a, the melting temperature (Tm) of 100 µM calf-thymus 
DNA in 5 mM phosphate buffer, 2 mM NaCl (pH = 7.2) was measured to be 57 ± 2 °C.  
A small shift in Tm to 63 ± 2 °C was observed in the presence of 20 µM 6 (Figure II.7a).  
A similar ∆Tm was also observed upon addition of 20 µM MgCl2 (∆Tm = 5 °C), an 
indication that the modest shift is due to the presence of a divalent cation and not 
intercalation.  In contrast, Figure II.7a shows that the addition of 20 µM 5 to the DNA 
solution results in a large shift in the melting temperature to 78 ± 2 °C.  The large 
increase in the DNA melting temperature observed for 5, ∆Tm = 21 °C, is consistent 
with intercalation of the complex and is similar to that previously measured for the 
known intercalator [Rh(phi)2(phen)]3+ (phi = 9,10-phenanthrenequinone diimine).129
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Figure II.7. (a) Thermal denaturation of 100 µM calf-thymus DNA (1 mM 
phosphate, 2 mM NaCl, pH = 7.2) alone (o), and with 20 µM 5 (•) and 6 (∆).  (b) 
Relative viscosity changes of solutions containing 200 µM sonicated herring 
sperm DNA  as the concentration of EtBr (o), 5 (•), Hoechst 33258 (?), and 6 (?) 
is increased (see text). 
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Intercalation of molecules between DNA bases is known to increase the viscosity 
of the solution owing to unwinding and elongation of the double helix.130  It is evident 
from Figure II.7b that the addition of 5 to DNA results in an increase in the relative 
viscosity of the solution, although to a lesser extent than the changes observed for the 
same concentration of ethidium bromide (EtBr) which is known to intercalate between 
the DNA bases with Kb = 1.7 × 105 M-1.131,132 In contrast, similar concentrations of 6, 
and 7, much like the minor groove binder Hoechst 33258, do not result in changes in the 
relative viscosity (Figure II.7b).  Since the DNA binding constants measured by using 
dialysis were 1×104   M-1, 4×103 M-1 and 2.8 × 103 M-1 for 5, 6, and 7 respectively, the 
greater increase in viscosity observed for EtBr as compared to 5 at each [probe]/[DNA] 
is likely due to the lower binding constant of the latter to DNA.   
  The large ∆Tm and increase in viscosity induced by 5 are consistent with its 
intercalation between the DNA bases, whereas the modest value of ∆Tm and the lack of 
increase in viscosity support a non-intercalative binding mode for both 6 and 7.  It 
should be noted that the DNA binding constants measured using dialysis for 5 and 6 are 
~2-3 orders of magnitude lower than those determined from the optical titrations, which 
can be explained by the aggregation of 5 and 6 aided by the DNA polyanion. These 
results clearly demonstrate the importance of using several techniques to ascertain 
whether intercalation is occurring and underscore the fact that optical titrations alone 
may result in erroneous assignments of DNA binding modes and binding constants. 
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DNA photocleavage 
As shown in Figures II.8a and II.9, 5, 6, and 7 are able to photocleave plasmid 
DNA upon absorption of photons in the visible region (λirr ≥ 395 nm, 15 min).  The 
control lane in Figure II.8a (Lane 1), which contains 100 µM pUC18 plasmid alone in 
the dark, shows the position of the undamaged supercoiled pUC18 plasmid (Form I) 
with a small amount of nicked, circular DNA (Form II).  The migration of cut, linear 
plasmid (Form III) is depicted in Lane 2 (Figure II.8a) for pUC18 plasmid treated with 
SmaI restriction enzyme.  It is evident from Lanes 3 and 5 (Figure II.8a) that exposure of 
100 µM pUC18 plasmid to 20 µM 5 and 6 in the dark, respectively, does not result in 
DNA cleavage.  Irradiation of 100 µM pUC18 in the presence of 20 µM 5 and 6 (λirr ≥ 
395 nm, 15 min) results in the formation of nicked  DNA (Form II), as shown in Lanes 4 
and 6, respectively (Figure II.8a).  Although complex 6 exhibits ~30% greater molar 
absorptivity than 5 at ~430 nm, greater photocleavage is observed for 5 (Lane 4) as 
compared to 6 (Lane 6).  The difference in the DNA photocleavage may be due to the 
ability of 5 to intercalate, thus resulting in greater reactivity. The photocleavage of 100 
µM pUC18 plasmid (form I) by 10 µM 7 (λirr ≥ 395 nm, 15 min) is shown in Figure II.9. 
Lane 1 shows the position of 100 µM pUC18 plasmid alone in the dark, and it is similar 
to Lane 3 (plasmid + 7 in the dark), which reveals that 7 does not cleave the plasmid 
without irradiation. Nicked, circular plasmid (form II) is formed upon irradiation of 7 
with visible light in air (lane 4) and in deoxygenated solution (lane 5).  
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Figure II.8.  Ethidium bromide stained agarose gels (2%) of 100 µM pUC18 
plasmid in the presence of 20 µM metal complex in 5 mM Tris, 50 mM NaCl (pH = 
7.5) irradiated with λirr > 395 nm.  (a) Lane 1:  plasmid only, dark; Lane 2:  plasmid 
+ SmaI; Lane 3:  plasmid + 5, dark; Lane 4:  plasmid + 5, irr. 15 min; Lane 5:  
plasmid + 6, dark; Lane 6:  plasmid + 6, irr. 15 min.  (b) Lane 1: plasmid only, dark; 
Lane 2:  plasmid only, irr. 20 min; Lane 3:  plasmid + 6, dark; Lane 4:  plasmid + 6, 
irr. 20 min, air; Lane 5: plasmid + 6, irr. 20 min, 50% D2O; Lane 6:  plasmid + 6, irr. 
20 min, under N2; Lane 7:  plasmid + 6, irr. 20 min, freeze-pump-thaw. 
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Figure II.9.  Ethidium bromide stained agarose gel (2%) of 100 µM pUC18 
plasmid, showing the photocleavage (λirr > 395 nm, 15 min) by 10 µM metal 
complex in 5 mM Tris, 50 mM NaCl, pH = 7.5.  Lane 1:  plasmid, dark; Lane 2:  
plasmid + SmaI; Lane 3:  plasmid + 7, dark; Lane 4:  plasmid + 7, irr., air; Lane 5:  
plasmid + 7, irr, freeze-pump-thaw; Lane 6, plasmid + 5, dark; Lane 7:  plasmid + 
5, irr, air;  Lane 8:  plasmid + 6, dark; Lane 9:  plasmid + 6, irr., air. 
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Although some of the photocleavage by these complexes observed with λirr ≥ 
395 nm appears to depend on the presence of oxygen, cleavage is still observed in 
deoxygenated solutions. Figure II.8b shows that irradiation (λirr ≥ 395 nm, 20 min) of 
100 µM plasmid alone (5 mM Tris, pH = 7.5, 50 mM NaCl) does not result in 
photocleavage (Lanes 1 and 2). The amount of photocleavage by 20 µM 6 (5 mM Tris, 
pH = 7.5, 50 mM NaCl) is similar when conducted in 50% D2O (Lane 5) as compared to 
that in H2O (Lane 4) under similar conditions. Samples containing 100 µM plasmid and 
20 µM 6 (5 mM Tris, pH = 7.5, 50 mM NaCl) bubbled with N2 (Lane 6) or subjected to 
five freeze-pump-thaw cycles (Lane 7) resulted in slightly less photocleavage than those 
performed in air (Lane 4), but a significant degree of photocleavage is apparent under 
deoxygenated conditions. Figure II.9 shows that 7 is also able to photocleave DNA in 
the absence of oxygen (Lane 5); although, similar to 5 and 6, to a lesser degree. These 
results indicate that oxygen plays a role in the observed DNA photocleavage of 5, 6 and 
7, but that an oxygen-independent pathway that results in cleavage is also operative. The 
DNA photocleavage by Rh(III) complexes possessing 9,10-phenanthrenequinone 
diimine (phi) ligands had been previously shown to follow both oxygen-dependent and 
independent mechanisms.133  
It should be noted that Rh2(µ-O2CCH3)4 (1), and [Rh2(µ-
O2CCH3)2(phen)2](O2CCH3)2 (3) do not photocleave DNA directly, but require an 
electron acceptor in solution for reactivity.60 It is believed that the photogenerated 
mixed-valent Rh2(II/III) complex is the reactive species that effects DNA cleavage.60 As 
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shown in Figures II.8 and II.9, 5, 6, and 7 are able to photocleave DNA directly, without 
an electron acceptor in solution. Recent calculations and experimental results concerning 
metal-to-ligand charge transfer (MLCT) excited states of Ru(II) and Re(I) dppz 
complexes may explain the difference in photoreactivity observed for the dirhodium-
dppz family of complexes as compared to Rh2(µ-O2CCH3)4 (1) and [Rh2(µ-
O2CCH3)2(phen)2](O2CCH3)2 (3).  Experiments and calculations support the conclusion 
that the lowest-lying excited states in [Ru(bpy)2(dppz)]
2+ and fac-[Re(CO)3(dppz)(py)]
+ 
are Md→π*(phz) MLCT in nature, and that the transferred electron is localized in the 
phenazine (phz) part of the dppz ligand.134,135 In both complexes this 3MLCT state is 
non-emissive, and emission is observed from a slightly higher energy triplet state in 
equilibrium with the Md→π*(phz) 3MLCT. A different ordering of states was later 
calculated for [Ru(bpy)2(dppz)]
2+, but it was still predicted that the lowest-lying 3MLCT 
state remained localized on the phenazine part of the dppz ligand.136 In 5, 6 and 7, a 
similar low-lying Md→π*(phz) 3MLCT state is present as shown by DFT and TD-DFT 
calculations (Chapter III).  The spatial separation of the charge would be expected to 
render this excited state long-lived, which would then result in DNA cleavage by the 
oxidized dirhodium core.         
Cytotoxicity and photocytotoxicity 
 The toxicity of all the complexes towards human skin cell (Hs-27) cultures was 
determined by measuring the percent survival in the presence of various amounts of 
complex relative to a control, that was not exposed to cytotoxic agents.  Interpolation of 
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the data points was used to determine the concentration of complex required to achieve 
50% cell death, LC50 (LC = lethal concentration).  The photocytotoxicity was 
determined from measurements of LC50 values for Hs-27 cell cultures exposed to 400-
700 nm light for 30 min (5 J/cm2).  Table II.10 shows the cytotoxicity and 
photocytotoxicity of the compounds studied. As an example, plots of percent Hs-27 
survival as a function of increasing concentrations of two of the compounds, 5 and 6, in 
the dark and irradiated with visible light are shown in Figure II.10.  The LC50 values 
determined for compounds 1 – 4, which do not contain the dppz ligand, in the dark are 
similar to those obtained upon irradiation (30 min exposure). In contrast, the metal 
complexes containing the electron acceptor dppz ligand show differences in the LC50 
values obtained under the same conditions. In the case of the mono-substituted 
compound, 5, the LC50 value determined in the dark is slightly higher than the one 
determined upon irradiation, 27 ± 2 µM and 21 ± 3 µM, respectively. Higher LC50 
values were measured for the bis-dppz compound 6 (135 ± 8 µM) and the mixed-ligand 
compound 7 (208 ± 10 µM) in the dark indicative of significantly lower cytotoxicity.  
Upon irradiation with visible light, the cytotoxicity of 6 and 7 increase significantly, 
resulting in LC50 = 39 ± 1 µM and 44 ± 2 µM, respectively. There is also an increase in 
the cytotoxicity of the trifluoroacetato-bridged compound 8 (LC50 = 58 ± 3) upon 
irradiation (LC50 = 27 ± 1), although, it is not as high as those encountered for those with 
bridging acetate ligands 6 and 8. It should be noted that the LC50 value measured for 6 
and 7 in the dark are either similar or higher to that of cisplatin (131 ± 10 µM) for Hs-27  
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Table II.10. Cytotoxicity (LC50) and photocytotoxicity (LC50*) values. 
Complex LC50 (µM)a LC50* (µM)b
Hematoporphyrin  21 ± 1 3.8 ± 0.2 
Cisplatin  131 ± 10 110 ± 8 
Rh2(µ-O2CCH3)4 1 15 ± 2 13 ± 2 
Rh2(µ-O2CCF3)4 2 7.7 ± 0.5 8.0 ± 0.5 
[Rh2(µ-O2CCH3)2(phen)2]2+ 3 290 ± 15 294 ± 15 
[Rh2(µ-O2CCF3)2(phen)2]2+ 4 152 ± 7 151 ± 8 
[Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppz)(MeOH)]+ 5 27 ± 2 21 ± 3 
[Rh2(µ-O2CCH3)2(dppz)2]2+ 6 135 ± 8 39 ± 1 
[Rh2(µ-O2CCH3)2(dppz)(bpy)]2+ 7 208 ± 10 44 ± 2 
[Rh2(µ-O2CCF3)2(dppz)2]2+ 8 58 ± 3 27 ± 1 
aHs-27 human skin cells exposed to each compound for 30 min in the dark.  
bHs-27 human skin cells exposed to each compound for 30 min under irradiation.  
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 Figure II.10.  Plot of percent survival of human skin cells (Hs-27) as a function of 
concentration of (a) 5 and (b) 6 in the dark (•) and irradiated with 400–700 nm 
light for 30 min (o).  
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cells under similar experimental conditions in the dark. As expected, irradiation with 
visible light has little effect on the cytotoxicity of cisplatin, LC50 = 110 ± 10 µM.  It 
should be noted that the LC50 value measured here for cisplatin is generally greater than 
those previously reported, however, the difference can be explained by the short 
exposure time required for the direct comparison to the photolyzed samples in the 
present study and different toxicity of the complex as a function of cell line.  For 
comparison the LC50 values reported for 24 hr exposure to cisplatin of human epidermal 
cells, human uterus cancer cells (HeLa), and human leukemia cells (U-937) were <4 µM, 
8 µM, and 50 µM, respectively.137,138 In a different study, 24 hr exposure of cisplatin to 
HeLa cells resulted in LC50 = 0.50 ± 0.05 µM,139 and human colon cancer cells in 
contact with cisplatin for 2 hr led to LC50 = 26 µM.140 In addition, the LC50 values 
recently reported for a variety of cells lines for cisplatin range from 7 µM to 164 µM (24 
hr).141     
 The cytotoxic effect of 5 in the dark is not unexpected given its ability to 
intercalate DNA and shift its melting temperature by 21 oC.  These features may disrupt 
crucial cellular functions, such as transcription and DNA replication.  Irradiation of Hs-
27 cultures exposed to 5 with visible light does not appear to result in significant 
additional cell death, although the DNA photocleavage by 5 is greater than what is 
observed for 6 (Figure II.9a).  In contrast, the LC50 values of 6 and 7 decrease upon 
photolysis.  Figure II.10 shows 100% survival of Hs-27 cells exposed to 30 µM 6 in the 
dark, but the same concentration of 6 results in ~40% cell death when the culture is 
irradiated with visible light. Also, the cytotoxicity of 7 is increased in a 79 ± 10% upon 
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irradiation, which is similar to that determined for the main component of Photofrin®, 
hematoporphyrin, which exhibits a 82 ± 10% increase under these irradiation conditions. 
Compound 7, however, has the advantage of being less cytotoxic than hematoporphyrin 
in the dark. The inability of 6 and 7 to intercalate the DNA base π-stack may account for 
their low LC50 value in the dark relative to that measured for 5. Additional factors 
besides intercalation, however, are likely to play a role in the cytotoxicity of dirhodium 
complexes, since the LC50 values for the non-intercalating complex Rh2(µ-O2CCH3)4 
(Kb = 4.6 × 102 M-1) are 15 ± 2 µM and 13 ± 2 µM in the dark and irradiated, 
respectively. Also, compound 8 has a moderately high cytotoxicity (LC50 = 58 ± 3) 
despite the fact that is unable to intercalate due to the presence of the two dppz ligands 
as in compound 6. Nevertheless, the low toxicity of 6 and 7 in the dark and their increase 
upon irradiation are desirables features for a potential photochemotherapy agent, where 
an otherwise nontoxic compound becomes lethal upon exposure to low energy visible 
light.     
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Concluding Remarks 
New dirhodium complexes possessing the ligand dipyrido[3,2-a:2´,3´-
c]phenazine (dppz), cis-[Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppz)(MeOH)]+ (5), [Rh2(µ-
O2CCH3)2(dppz)2]
2+  (6), [Rh2(µ-O2CCH3)2(dppz)(bpy)]2+ (7), and  [Rh2(µ-
O2CCF3)2(dppz)2]
2+ (8) were synthesized and characterized. These complexes 
photocleave pUC18 plasmid in vitro under irradiation with visible light (λirr ≥ 400 nm, 
15-20 min), resulting in the nicked, circular form. The toxicity of these complexes 
toward human skin cells increases when the cell cultures are irradiated with visible light. 
In particular, compound 7 shows an increase in its cytotoxicity upon irradiation similar 
to that of hematoporphyrin. Although the mechanism that results in cell death by 
photolysis of 7 remains unknown, this compound is a promising candidate for further 
PDT studies. 
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CHAPTER III 
EFFECT OF GLUTATHIONE ON THE ACTIVITY OF 
DIRHODIUM(II,II) DPPZ COMPLEXES  
Introduction 
The main goals of medicinal chemistry are to find new lead compounds as well 
as to continually improve the properties of old ones. It is clear that, to succeed in the 
latter objective, it is necessary to understand the chemical properties and the reactivity of 
the compound of interest. Recent advances in understanding the mechanism of action of 
dirhodium compounds have been discussed in some detail in Chapter I. It is well known 
that most of these agents have DNA as their main target,35 but they can also readily react 
with proteins and peptides, particularly those containing nitrogen and sulfur atoms.142-146 
Glutathione (γ-glutamylcysteinyl, GSH), a non-protein tripeptide is the most prevalent 
intracellular thiol with concentrations up to 10 mM.147,148 The presence of glutathione 
can be either detrimental or favorable to the activity of the metal complexes.147-149 For 
example, a study performed on human small cell lung carcinoma showed that, in 
cisplatin-resistant cells, the amount of GSH is higher than in the parent sensitive cells.148 
Nevertheless, in the case of platinum(IV) complexes, which undergo ligand substitution 
reactions more slowly than their platinum(II) analogues, the presence of thiol-containing 
molecules is required to activate by reduction the more reactive +2 state.149
Studies of the interaction of Rh2(µ-O2CCH3)4 and its analogues with S-based 
compounds have determined the importance of these reactions in the activity of these 
complexes.35 Early reports by Bear and coworkers revealed that Rh2(µ-O2CCH3)4 can 
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inhibit enzymes containing sulfhydryl groups in or near their active site, while enzymes 
lacking this group were not affected. Table III.1 lists enzymes with and without the 
sulfhydryl groups along with the inhibitory activity by Rh2(µ-O2CCH3)4.143  
Subsequent research has been devoted to the understanding of the reactivity of 
dirhodium(II,II) complexes with sulfur-containing molecules; information gathered to 
this point, however, does not allow for a complete picture of the reaction mechanism to 
be revealed. For instance, the formation of an axial adduct of Rh2(µ-O2CCH3)4 and 
C6H5CH2SH was reported in 1980 (Figure III.1).150 It has also been observed by using 
1H-NMR spectroscopic titration that L-cysteine displaces acetate ligands from Rh2(µ-
O2CCH3)4 without disrupting the Rh2 core.151 A report from our group focused on the 
reactions of [Rh2(O2CCH3)2(diimine)2(CH3CN)2]2+ (diimine = bpy, phen) with benzene 
thiolate and 2-aminothiophenol, which acted as mimics of L-cysteine and glutathione, 
respectively.145-146 It was shown that, when the dirhodium complex reacts with a 10-fold 
excess of thiolate, the two acetate molecules are displaced and the product formed, 
Rh2(η1-C6H5S)2(µ-C6H5S)2(diimine)2, contains a Rh2(II,II) unit bridged by thiolate 
molecules. If this complex is exposed to a flow of O2(g) for 15 minutes, the Rh2 unit is 
disrupted and only Rh(III) complexes are recovered as products.145-146 From this last 
study a reaction scheme (Figure III.2) was proposed by us which shows that the Rh2 unit 
is stable to the presence of the thiolate ligands until O2(g) is introduced in the reaction.146
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Table III.1 Inhibitory activity of Rh2(µ-O2CCH3)4 (modified from ref. 143) 
Enzyme Inhibition by Rh2(µ-O2CCH3)4
Glucose oxidase* 
Peroxidase* 
Pyruvate kinase 
Glycerolphosphate dehydrogenase 
Glucose-6-phosphate dehydrogenase 
No 
No 
Yes 
Yes 
Yes 
* Enzymes without essential sulfhydryl groups. 
 
 
 
 
 
 
 
 
 Figure III.1. Schematic representation of adduct formed between 
Rh2(µ-O2CCH3)4 and C6H5CH2SH.  
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Figure III.2. Diagram of the proposed mechanistic pathway of the reactions
between [Rh2(µ-O2CCH3)2(phen)2]2+ and molecules containing sulfhydryl group.
 
 
 
 
 
 
 82
The research described in this chapter involves the reactivity of compounds of 
the [Rh2(µ-O2CCH3)2(dppz)(N-N)]2+ type, where N-N = dppz (dipyrido[3,2-a:2',3'-
c]phenazine), and bpy (2,2'-bipyridine), with glutathione, as well as the effect of 
glutathione in the DNA-photocleavage ability of dirhodium(II,II) dppz complexes. In 
addition, DFT and TD-DFT calculations on the model complex [Rh2(µ-
O2CCH3)2(dppz)(bpy)(H2O)2]2+ are presented in order to explain the behavior of the 
dirhodium-dppz family of complexes in the presence of glutathione. 
 
Experimental Section 
Materials 
Sodium chloride, sodium phosphate, gel loading buffer (0.05% (w/v) 
bromophenol blue, 40% (w/v) sucrose, 0.1 M EDTA (pH = 8.0), 0.5% (w/v) sodium 
lauryl sulfate), Tris base, Tris/HCl, and ethidium bromide were purchased from Sigma 
and used as received. The pUC18 plasmid was purchased from Bayou Biolabs and 
purified using the Concert Miniprep System from Life Technology.  SmaI was purchased 
from Invitrogen and used as received.  Acetonitrile, and dichloromethane were dried 
over 3 Å and 4 Å molecular sieves, respectively, and distilled under a nitrogen 
atmosphere prior to use. RhCl3 was purchased from Pressure Chemicals Inc. The 
reagents sodium acetate, 2,2'-bipyridine, 1,10-phenanthroline were purchased from 
Acros and used without further purification. The ligands L-cysteine and glutathione were 
purchased from Sigma and used without further purification. HPLC-grade water and 
glacial acetic acid were obtained from EM. The compounds Rh2(µ-O2CCH3)4 and dppz 
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(dppz = dipyrido[3,2-a:2',3'-c]phenazine) were synthesized by previously reported 
methods.105,106  
Methods  
DNA Photocleavage 
The DNA photocleavage experiments were carried out using 20 µL of total 
sample volume in 0.5 mL transparent eppendorf tubes containing 100 µM pUC18 
plasmid and 20 µM of each metal complex.  Irradiation of the solutions was performed 
either in air for ~20 minutes.  Following irradiation, 4 µL of the DNA gel loading buffer 
was added to each 20 µL sample.  The electrophoresis was carried out using either 1% or 
2% agarose gel stained with 0.5 mg/L eithidium bromide in 1X TAE buffer (40 mM tris-
acetate, 1 mM EDTA, pH ~ 8.2); other conditions are specified as needed. 
Computational Details 
Density functional theory (DFT) calculations were performed with the hybrid 
Becke-3 parameter exchange functional and the Lee-Yang-Parr non-local correlation 
functional (B3LYP) implemented in the Gaussian 98 program suite.152-154 Geometry 
optimizations were carried out using the SDD basis set-relativistic effective core 
potential (RECP), which combines the Huzinaga–Dunning double-ζ basis set on the 
main group elements with the Stuttgart–Dresden basis set-RECP combination on the 
rhodium metals, while for all other atoms, the 6-311G(d) basis set was employed.155 To 
model the Rh2 complexes in aqueous solution, the molecules were embedded in a 
dielectric medium as an approximation to include solvent polarization effects. The 
inclusion of the dielectric medium was considered using the Tomasi’s Polarized 
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Continuum Model (PCM) reaction field model for the optimization of molecular 
geometry and the calculation of excitation energies.156-157 Time-dependent calculations 
were performed using the Gaussian program suite. All calculations were done on an 
Altix 3700 128-processor SGI computer located at the Texas A&M supercomputing 
facility. 
Reactions between [Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6) and Glutathione (GSH) 
To separate aqueous solutions (5 mL) of 6 (0.1 mM) was slowly added 1, 2, 3, 4, 
and 5 mL of an aqueous solution (pH = 7) of GSH (1.0 mM). In all cases, the red-orange 
solutions rapidly turned blue as the GSH was added. The reaction was followed using 
UV-spectroscopy. The blue color remains for ca. 8 for the solution containing 1 mL of 
1.0 mM of GSH, and up to ~24 hours for the solution treated with 5 mL of 1.0 mM of 
GSH. After which time the reaction mixture slowly turns to an orange color. 
Reactions between [Rh2(µ-O2CCH3)2(dppz)(bpy)](O2CCH3)2 (7) and Glutathione (GSH)  
To separate aqueous solutions (5 mL) of 7 (0.1 mM) was slowly added 1, 2, 3, 4, 
and 5 mL of an aqueous solution (pH = 7) of GSH (1.0 mM). In all cases, the red-orange 
solutions instantaneously turned blue as the GSH was added. The reaction was followed 
using UV-spectroscopy. The blue color persisted for ca. 12 for the solution containing 1 
mL of 1.0 mM of GSH, and up to ~28 hours for the solution treated with 5 mL of 1.0 
mM of GSH. After which time the reaction mixture slowly turns to an orange color. 
Reactions between [Rh2(µ-O2CCH3)2(bpy)2](O2CCH3)2 (9) and Glutathione (GSH) 
An aqueous solution (5 mL) of 9 (0.1 mM) was slowly treated with 1, 2, 3, 4, and 
5 mL of an aqueous solution (pH = 7) of GSH (1.0 mM). In all cases, the red-orange 
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solutions quickly turned blue as the GSH was added, and after a period of c.a. 1.0 - 1.5 
hours they became dark yellow in color. 
Reduction of [Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6) in Ethanol 
A solution of Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6) in ethanol (10 mL) was 
refluxed under N2(g) for 15 minutes. During the course of the reaction an intense blue 
color developed, which disappeared upon exposure of the solution to air. 
Reduction of [Rh2(µ-O2CCH3)2(dppz)(bpy)](O2CCH3)2 (7) in Ethanol 
A solution of Rh2(µ-O2CCH3)2(dppz)(bpy)](O2CCH3)2 (7) in ethanol (10 mL) 
was refluxed under N2(g) for 15 minutes. During the course of the reaction an intense 
blue color developed, which disappeared upon exposure of the solution to air. 
Single-cell Electrophoresis 
Human skin cells (~500,000 cells), Hs-27, were incubated with 120 µM 7 for 30 
min in PBS (PBS with Ca2+ and Mg2+).  Irradiation was conducted with visible light 
(400-700 nm) for 30 min, after which the cells were embedded in 1% low melting 
agarose in PBS without Ca2+ or Mg2+.  The cells were immediately lysed in cold lysis 
solution (2.5 M NaCl, 100 mM EDTA, 1% N-laurylsarcocine, 10 mM Tris-base, pH = 
10, with 10% DMSO and 1% Triton X-100) for one hour at 4 °C.  The DNA was 
allowed to unwind for 20 min in electrophoresis buffer (300 mM NaOH, 1 mM EDTA, 
pH = 13.2) at 4°C and the gel was washed in neutralizing buffer (400 mM Tris-HCl, pH 
= 7.5) three times for 5 min.  The gel was run at 20 V, 300 mA for 20 min.  The gel was 
stained with propidium iodide and was imaged under a fluorescence microscope in the 
orange range of the spectrum at 562-588 nm (λexc = 488 nm).155
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Results and Discussion 
Reactions between [Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6) and [Rh2(µ-
O2CCH3)2(dppz)(bpy)](O2CCH3)2 (7) with glutathione (GSH)  
The reactions of [Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6) and [Rh2(µ-
O2CCH3)2(dppz)(bpy)](O2CCH3)2 (7) with different amounts of glutathione (GSH), 
ranging from 2 to 10 equivalents undergo the same color change and produce a deep 
blue colored solution. An intense new absorption band (ε = 1.1 ×102 M-1cm-1) at ~810 
nm appears in the visible spectrum. The color remains for hours until it slowly 
disappears to give an orange solution. The final UV spectra do not show the original 
band at 810 nm, and they resemble the spectra of the initial compounds. The changes 
observed in compound 7 when reacted with 2 equivalents of reduced glutathione are 
shown in Figure III.3. The lifetime of the blue product was measured and is shown in 
Table III.2. 
 
Table III.2 t1/2 of product formed by the reaction of 6 and 7 with GSH 
Compound Equivalents of GSH t1/2 (hours)a
 
 
6 
 
 
2 
4 
6 
8 
10 
08.0 ± 0.2 
10.1 ± 0.2 
14.2 ± 0.3 
18.5 ± 0.3 
23.8 ± 0.5 
 
 
7 
 
 
2 
4 
6 
8 
10 
12.5 ± 0.2 
16.2 ± 0.3 
20.5 ± 0.3 
24.3 ± 0.5 
28.2 ± 0.7 
a t1/2 was obtained from the average of two individual measurements 
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 Figure III.3. Changes observed in the UV-spectrum of compound 7 after the 
addition of glutathione. 
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As observed in Figure III.3, after the blue compound disappears the initial 
compound 7 is partially regenerated (~65%). The same result is observed for compound 
6 (~69%). Results from the ESI-MS experiments also provide additional evidence that 
the parent compounds are regenerated. Aliquots of each of the reactions were analyzed 
by this technique and in all cases the main peaks belong to oxidized glutathione and 
compounds 6 or 7, respectively. Minor peaks also appeared, which are most likely due to 
partial decomposition of the compounds, although no assignment was possible. 
In the case of compound [Rh2(µ-O2CCH3)2(bpy)2](O2CCH3)2 (9), which does not 
contain the dppz ligand, no initial compound was recovered after the reaction, as 
observed by UV-spectroscopy. This result was confirmed by ESI-MS, which did not 
reveal any peaks corresponding to the dirhodium species. The yellow-brown precipitate 
recovered is insoluble in water and methanol. Products of the same color and similar 
solubility properties are also obtained from the reactions of 6 and 7 with glutathione, and 
this is the source of the loss of ~30 - 35 % of the complexes observed in the UV spectra. 
It is known that dirhodium complexes of the general structure [Rh2(µ-
O2CCH3)2(diimine)2]2+ (diimine = bpy, phen) are reduced in the presence of an alcohol 
such as ethanol or isopropanol.159-161 Pruchnik et al. reported several examples in which 
the diimine complexes were reduced by one electron after refluxing a solution of the 
compound in either ethanol or isopropanol/water under N2(g).159-161 During the reaction, 
the solution turns blue, and the reduced complex is isolated. In order to test if 
compounds containing the dppz ligand are reduced in the same manner, solutions of 
compounds 6 and 7 in ethanol were refluxed under N2(g) for 15 minutes. The solution 
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changes color from yellow-orange to blue, which indicates the formation of the reduced 
species. This process is reversible and the original complex can be recovered by 
exposing the solution to air. The blue color obtained in these reactions resembles the 
color observed in the reactions of 6 and 7 with reduced glutathione. 
 To obtain more information about the reactions of the Rh2-dppz complexes with 
glutathione, EPR studies of the blue compound were undertaken. A sample of the 
reaction of 7 with two equivalents of GSH was examined by EPR spectroscopy. Figure 
III.4 shows the frozen-glass (77 K) EPR spectra of the blue product of the reaction of 7. 
The spectrum is isotropic with g ≈ 2.0, and the signal is broad (≈ 50 G), suggesting a 
delocalized organic radical. There is no hyperfine splitting due to 103Rh (I = ½) centers, 
which suggests that the radical is mainly delocalized on the ligand(s). Isotropic signals 
with similar characteristics have been observed previously by Bear and co-workers, who 
reported that upon reduction of members of the family of [Rh2(µ-O2CCH3)3(L)]+ 
complexes, L = multidentate ligand containing a 1,8-naphthyridine fragment (Figure 
III.5), isotropic signals with g = 1.99 with no hyperfine splitting due to 103Rh were 
obtained.162 The authors concluded that the electron was added to a ligand-based orbital 
and that extensive delocalization of the electron was the cause of the broad signal.162 In 
addition, our group reported an EPR spectroscopic measurement of the product of the 
one-electron reduction of [Rh2(µ-O2CCH3)2(bpy)2][O2CCH3]2 in an acetonitrile frozen 
glass solution as a broad featureless isotropic signal at g ≈ 2.00.44 Therefore, it is 
plausible to assume that GSH reduces the Rh2-dppz complexes to form a radical species 
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 Figure III.4. EPR spectrum of compound 7 after the addition of glutathione.
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 Figure III.5. a) Dirhodium complex used in the study by Bear and co-workers (see 
text) b) EPR spectrum of complex shown in (a) after reduction (taken from ref. 162). 
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with the electron delocalized on the ligand(s). Exposure to air regenerates the initial 
Rh2II/II compound. 
The afore-mentioned results would only be possible if the LUMO of the 
dirhodium-dppz complexes is a mainly ligand-based orbital. It is well known that 
dirhodium complexes possess an electronic structure that is mainly dominated by the 
Rh2 core. For example, in Rh2(µ-O2CCH3)4 the HOMO and LUMO are π* and σ* 
orbitals, respectively. The π* orbitals are formed by the out-of-phase interaction of the 
dxz and dyz metal orbitals, while the σ* orbital is originated from the rhodium dz2 
orbitals.163,164  In our group, however, we have observed that some dirhodium complexes 
can have LUMO orbitals localized on the ligands and not on the metal centers.44 It is 
evident that the nature of the frontier orbitals is important to understand the reaction 
between dirhodium-dppz complexes and sulphur-containing compounds such as 
glutathione.  
DFT calculations on the model complex [Rh2(µ-O2CCH3)2(dppz)(bpy)(H2O)2]2+  
DFT calculations were performed on the model complexes Rh2(µ-O2CCH3)4 and 
[Rh2(µ-O2CH)2(dppz)(bpy)(H2O)2]2+ and the results are summarized in Figure III.6 and 
Figure III.7.  
 In the parent complex Rh2(µ-O2CCH3)4, the frontier orbitals of the Rh2(µ-
O2CCH3)4 complex are dominated by the metal-metal interaction. The electronic 
configuration of the Rh2 core is as follows: σ2π4δ2π*2δ*2σ∗0δ*0, with a net single bond  
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 LUMO + 2 (166), -0.09957 eV 
 
 
LUMO + 1 (165), - 0.10080 eV 
 
 
 
 
 
 
 
 
 LUMO (164), - 0.10749 eV 
 
 
 Figure III.6. Illustration of the 0.04 contour surface diagrams for the
DFT calculated three lowest unoccupied MOs for the model complex
[Rh2(µ-O2CH)2(dppz)(bpy)(H2O)2]2+.  
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HOMO – 2 (161), - 0.24846 eV 
HOMO – 1 (162), - 0.24718 eV 
HOMO (163), - 0.24640 eV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HOMO – 3 (160), - 0.25153 eV 
 
Figure III.7. Illustration of the 0.04 contour surface diagrams for the
DFT calculated four highest occupied MOs for the model complex
[Rh2(µ-O2CH)2(dppz)(bpy)(H2O)2]2+. 
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between the two rhodium atoms. The HOMO and LUMO orbitals of the Rh2(µ-
O2CCH3)4 molecule are the π* and σ* orbitals, respectively. The σ and σ* bonds 
originated from the interaction between the rhodium dz2 orbitals, whereas the π and π* 
orbitals correspond to the overlap of the dxz and dyz metal orbitals. In addition, the 
positive and negative overlap between the two rhodium dxy orbitals form the δ  and δ* 
orbitals. The dx2-y2 orbitals participate in the metal-ligand σ bonds, and they are not as 
involved as the other metal orbitals in the metal-metal interaction. Note that the δ* 
orbital is higher in energy than the π* orbital, a fact that can be explained by the 
interaction between the rhodium dxy orbitals and the Oπ orbitals that raise the energy of 
the δ* orbital.  
For the model complex [Rh2(µ-O2CH)2(dppz)(bpy)(H2O)2]2+, two bridging 
ligands are replaced by two diimine molecules, dppz and bpy, each one on a different 
rhodium atom. The δ and δ * orbitals are further stabilized with respect to the other 
orbitals, and the π and π* orbitals are no longer doubly degenerate due the lower 
symmetry of the complex. As a consequence of the stabilization of the δ * orbital, the 
HOMO in the model complex is a Rh-Rh π* orbital. The [Rh2]4+σ* orbital does not 
appear as the LUMO of the system. In addition, located between the π*[Rh-Rh] (HOMO) 
and σ*[Rh-Rh] orbitals are two ligand-based orbitals. The LUMO is a π* orbital of the 
dppz ligand, and the second-lowest unoccupied orbital (SLUMO) has predominantly bpy 
and dppz character. 
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TD-DFT calculations on the model complex [Rh2(µ-O2CCH3)2(dppz)(bpy)(H2O)2]2+
TD-DFT calculations were performed on the model complex [Rh2(µ-
O2CH)2(dppz)(bpy)(H2O)2]2+ and the results are summarized in Table III.3. 
 
Table III.3 Results of TD-DFT calculation on model complex [Rh2(µ-
O2CCH3)2(dppz)(bpy)(H2O)2]2+
Excited State 
 
λ, nm (f) 
  
Major contributions  
1 558.66 (0.0002) 162 ? 166 
2 551.45 (0.0014) 163 ? 166 
3 419.44 (0.0007) 159 ? 166 
4 401.85 (0.0002) 162 ? 164 
162 ? 165 
5 397.50 (0.0435) 163 ? 164 
163 ? 165 
6 387.90 (0.1138) 160 ? 166 
163 ? 164 
7 379.97 (0.0020) 162 ? 164 
 
 
The optical spectra of Rh2-dppz complexes in different solvents consist of a weak 
(ε ≈ 350 M-1cm-1) low-energy band in the 550 - 600 nm region. The next feature is a 
shoulder that appears at ~430 nm with an ε ≈ 4000 M-1cm-1. Stronger bands appear at 
~400 nm (ε ≈ 15000 M-1cm-1) and ~290 nm (ε ≈ 60000 M-1cm-1). It must be highlighted, 
that the peak at 400 nm, as noted earlier, is very important for the DNA photocleavage 
properties of these complexes.  
The lowest energy band, appearing at ~580 nm, is similar to the lowest energy 
transition in the parent molecule Rh2(µ-O2CCH3)4. This peak has been previously 
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assigned to a π*[Rh-Rh] ? σ*[Rh-Rh] transition. The TD-DFT calculations indicate that this 
band involves transitions from orbitals 162 (HOMO-1) and 163 (HOMO), which are 
π*[Rh-Rh] in character, to the orbital 166 (LUMO), the σ*[Rh-Rh] orbital. 
In the case of the band appearing at ~400 nm, the results on the model complex 
[Rh2(µ-O2CCH3)2(dppz)(bpy)(H2O)2]2+ indicate that it belongs to a metal-to-ligand 
charge transfer (MLCT) band. The major contribution to this MLCT band is from the 
transitions arising from the HOMO π*[Rh-Rh] orbital (163) to the LUMO (164) and 
LUMO+1 (165) orbitals (Table III.3). This band also has a minor contribution from 
transitions from one of the π*[Rh-Rh] orbitals (162) to the ligand-based LUMO (164) and 
LUMO+1 (165) orbitals. It should be noted that this band appears in dirhodium 
complexes containing other diimine ligands, e.g; bpy, phen. Pruchnik et al., used the 
Fenske-Hall molecular-orbital method to study these complexes and also assigned this 
band to a charge-transfer transition, although the electron was said to originate from the 
σ[Rh-Rh] orbital.165 The difference with respect to the present calculation is attributed to 
the different methods used. 
DNA photocleavage in the presence of glutathione 
As shown in Figures III.8 and III.9, both 6 and 7 are able to photocleave plasmid 
DNA upon absorption of photons in the visible region (λirr ≥ 395 nm, 20 min).  The 
control lanes in Figures III.8 and III.9 (Lane 1), which contain only 100 µM pUC18 
plasmid alone in the dark, show the position of the undamaged supercoiled pUC18 
plasmid with a small amount of nicked, circular DNA as an impurity.  Irradiation of 100 
µM pUC18 in the presence of 20 µM  
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Figure III.8.  Ethidium bromide stained agarose gel (2%) of 100 µM pUC18 
plasmid, showing the photocleavage (λirr > 395 nm, 20 min) by 20 µM metal complex 
in 5 mM Tris, 50 mM NaCl, pH = 7.5.  Lane 1:  plasmid, dark; Lane 2:  plasmid + 6 + 
50 µM glutathione, irr.; Lane 3:  plasmid + 6 + 50 µM glutathione, irr.; Lane 4:  
plasmid + 6 + 100 µM glutathione, irr.; Lane 5:  plasmid + 6 + 200 µM glutathione, 
irr.; Lane 6, plasmid + 6 + 300 µM glutathione, irr.; Lane 7:  plasmid + 6 + 400 µM 
glutathione, irr.;  Lane 8:  plasmid + 6 + 500 µM glutathione, irr. 
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 Figure III.9.  Ethidium bromide stained agarose gel (2%) of 100 µM pUC18 
plasmid, showing the photocleavage (λirr > 395 nm, 20 min) by 20 µM metal complex 
in 5 mM Tris, 50 mM NaCl, pH = 7.5.  Lane 1:  plasmid, dark; Lane 2:  plasmid + 7 + 
50 µM glutathione, irr.; Lane 3:  plasmid + 7 + 50 µM glutathione, irr.; Lane 4:  
plasmid + 7 + 100 µM glutathione, irr.; Lane 5:  plasmid + 7 + 200 µM glutathione, 
irr.; Lane 6, plasmid + 7 + 300 µM glutathione, irr.; Lane 7:  plasmid + 7 + 400 µM 
glutathione, irr.;  Lane 8:  plasmid + 7 + 500 µM glutathione, irr. 
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6 and 7 (λirr ≥ 395 nm, 20 min) results in the formation of nicked DNA, as shown in 
Lanes 2 of Figures III.8 and III.9. Lanes 3-8 show the effect of the addition of increasing 
amounts of glutathione (2.5 – 25 equivalents, 50 – 500 µM) on the ability of 6 and 7 to 
photocleave supercoiled pUC18 plasmid. As it can be observed, increasing the 
concentration of glutathione decreases the amount of cleaved DNA. This inhibition is 
not complete though, and even at quantities as high as 25 equivalents, compounds 6 and 
7 are still active. A plausible explanation for this behavior is that glutathione reduces the 
metal complexes, and the compounds in this reduced state cannot transfer the electron 
from the dirhodium core to the ligand as efficiently as they can in their original oxidation 
state.  
Single-cell electrophoresis experiments 
The single-cell gel electrophoresis (SCGE) assay, also known as the comet assay, 
is a rapid and sensitive technique for detecting DNA damage at the level of individual 
cells.158,166,167 The types of DNA damage that can be observed with this method are 
DNA single- and double-strand breaks, alkali labile sites, DNA-protein crosslinks, 
among others.158,166,167 In the experiment, the cells are embedded in agarose gel and 
lysed under mild alkaline conditions to remove cellular proteins. During the 
electrophoresis, undamaged DNA migrates slowly and close to the nucleoid, whereas 
broken DNA fragments migrates away from the nucleoid, giving the appearance of a 
comet tail.  
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igure III.10. Single cell electrophoresis of human skin cells exposed to
20 µM 7 for 30 min then (a) kept in the dark for 30 min and (b)
radiated with visible light for 30 min; the red color indicates stained
DNA. 
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Single-cell electrophoresis experiments were performed in the presence of 120 
µM 7 in the dark and under irradiation conditions with visible light in order to 
investigate if photolysis results in DNA damage (Figure III.10). Human skin fibroblasts 
contain glutathione in levels in the range of 5 - 10 nmol/108 cells (~ 50 – 100 µM) and 
represent an ideal model to study the effect of glutathione on the ability of these 
complexes to cleave DNA after irradiation.168 When the human skin cells are exposed to 
7 for 1 h in the dark, the stained DNA remains within the cells (Figure III.10a). In 
contrast, upon irradiation (30 min, 400-700 nm, 5 J/cm2), approximately half of the cells 
exhibit a “comet tail” indicative of the presence of damaged DNA in the cells (Figure 
III.10b). This indicates that despite the presence of glutathione in the cells, compound 7 
has the ability to cause damage to DNA localized in the cell nucleus. It is important to 
note, that in a study of hematoporphyrin, it was observed that this compound does not 
show comet tails either with or without irradiation.169 From these results, it was 
concluded that the reactive species generated by photo-activated hematoporphyrin were 
unable to reach nuclear DNA.169 In the case of compound 7, it is possible that either the 
molecule itself or its photo-generated products are able to penetrate the nucleus and 
damage the DNA found in the interior. 
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Concluding Remarks 
Glutathione reacts with [Rh2(µ-O2CCH3)2(dppz)2]2+  (6), and [Rh2(µ-
O2CCH3)2(dppz)(bpy)]2+ (7) producing a reduced complex that re-oxidizes to the 
original compound. Likewise, ethanol is also capable of reducing 6 and 7 under N2(g), 
and the process is reversed by exposing the solutions to air. The EPR spectrum of the 
reduced complex 7 is a broad, featureless isotropic signal (g ≈ 1.99) that resembles those 
observed for other dirhodium complexes wherein the electron is delocalized onto the 
ligand. DFT calculations on the model complex [Rh2(µ-O2CH)2(dppz)(bpy) (H2O)2]2+ 
show that, indeed, the LUMO and LUMO + 1 orbitals are mainly ligand in character, 
and it is concluded that the electron added upon reduction is delocalized onto the dppz 
ligand(s). The addition of glutathione in the photocleavage studies result in a decrease 
activity of the complexes, although it does not inhibit it completely. Compounds 6 and 7 
can tolerate up to 25 equivalents of glutathione and still be capable of induce DNA 
cleavage upon irradiation. In this chapter it was also shown that compound 7 can damage 
DNA in human skin cells as observed in the single cell electrophoresis experiments. 
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CHAPTER IV 
DIRHODIUM(II,II) COMPLEXES: UNDERSTANDING THEIR 
IN VITRO ACTIVITY*
Introduction 
Medicinal inorganic chemistry is an area of bioinorganic chemistry that is still in 
its infancy. The topic is at the interface between medicine and chemistry but differs from 
medicinal organic chemistry in two aspects: firstly, medicinal inorganic chemistry makes 
use of many more elements, and secondly it is less developed than its organic 
counterpart. Medicinal inorganic chemistry has witnessed some outstanding successes, 
most notably cisplatin for treatment of cancer and gadolinium complexes in magnetic 
resonance imaging (MRI) applications,170-175 but there are many new promising 
applications to pursue.176,177  
Therapeutic applications of inorganic compounds depend greatly not only on the 
metal ions themselves but also on the ligands bound to them. Ligands are useful for 
mediating the bioavailability of metal ions, they can deliver the compounds to certain 
tissues or organs, and more importantly they can modify the reactivity of the metal 
centers.177-179 Therefore, studies aimed at the understanding of the effect of ligands and 
substitutents on a particular metal ion are important if improved therapeutic 
effectiveness is to be achieved.   
 
* Reprinted in part from “Dirhodium (II,II) Complexes: Molecular Characteristics that 
Affect in Vitro Activity” Angeles-Boza, A. M.; Chifotides, H. T.; Aguirre, J. D.; Chouai, 
A.; Fu, P. K.-L.; Dunbar, K. R.; Turro, C. J. Med. Chem. 2006, 49(23), 6841-6847; 
Copyright 2006, with permission from the American Chemical Society. 
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  Recent studies of various dirhodium compounds have indicated that there is a 
correlation between their molecular characteristics including the ligand environment and 
their cytotoxic behavior.42,54-58 An important factor that likely affects the biological 
properties of these compounds is their ability to react with the cellular target(s), which 
includes the lability of the groups bound to the dirhodium core, and the presence of open 
coordination sites. Evidence of the importance of these factors can be found from the 
reactions of dirhodium compounds with single-stranded oligonucleotides containing 
dipurine sites. In these reactions the following order of reactivity was observed 
Rh2(O2CCH3)4 << cis-[Rh2(O2CCH3)2(CH3CN)6](BF4)2 <  Rh2(O2CCF3)4, which 
correlates with the lability of the equatorial groups.55 Furthermore, a recent study 
showed that the extent of interstrand cross-link formation by dirhodium compounds of a 
DNA fragment containing 123 base pairs also correlates with the lability of the leaving 
groups.56 In this part of the thesis an evaluation of the type and lability of the 
equatorially bound groups to the dirhodium core on the cytotoxicity of the complexes 
towards human skin cells has been uundertaken. The determination of some general 
correlations between the molecular characteristics of these compounds and their 
cytotoxic behavior has been established. These findings are aimed at improving the 
design of more effective dirhodium compounds as potential drugs and PDT agents.  
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Experimental Section 
Materials 
 The ligands dipyrido[3,2-a:2',3'-c]phenazine (dppz) and benzodipyrido[3,2-
a:2',3'-c]phenazine (dppn) were synthesized according to reported procedures.103;177 The 
dirhodium complexes Rh2(O2CCH3)4 (1), Rh2(O2CCF3)4 (2), [Rh2(O2CCH3)2(phen)2]
2+ 
(3), [Rh2(O2CCF3)2(phen)2]
2+ (4), [Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppz)(MeOH)]+ (5), 
[Rh2(O2CCH3)2(dppz)2]
2+ (6), and [Rh2(O2CCH3)2(dppz)(bpy)]2+ (7) were synthesized as 
reported in Chapter II. The starting material RhCl3·nH2O was purchased from Pressure 
Chemicals and used as received. The compounds 2,2'-bipyridine (bpy), 1,10-
phenanthroline (phen), 2,3-diaminonaphthalene were purchased from Acros. The 
compounds 9-ethylguanine (9-EtGuaH), sodium phosphate (dibasic, anhydrous) and 
NaCl were purchased from Sigma. The deuterated solvents D2O-d2, CD3COCD3-d6, 
CD3OD-d4, and C6D6-d6 were purchased from Aldrich. 
Synthesis of [Rh2(µ-O2CCF3)2(dppz)2](O2CCF3)2 (8) 
 A solution of Rh2(µ-O2CCF3)4 (126.3 mg, 0.19 mmol) in CH3CN (16 mL) was 
treated with solid dppz (108.2 mg, 0.38 mmol) and the suspension was heated to reflux 
for 16 h. After this time period, the red mixture was cooled to room temperature, the 
solution was filtered and the red solid washed with CH3CN. Yield = 206.7 mg, 89%. 
ESI-MS: m/z 499.2 ([Rh2(µ-O2CCF3)2(dppz)2]2+). 1H NMR: (CD3OD/CDCl3) δ (ppm) 
9.35 (d, 4H, dppz), 8.95 (d, 4H, dppz), 8.45 (m, 4H, dppz), 8.25 (m, 4H, dppz), 8.10 (m, 
4H, dppz). Anal. Calcd for C44H20N8O8F12Rh2·H2O: C, 42.60; H, 1.79; N, 9.03. Found: 
C, 42.64; H, 1.75; N, 8.98. 
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Synthesis of [Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppn)(CH3OH)](O2CCH3) (10) 
 A suspension of dppn (90 mg, 0.39 mmol) and Rh2(µ-O2CCH3)4(CH3OH)2 (171 
mg, 0.39 mmol) in acetone (15 mL) was stirred at room temperature under N2 for 48 h. 
The resulting green precipitate was filtered and washed with acetone (3 x 5 mL). The 
solid was suspended in CH3OH (50 mL) and stirred at room temperature for 24 h. The 
resulting green solution was filtered, concentrated under reduced pressure to 2 mL, and 
the product was precipitated by addition of Et2O. The green solid was collected by 
filtration, washed with Et2O, and dried under vacuum (93 mg, 40%). 1H-NMR 
(CD3OD/CDCl3, 1:1 v:v) δ (ppm): 9.77 (d, 1H), 9.12 (s, 1H), 8.86 (dd, 1H), 8.35 (d, 
1H), 8.15 (dd, 1H), 7.76 (dd, 1H), 2.49 (s, 3H, CH3CO2), 2.45 (s, 3H, CH3CO2), 2.02 (s, 
3H, CH3CO2), 1.23 (s, 3H, CH3CO2); ESI-MS m/z 715 (100%, [Rh2(µ-
O2CCH3)2(dppn)(O2CCH3)]+). 
Synthesis of [Rh2(µ-O2CCH3)2(dppn)2](O2CCH3)2 (11) 
 A mixture of dppn (100 mg, 0.30 mmol) and Rh2(µ-O2CCH3)4(CH3OH)2 (76.2 
mg, 0.15 mmol) in CH3CN (10 mL) was heated under nitrogen for 24 h. After cooling, 
the precipitate was collected by filtration, washed with CH3CN (3 x 5 mL), and dried 
overnight under vacuum to provide a red solid (144 mg, 87%). 1H NMR (CD3OD) δ 
(ppm): 9.03 (d, 1H), 8.62 (d, 1H), 8.08 (s, 1H), 7.73 (t, 1H), 7.60 (d, 1H), 7.41 (dd, 1H), 
2.60 (s, 6H, CH3CO2), 1.73 (s, 6H, CH3CO2); MS m/z 494 (100%, [Rh2(µ-
O2CCH3)2(dppn)2]2+); Anal. Calcd for C52H36N8O8Rh2·4H2O: C, 52.97; H, 3.76; N, 9.51. 
Found: C, 53.07; H, 3.42; N, 10.16. 
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Synthesis of cis-[Rh2(µ-O2CCH3)2(dppn)(bpy)](O2CCH3)2 (12) 
 Following the procedure described for cis-[Rh2(µ-O2CCH3)2(dppn)2](O2CCH3)2, 
a mixture of 8 (270 mg, 0.35 mmol) and bpy (55 mg, 0.35 mmol) in CH3CN (10 mL) 
was heated under N2 for 24 h to produce a dark red solid (173 mg, 42%). 1H NMR 
(CD3OD) δ (ppm): 9.42 (d, 1H), 9.05 (s, 1H), 8.61 (d, 1H), 8.32 (d, 1H), 8.27 (dd, 1H), 
7.78-7.68 (m, 3H), 7.53 (t, 1H), 7.31 (t, 1H), 2.57 (s, 6H, CH3CO2), 1.75 (s, 6H, 
CH3CO2); ESI-MS m/z 406 (100%, [Rh2(µ-O2CCH3)2(dppn)2]2+); Anal. Calcd for 
C52H36N8O8Rh2·4H2O: C, 47.90; H, 4.02; N, 8.38. Found: C, 47.96; H, 3.54; N, 8.69. 
Synthesis of [Rh2((µ-O2CCF3)2(CH3CN)6](BF4)2 (13) 
 To a 10 mL solution of Rh2(µ-O2CCF3)4 (0.27 g, 0.61 mmol) in CH3CN/CH2Cl2 
(1/1) was slowly added a solution of 1.0 M Et3OBF4 in CH2Cl2 (1.4 mL). The solution 
was stirred at r.t. for 12 h. The volume was reduced to 4 mL under vacuum. The solid 
was recovered by filtration on a sintered glass frit and washed several times with cold 
CH3CN. The crude purple product was redissolved in 7 mL of CH3CN and stored at -10 
°C for 24 hours. Purple microcrystals of [Rh2((µ-O2CCF3)2(CH3CN)6](BF4)2 were 
isolated by filtration and the product was dried under vacuum for 4 h. Yield = 0.32 g 
(60.1 %).1H NMR (CD3CN) δ (ppm): 2.46 (s, 12H), 1.96 (s, 6H). 
Synthesis of N,N'-di-p-fluoroformamidine (DPhFFH) 
 P-fluoroaniline (56.8 ml, 0.6 mol) was treated with ethylorthoformate (50.0 ml, 
0.3 mol). The mixture was heated to reflux and the ethanol formed in the reaction was 
removed by distillation. The white solid that formed was dissolved in hot toluene and the 
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solution was stored for 48 h. White crystals of  N,N'-di-p-fluoroformamidine were 
isolated by filtration. The product was recrystallized from toluene an additional time, 
and the white product was isolated by suction filtration and dried under vacuum for 12 h. 
Yield = 66.7 g (96.2 %).1H NMR (CDCl3) δ (ppm): 8.03 (s, 1H), 7.01 (s, 4H), 6.98 (s, 
4H), 6.29 (s, 1H). 
Synthesis of [Rh(cod)(DPhFF)]2
 The compound [Rh(cod)(DPhFF)]2 was prepared by a modification of the 
literature method. The KDPhFF salt was prepared in situ by stirring a toluene solution 
(25.0 mL) of N,N'-di-p-fluoroformamidine (292.8 mg, 1.26 mmol) with KOBut (141.2 g, 
1.26 mmol) for 30 minutes. To this solution was added a toluene solution of 
[Rh(cod)Cl]2 (310.7 mg, 0.63 mmol). The mixture was stirred for 12 h. at r.t. and the 
resulting orange solution was filtered and concentrated to ca. 5 mL. Addition of hexanes 
produced an orange solid that was isolated by filtration in 83% yield (462 mg).  
Synthesis of [Rh2(DPhFF)2(CH3CN)6](BF4)2 (14) 
 The compound [Rh2(DPhFF)2(CH3CN)6](BF4)2 was prepared by a modification of 
the literature method. A solution of [Rh(cod)Cl]2 (124.5 mg, 0.14mmol) in 
CH2Cl2/acetonitrile (1/1, 40 mL) was treated with AgBF4 (112.1 mg, 0.58 mmol) in the 
absence of light. The mixture was stirred at r.t. for 6 h., and subsequently refluxed for 24 
h, after which time visible Ag metal deposits were present. The mixture was filtered 
through a Celite plug, concentrated to ~8 mL under reduced pressure, treated with 12 mL 
of diethyl ether, and finally chilled to -10 °C. A red mycrocrystalline solid was collected 
by suction filtration, washed with diethyl ether and dried in vacuo. Yield = 115.2 mg 
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(75.6 %). 1H NMR (CD3CN) δ (ppm): 7.51 (t, 1H, NCHN), 7.11 (m, 4H, Ar-H), 7.02 
(m, 4H, Ar-H), 2.54 (s, 12H, eq-CH3CN), 1.96 (s, 6H, ax-CH3CN). 
Synthesis of [Rh2(µ-DPhFF)2(phen)2(CH3CN)2](BF4)2 (15) 
 A solution of [Rh2(DPhFF)2(CH3CN)6](BF4)2 (14) (130.9 mg, 0.12mmol) in 
acetonitrile (60 mL) was treated with 1,10-phenanthroline (43.4 mg, 0.24 mmol). The 
mixture was refluxed for 24 h, after which time the volume was reduced to 10 mL under 
reduced pressure and layered with diethyl ether until a dark red solid appeared. The solid 
was recovered by filtration on a sintered glass frit and washed several times with diethyl 
ether. The product was dried under vacuum for ~10 h. Yield = 0.12 g (77.9 %). 1H NMR 
(CD3CN) δ (ppm): 8.58 (dd, 4H, phen), 8.30 (t, 2H, NCHN), 8.14 (dd, 4H, phen), 7.67 
(s, 4H, phen), 7.44 (dd, 4H, phen), 7.11 (m, 4H, Ar-H), 7.02 (m, 4H, Ar-H), 1.96 (s, 6H, 
ax-CH3CN). 
Synthesis of [Rh2(µ-DPhFF)2(dppz)(CH3CN)4](BF4)2 (16) 
 A solution of [Rh2(DPhFF)2(CH3CN)6](BF4)2 (14) (100.5 mg, 0.09 mmol) in 
acetonitrile (50 mL) was treated with dppz (25.4 mg, 0.09 mmol). The mixture was 
refluxed for 24 h, after which time the volume was reduced to 20 mL under reduced 
pressure and layered with diethyl ether until a red solid appeared. The solid was 
recovered by filtration on a sintered glass frit and washed several times with diethyl 
ether. The product was dried under vacuum overnight. Yield = 0.107 g (92.1%). 1H 
NMR (CD3CN) δ (ppm): 9.15 (d, 2H, dppz), 8.78 (d, 2H, dppz), 8.35 (m, 2H, dppz), 
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8.29 (t, 2H, NCHN), 8.18 (m, 2H, dppz), 8.10 (m, 2H, dppz), 7.13 (m, 4H, Ar-H), 7.04 
(m, 4H, Ar-H), 2.51 (s, 6H, eq-CH3CN), 1.96 (s, 6H, ax-CH3CN). 
Synthesis of [Rh2(DPhFF)2(dppz)2(CH3CN)2](BF4)2 (17) 
 A solution of [Rh2(DPhFF)2(CH3CN)6](BF4)2 (14) (120.0 mg, 0.11mmol) in 
acetonitrile (60 mL) was treated with dppz (64.9 mg, 0.23 mmol). The mixture was 
refluxed for 24 h and the volume was reduced to 20 mL under reduced pressure. The red 
solid was recovered by filtration on a sintered glass frit and washed several times with 
cold acetonitrile (3 × 10 mL) and diethyl ether (2 × 10 mL). The product was dried under 
vacuum overnight. Yield = 0.149 g (90.8 %). 1H NMR (CD3CN) δ (ppm): 9.01 (d, 4H, 
dppz), 8.77 (d, 4H, dppz), 8.41 (m, 4H, dppz), 8.29 (t, 2H, NCHN), 8.16 (m, 4H, dppz), 
8.11 (m, 4H, dppz), 7.13 (m, 4H, Ar-H), 7.04 (m, 4H, Ar-H), 2.51 (s, 6H, eq-CH3CN), 
1.96 (s, 6H, ax-CH3CN). 
Methods 
X-ray Crystallographic Studies 
X-ray Structural Study of [Rh2(µ-DPhFF)2(dppz)(CH3CN)4](BF4)2 (16).  For 
the X-ray crystallographic analysis, a red prismatic crystal of 16 (approximate 
dimensions:  0.31 x 0.22 x 0.19 mm3) was selected.  The crystal was coated with 
Paratone oil, transferred to a nylon loop, and placed in a cold N2 stream at 110(2) K. A 
total of 46,455 reflections were collected in the range 1.65o ≤ θ  ≤ 27.51o.  The structure 
was solved and refined in the space group P-1. The final refinement cycle was based on 
16,345 unique reflections (11,457 with Fσ2 > 2σ( Fσ2)), 897 parameters, and 34 
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restraints (R1 = 0.0719, wR2 = 0.1653). The maximum and minimum peaks in the final 
difference Fourier map corresponded to 1.329 and –1.696 e/Å3, respectively, with a 
goodness-of-fit value of 1.081. 
Ligand Exchange Kinetics 
 Reaction of Rh2(O2CCH3)4(H2O)2 with 9-EtGH. In a typical reaction, a slurry of 
9-EtGuaH (25mg, 0.14 mmol) in H2O (5 mL) was added to a solution of 
Rh2(O2CCH3)4(H2O)2 (30 mg, 0.063 mmol) in 5 mL of H2O.  The reaction solution was 
heated at a constant temperature (± 3 ºC) for a few days during which time its color 
gradually changed from aqua to emerald green.  Small aliquots (200 µL) were removed 
from the reaction solution at various time intervals (depending on the rate of the reaction 
at the particular temperature), lyophilized several times, redissolved in D2O-d2 and 
monitored by 1H NMR spectroscopy to determine the progress of the reaction. The areas 
of the H8 protons of the reaction product Rh2(O2CCH3)2(9-EtGua)2 (head-to-head and 
head-to-tail isomers) in each sample were integrated against the area of the H8 proton of 
the unreacted 9-EtGuaH. 
 Reaction of Rh2(O2CCF3)4 with 9-EtGH. In a typical reaction, a slurry of 9-
EtGH (25mg, 0.14 mmol) in H2O (5 mL) was added to a solution of Rh2(O2CCF3)4 (46 
mg, 0.070 mmol) in 5 mL of H2O.  The reaction solution was heated at a constant 
temperature (± 3 ºC) for several hours during which time its color gradually changed 
from blue to emerald green.  Small aliquots (350 µL) were removed from the reaction 
solution at various time intervals (depending on the rate of the reaction at the particular 
temperature), lyophilized a few times and redissolved in exactly 450 µL of (CD3)2CO-d6. 
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To each sample, a precise amount of C6D6-d6 (1.5 µL) was added and the sample was 
monitored by 1H NMR spectroscopy.  The area of the H8 protons of [Rh2(O2CCF3)2(9-
EtGuaH)2](O2CCF3)2 in each sample was integrated against the area of the internal 
C6D6-d6. Sampling of the reaction was discontinued when the integration area of the H8 
protons (from the product) remained constant with respect to the integration area of the 
internal C6D6-d6. The internal C6D6-d6 had to be added to the NMR sample because, 
although [Rh2(O2CCF3)2(9-EtGuaH)2](O2CCF3)2 is readily soluble in (CD3)2CO-d6, 9-
EtGuaH is not (to monitor the unreacted amount). The 1H NMR spectra of the reaction 
aliquots could not be monitored in D2O-d2, because [Rh2(O2CCF3)2(9-
EtGuaH)2](O2CCF3)2 is not completely soluble in D2O-d2. Efforts to monitor the 
progress of the reaction by 19F NMR spectroscopy were not successful because the 
resonances of the free and bound trifluoroacetate (CF3CO2-) are very close, making the 
integration values unreliable. Monitoring the substitution reactions of the acetate and 
trifluoroacetate bridging groups with other reagents, e.g., HCOOH or Na2CO3 was not 
possible, because the reactions with dirhodium trifluoroacetate are complete within 
minutes and thus not possible to monitor by NMR spectroscopy. 
In Vitro Cytotoxicity Measurements 
 Human skin fibroblasts (Hs-27) were obtained from the American Type Culture 
Collection, cell line CRL-1634 (Manassas). Cells were cultured in Dulbecco’s modified 
Eagle medium, containing 10% fetal bovine serum (Life Technologies), 50 µg/mL 
gentamicin, 4.5 mg/ml glucose, and 4 mM L-glutamine (Invitrogen Life Technology).  
Cell cultures were incubated in a humidified atmosphere containing 5% CO2 at 37 
oC.  
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For assessing the cytotoxicity and photocytotoxicity of different compounds, 
subconfluent (50% - 80% confluent) monolayers of Hs-27 in 60 mm culture dishes were 
used.  The monolayers were washed twice with phosphate-buffered saline (PBS) to 
ensure that the culture dishes were free of any culture medium, fresh PBS containing 
different concentrations of each compound were added to cover the fibroblasts. After 
this procedure, the cells were removed from the dishes by trypsinization, seeded into 24-
well culture dishes, and incubated for 2 to 4 days or until the untreated control group 
reached confluence.  N-lauroyl sarcosine (200 µL, 40 mM) was then added to each well 
and the cells were allowed to lyse for at least 15 min.  Quantitative determination of the 
protein content in each well was undertaken using Peterson's Modification of the Micro-
Lowry Method (Sigma reagent kit), where the lysate was treated with 200 µL Lowry 
reagent for 20 min and then with 100 µL Folin-Ciocalteau phenol reagent for 30 min or 
until color developed.  A portion of the contents (200 µL) of each well was transferred to 
a 96-well plate for absorbance determination using a multiwell plate reader (Dynatech 
Laboratory).  The absorbance at 630 nm was monitored, which is proportional to the 
total protein content and the number of cells in each well. 
Instrumentation 
 The 1H-NMR spectra for the synthesis of the complexes were recorded on a 
Varian spectrometer at 300 MHz. The 1H-NMR spectra for the kinetics studies were 
recorded at 20 ºC on a 500 MHz Varian Inova spectrometer with a 5 mm switchable 
probehead. The 1H-NMR spectra for the dirhodium tetraacetate and trifluoroacetate 
reactions with 9-EtGuaH were referenced to the residual proton impurities of the 
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deuterated solvents D2O-d2 and (CD3)2CO-d6, respectively. The 1H-NMR spectra for the 
compounds 8, and 10-13 were referenced to the residual proton impurities of the 
deuterated solvents CD3OD-d4 and CD3OD-d4/CD3Cl, respectively. Absorption spectra 
were recorded in a UV-1601PC Shimadzu spectrophotometer. Mass spectra were 
acquired on a PE SCIEX QSTAR Pulsar electrospray ionization mass spectrometer at 
Texas A&M University. Elemental analyses were performed by Atlantic Microlab Inc., 
P.O. Box 2288, Norcross, GA 30091. 
 
Results and Discussion 
Syntheses 
 The cytotoxicities of the dirhodium compounds 1-16 have been studied with 
respect to their structural features. The compounds Rh2(µ-O2CCH3)4 (1), Rh2(µ-
O2CCF3)4 (2), [Rh2(µ-O2CCH3)2(phen)2]2+ (3), and [Rh2(µ-O2CCF3)2(phen)2]2+ (4) were 
previously reported. [Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppz)(MeOH)]+ (5), [Rh2(µ-
O2CCH3)2(dppz)2]
2+ (6), and [Rh2(µ-O2CCH3)2(dppz)(bpy)]2+ (7) were synthesized as 
detailed in Chapter II. The synthetic routes for the newly synthesized dirhodium(II,II) 
complexes 8, 10-17 are outlined in Schemes IV.1 and IV.2.  
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Scheme IV.1. Synthetic routes used to prepare compounds 8, 10 - 12, and 16. 
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Scheme IV.2. Synthetic routes used to prepare compounds 14-17. 
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 The ligand dppn was introduced into compounds 10-12 due to its higher 
lipophilicity as compared to dppz. Heating 1 with two equivalents of dppn in refluxing 
CH3CN yields 11 (87%) as a red solid. The reaction temperature and time are critical for 
the formation of 11. If the reaction is performed at lower temperatures or for shorter time 
periods, a mixture of the mono and bis dirhodium complexes are obtained. Compound 
10 is synthesized at a 40% yield by the reaction of 1 with 1 eq of dppn. The intermediate 
product Rh2(µ-O2CCH3)2(η2-O2CCH3)(η1-O2CCH3)(dppn) in the reaction possesses a 
chelating acetate ion, which occupies eq/ax positions of one rhodium atom.43 This 
intermediate exhibits low solubility in both polar and non-polar solvents; it is converted, 
however, into the more soluble product 10, by stirring a slurry of the insoluble 
compound in methanol until a clear green solution is obtained. In the last step, one 
acetate group is displaced by methanol. Compound 10 is reacted with one equivalent of 
2,2'-bipyridine in acetonitrile to produce 12 in a 42% yield.  
It is well-known that formamidinato ligands are less labile than the carboxylato 
ligands. For this reason, compounds 14-16 were synthesized so they could be compared 
to their acetato analogues. Compound 14 is synthesized by reacting [Rh(cod)(DPhFF)]2, 
which does not contain a Rh-Rh bond, with an excess of AgBF4. The oxidation of the 
rhodium atoms from the oxidation state +1 to the +2 state results in the formation of 14, 
which contains a Rh-Rh bond, and in which the cyclooctadiene ligands have been 
displaced by acetonitrile molecules due to the strong trans effect exerted by the N atoms 
of the formamidinato ligands. Compound 14 serves as the starting material for the 
preparation of 15 and 16, as shown in Scheme IV.2. Compound 15 is readily prepared by 
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reacting 14 with two equivalents of 1,10-phenanthroline in acetonitrile. This complex 
exhibits a high solubility in CH3CN but is poorly soluble in H2O. Likewise, compounds 
16 and 17 can be prepared by displacing either two or four eq-CH3CN ligands from 14 
with one or two dppz molecules, respectively. These compounds are also soluble in 
CH3CN, but not very soluble in water. As compared to their acetato counterparts, 
compounds 14-16 are more lipophilic.  
Crystals suitable for X-ray crystallography were grown from a solution of 16 in 
CH3CN in the presence of toluene. The molecular structure of the complex consists of a 
dinuclear Rh2(II,II) core with two formamidato bridging ligands in a cis disposition, a 
chelating dppz ligand coordinated to one Rh atom, and two acetonitrile molecules bound 
to the other rhodium center. The axial positions are occupied by acetonitrile molecules 
(Figure IV.1). The Rh-Rh distance in 16, 2.581(1) Å, is similar to that found for [Rh2(µ-
DTolF)2(bpy)(CH3CN)4](BF4)2 (2.5783(3) Å) (DtolF = N,N'-di-p-tolylformamidinate), 
although slightly shorter than that found for [Rh2(µ-DTolF)2(bpy)(CH3CN)3](BF4)2 
(2.638(3) Å), which contains only one axial ligand. The Rh-Ndppz bonds, 2.032(3) to 
2.043(3) Å, are longer to those found in 6a, (2.005(4) to 2.016(4) Å), and 6b, (1.995(7) 
to 2.018(7) Å), but they are similar to the Rh-Nbpy reported for [Rh2(µ-
DTolF)2(bpy)(CH3CN)4](BF4)2 (2.035(2) Å and 2.051(2) Å). This lengthening is 
attributed to the stronger trans influence of the formamidinato ligand as compared to the 
acetato ligands. Selected crystal parameters for compounds 16 are listed in Table IV.1. A 
summary of selected bond distances and angles for compound 16 is listed in Tables IV.2 
and IV.3, respectively. 
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Figure IV.1. Thermal ellipsoid plot at the 50% probability level of the cation in 16. 
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Table IV.1. Crystal data and structural refinement parameters for compound 16. 
 
Empirical formula  C76.50H68B2F12N12Rh2
Formula weight  1610.87 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
a  11.667(2) Å 
b  13.105(3) Å 
C 25.238(5) Å 
α 78.80(3) ° 
β 84.52(3) ° 
γ 72.52(3) ° 
Volume 3607.5(12) Å3
Z 2 
Density (calculated) 1.483 Mg/m3
Crystal size 0.31 x 0.22 x 0.19 mm3
Theta range for data collection 1.65 to 27.51°. 
Reflections collected 16345 
Independent reflections 11457 [R(int) = 0.0719] 
Data / restraints / parameters 11457 / 34 / 897 
Goodness-of-fit on F2 1.081 
Final R indices [I>2sigma(I)] R1 = 0.0719, wR2 = 0.1653 
R indices (all data) R1 = 0.1106, wR2 = 0.1790 
 
R1 = Σ⎪⎪Fo⎪ - ⎪Fc⎪⎪/Σ⎪Fo⎪; wR2 = [Σ[w(F02-Fc2)2]/Σ[w(F02)2]]1/2
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Table IV.2.   Selected bond distances (Å) for compound 16. 
 
 Bond Distances (Å)
Rh(1)-Rh(2)  2.582(1)
Rh(1)-N(1)  2.026(8)
Rh(1)-N(2)  2.041(7)
Rh(1)-N(5)  2.045(8)
Rh(1)-N(7)  2.049(7)
Rh(1)-N(11) 2.222(9)
Rh(2)-N(9)  2.031(8)
Rh(2)-N(10) 2.025(9)
Rh(2)-N(6)  2.021(8)
Rh(2)-N(8)  2.030(8)
Rh(2)-N(12) 2.171(9)
 
  
 
Table IV.3.   Selected bond angles (°) for compound 16. 
 
 Bond Angles (°)
N(11)-Rh(1)-Rh(2) 174.4(2)
N(12)-Rh(2)-Rh(1) 179.1(2)
N(2)-Rh(2)-Rh(1) 92.7(2)
N(1)-Rh(1)-Rh(2) 90.5(2)
N(5)-Rh(1)-N(7) 88.0(3)
N(1)-Rh(1)-N(7) 94.6(3)
N(1)-Rh(1)-N(2) 80.7(3)
N(6)-Rh(2)-N(8) 90.3(3)
N(9)-Rh(2)-N(10) 90.0(3)
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Effect of substituent on bridging ligands 
 In order to explore the effect of the bridging ligand on the cytotoxicity of the 
dirhodium complexes 2, 4, 8 (which represent the trifluoroacetate analogs of 1, 3, 6, 
respectively) were synthesized (Figure IV.2). Compounds 1-4, 6, and 8 were evaluated 
for their capability to inhibit cell growth in vitro using human skin fibroblasts (Hs-27) 
and the LC50 values (concentration required to kill 50% of the cells) are listed in Table 
IV.4. The LC50 values of the acetate derivatives 1, 3, and 6 were found to be 15 ± 2, 290 
± 15, and 135 ± 8, respectively, and those for the trifluoroacetate analogs 2, 4, and 8 
were 7.7 ± 0.5, 152 ± 7, and 58 ± 3, respectively. The LC50 values for each complex with 
acetate bridging ligands is, in each case, twice the magnitude of that of its 
trifluoroacetate counterpart. Since the charge and the lipophilicity of the other ligands 
within the subsets of dirhodium complexes 1/2, 3/4 and 6/8 are the same, the observed 
differences in the cytotoxicities were investigated with respect to the relative labilities of 
the acetate vs the trifluoroacetate leaving groups. Differences in the reactivity of 
complexes 1 and 2 with short oligonucleotides and double-stranded DNA have already 
been reported and correlated with the different labilities of the two leaving groups, 
CH3CO2
−
 as compared  to CF3CO2
−
.56,57 
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Figure IV.2. Schematic representations of compounds 1 - 4, 6, and 8. 
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Table IV.4. Cytotoxicity (LC50) values for complexes 1-4, 6, and 8. 
Complex LC50 (µM)a
Rh2(µ-O2CCH3)4 1 15 ± 2 
Rh2(µ-O2CCF3)4 2 7.7 ± 0.5 
[Rh2(µ-O2CCH3)2(phen)2]2+ 3 290 ± 15 
[Rh2(µ-O2CCF3)2(phen)2]2+ 4 152 ± 7 
[Rh2(µ-O2CCH3)2(dppz)2]2+ 6 135 ± 8 
[Rh2(µ-O2CCF3)2(dppz)2]2+ 8 58 ± 3 
aHs-27 human skin cells exposed to each compound for 30 min in the dark.  
 
Ligand exchange kinetics 
 The substitution reactions of 1 and 2 with 9-EtGuaH were performed at various 
temperatures between 40 and 75 ºC in order to gain insight into the relative lability of 
acetate and trifluoroacetate bridging ligands in dirhodium complexes. At each 
temperature, the product concentration follows pseudo-first order kinetics according to 
the equation: 
[C] = [Co](1 – e
−kTt)      (Eq. 1) 
where [C] is the product concentration, [Co] is the initial concentration of the reagent, kT 
is the rate of the reaction at a certain temperature T, and t represents reaction time. By 
fitting the experimental data points for 1 and 2 at each temperature T, the rate kT for each 
reaction at a certain temperature T is derived. For example, at 60 ºC, the product formed 
as a function of time and the corresponding fits to Eq. 1 for the reactions of 1 and 2 are 
shown in Figures IV.3 and IV.4, respectively. 
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Figure IV.3. Plot of the % product from the reaction of dirhodium 
tetraacetate with 9-EtGuaH, as a function of time (t) at 60 ºC (k60 (ac) = 
0.082 h-1). 
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Figure IV.4. Plot of the % product from the reaction of dirhodium 
trifluoroacetate with 9-EtGuaH, as a function of time (t) at 60 ºC (k60 (trif) = 
0.356 h-1). 
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Using fits of eq 1 as described above, the rate constant kT was determined for 
each reaction of 1 and 2 conducted at a given temperature T. For each complex, the plots 
of kT against 1/T resulted in a straight line and were subsequently fit to Eq. 2, with a 
slope equal to – Ea/R: 
ln kT   =   ln A   –   Ea(n) / RT      (Eq. 2) 
where Ea(n) is the activation energy of complex n and A represents the pre-exponential 
factor of the reaction. The least squares best fits to eq 2 for the reactions of 1 and 2 with 
9-EtGuaH afford activation energy values of Ea(1) = 69 ± 4 kJ/mol and Ea(2) = 35 ± 2 
kJ/mol, respectively.  
The 2:1 ratio of the acetate vs. the trifluoroacetate activation energies (for the 
systems under investigation) is in accord with the greater lability of the trifluoroacetate 
vs. the acetate group due to the lower basicity of CF3CO2- (pKb 13.5) as compared to 
CH3CO2- (pKb 9.2).178 This 2:1 ratio of the activation  energies for 
acetate/trifluoroacetate compounds 1 and 2 correlates well with the difference in the 
LC50 values of the acetate derivatives 1, 3 and 6 being half as cytotoxic as the 
trifluoroacetate derivatives 2, 4 and 8 (Table IV.4). Since the trifluoroacetate groups are 
substituted by the same nucleophile easier than the acetate ligand, the dirhodium 
compounds 2, 4 and 8 react faster than the acetate analogs 1, 3 and 6 with biomolecules 
within cells, and thus the lability of the leaving groups accounts for the higher toxicity of 
the trifluoroacetate derivatives.  
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It is notable that a relationship exists between the ligand exchange kinetics and 
the in vitro toxicity for other classes of compounds, which bind covalently to DNA.182 
For example, the response toxic level for cisplatin and carboplatin against Sarcoma 180 
cells of 9 and 150 mg/kg, respectively, correlates well with the greater lability of Cl- vs. 
the chelating C6H6O42- group, rendering cisplatin more toxic than carboplatin.183 
Likewise, in a series of diamine platinum(II) compounds, the complexes with chloride or 
oxalate leaving groups are cytotoxic against ovarian cancer cell lines at much lower 
concentrations than their congeners with the 1,1´-cyclobutanedicarboxylato leaving 
groups (for the same carrier ligand).184 The importance of the lability of the ligands has 
also been demonstrated in a series of platinum-amine complexes, in which the aqua 
derivatives of the series are the most toxic as compared to the tetramino complexes 
without labile ligands, which are the least toxic.185 Likewise in the series cis-Pt(NH3)2X2 
with various groups X, it is shown that the Pt-X bond strength has a substantial influence 
on the intrinsic reactivity of the compounds (e.g., complexes with the strongly bound 
isocyanate (-SCN-) and nitrite (-NO2) ligands show no antitumor potential).186 
Additionally, in the series of compounds [PtCI(R´R´´SO)(diam)]NO3 (diam = bidentate 
amine such as 1,2-diaminocyclohexane (dach) or 1,1-bis(aminomethyl)cyclohexane 
(damch) and R´R´´SO substituted sulfoxides such as dimethyl (Me2SO), methyl phenyl 
(MePhSO), methyl benzyl (MeBzSO), diphenyl (Ph2SO), and dibenzyl sulfoxide 
(Bz2SO)), the presence of the more labile Ph2SO sulfoxide group renders the platinum 
compounds more toxic than complexes with other sulfoxide groups.187 
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Effect of accessibility of coordination sites 
 The role of the lability of the equatorial ligands is also nicely demonstrated by 
comparing the cytotoxicities of compounds 5 and 10 (Figure IV.5) with those of 7 and 
12, as well as 6 and 11 (Figure IV.6), respectively (Table IV.5). Complexes 5 and 10 are 
eight and four times more cytotoxic than 7 and 12, respectively, and their toxicities are 
five and seven times greater than those measured for 6 and 11. The greater toxicities of 5 
and 10 relative to the other complexes is attributed to the presence of solvent molecules 
and monodentate acetate groups in the equatorial positions of one rhodium atom. These 
ligands are more labile than the diimine bpy, dppz and dppn ligands occupying the same 
equatorial positions in 6, 11, 7, and 12. The labile solvent molecules and the 
monodentate acetate groups in 5 and 10 provide potential ‘open sites’ accessible for 
nucleophilic substitution, as opposed to these sites being occupied by the chelating N-N 
diimine ligands in 6, 11, 7 and 12, which reduces the reactivity of the latter.43 This is 
supported by the fact that the dirhodium compound cis-[Rh2(µ-O2CCH3)2(η1-
O2CCH3)(bpy)(CH3OH)]+ with an analogous structure to 10, 11 has been shown to react 
with biologically relevant molecules such as 9-EtGuaH.188 In addition, the partially 
solvated complexes [Rh2(µ-O2CCF3)2(CH3CN)4]2+ (13) and [Rh2(DPhFF)2(CH3CN)4]2+ 
(14) are highly toxic, as determined by their low LC50 values (<5 µM), whereas the 
complexes [Rh2(µ-O2CCF3)2(phen)2]2+ (4), [Rh2(µ-O2CCF3)2(dppz)2]2+ (8), [Rh2(µ-
DPhFF)2(phen)2]2+ (15) and [Rh2(µ-DPhFF)2(dppz)2]2+ (17) containing diimine ligands 
instead of the labile acetonitrile molecules are less cytotoxic. Similarly, the higher 
toxicity of 1 as compared  
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Figure IV.5. Schematic representations of compounds 5, 7, and 10 – 12 
(L = CH3OH).  
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 Figure IV.6. Schematic representations of compounds 13 – 17 (L = CH3CN). 
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to 3 and 6 may be attributed to the greater lability of the carboxylate groups as 
compared to the chelating N-N diimine groups (phen and dppz for 3 and 6, 
respectively). A two to three-fold decrease in the cytotoxicity of Rh2(µ-O2CCH3)4 
towards human oral carcinoma KB cell lines has also been observed upon substituting 
two acetate groups with 2,2´-bpy and 1,10-phen.38  
 
Table IV.5. Cytotoxicity (LC50) values for complexes 5, 7, 10-17. 
Complex LC50 (µM)a
[Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppz)(MeOH)]+ 5 27 ± 2 
[Rh2(µ-O2CCH3)2(dppz)(bpy)]2+ 7 208 ± 10 
[Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppn)(MeOH)]+ 10 51 ± 5 
[Rh2(µ-O2CCH3)2(dppn)2]2+ 11 384 ± 24 
[Rh2(µ-O2CCH3)2(dppn)(bpy)]2+ 12 200 ± 20 
[Rh2(µ-O2CCF3)2(CH3CN)4]2+ 13 < 5 
[Rh2(µ-DPhFF)2(CH3CN)4]2+ 14 < 5 
[Rh2(µ-DPhFF)2(phen)2]2+ 15 25 ± 2 
[Rh2(µ-DPhFF)2(CH3CN)2(dppz)]2+ 16 n.a. 
[Rh2(µ-DPhFF)2(dppz)2]2+ 17 79 ± 4 
aHs-27 human skin cells exposed to each compound for 30 min in the dark.  
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Concluding Remarks 
The collective studies presented in this chapter indicate that the toxicity of the 
complexes synthesized is related to the lability of the leaving groups on the dirhodium 
core. The kinetic results for the activation energies for acetate/trifluoroacetate 
compounds 1 and 2 (2:1 ratio) correlate well with the LC50 values of the acetate 
derivatives 1, 3, and 6 being half as cytotoxic as the trifluoroacetate derivatives 2, 4, and 
8 and underscore the importance of the ligand lability/in vitro toxicity relationship. 
Additional evidence of the effect of the ligand lability and the accessibility of the 
equatorial sites of these dirhodium molecules is provided by comparing the toxicities of 
compounds 5 and 10 with those of 7 and 12, respectively. The labile solvent molecules 
and the monodentate acetate groups in 5 and 10 easily provide potential “open sites” 
accessible for nucleophilic substitution, as opposed to these sites being occupied by non-
labile groups that reduce the reactivity of the complexes. Further examples of this effect 
are found in the toxicity of compounds 13 and 14, which are several times more toxic 
than their analogues containing diimine ligands instead of acetonitrile molecules that can 
be easily displaced. Thus, the labile equatorial groups play a critical role in the toxicity 
of these complexes in vitro, which is expected to be related to the antitumor activity of 
similar dirhodium compounds. Careful tailoring of groups surrounding the dirhodium 
core in these complexes is expected to lead to more effective and less toxic drugs. 
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CHAPTER V 
GENERATION OF NEW DIRHODIUM(II,II) DPPZ COMPLEXES  
Introduction 
  Given the research outlined in the previous chapters, we considered a next 
logical step to be the synthesis and study of other sub-families of complexes in which 
the acetato ligands are replaced by other bridging ligands; in particular we are 
interested in those that are less labile than acetate since they might show a lower 
cytotoxicity. Unfortunately, the chemistry of dirhodium complexes containing 
diimine ligands with bridging ligands other than acetate is not well developed.189 
Only one example of substitution reactions of the tetrakis-
trifluoroacetamidodirhodium complexhas been reported and there are no examples 
of such chemistry for the acetamido derivative.189 A plausible reason for this situation 
is the fact that the acetamidato and trifluoroacetamidato ligands are much less easily 
substituted than their acetato counteparts. One way to overcome this problem is to 
use a starting material containing two diimine ligands already bound to the dimetal 
core and then replace the existing bridging groups by the desired ligands. 
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  In his search for a high yield synthesis of Rh24+(aq), Taube and co-workers 
developed a procedure for the synthesis of [Rh2(CO3)4]4-.190 Although they were 
never able to use this complex for its initial purpose, namely the synthesis of the 
fully hydrated Rh24+ complex, the compound later proved to be a convenient starting 
material for the synthesis of other Rh2(II,II) carboxylates.191 Roos et al., have 
demonstrated that the carbonato bridged complex readily reacts with various 
carboxylic acids to produce tetracarboxylate species in high yields.191 
  In this chapter, the syntheses of dirhodium diimine complexes containing 
carbonato bridging ligands, which can be used to prepare trifluoroamidato, 
pyrrolidinonato  and trifluoroacetato bridged Rh2(II,II)-dppz complexes is described.  
 
Experimental Section 
Materials 
All reactions were carried out under nitrogen using standard Schlenk-line 
techniques. The reagents RhCl3, 1,10-phenanthroline, 2-pyrrolidinone, sodium acetate, 
sodium chloride, NaBF4 and Na2CO3 were purchased from Aldrich and used without 
further purification. The compounds Rh2(µ-O2CCH3)4 (1),105 [Rh2(µ-
O2CCH3)2(phen)2](O2CCH3)2 (3),44 [Rh2(µ-O2CCH3)2(dppz)2](O2CCH3)2 (6), and dppz  
were synthesized by previously reported methods.106 
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Synthesis of cis-Rh2(µ-O2CO)2(phen)2(H2O)2  (18) 
  A red slurry of [Rh2(µ-O2CCH3)2(phen)2][O2CCH3]2 (0.103 g, 0.13 mmol) in 
H2O (25 ml) was added to a 1.0 M solution (30 ml) of Na2CO3 in H2O and the 
mixture refluxed for 1 h under N2(g), during which time the red slurry changed to a 
brown solution. The solution was concentrated to 7 ml and acetone was added (10 
mL). The product was recovered by filtration and recrystallized from a H2O/acetone 
(1/1) solution. Yield: 76.1 mg (81%). ESI-MS: m/z 686.9 ([Rh2(µ-O2CO)2(phen)2] + 
H+). Anal. Calc. for Rh2C26N4O10H24 (Rh2(µ-O2CO)2(phen)2(H2O)2·2H2O): C, 41.18; 
H, 3.19; N, 7.39. Found: C, 40.99; H, 3.34; N, 7.34 %. 1H NMR (300 MHz) in 
CD3OD, δ / ppm (mult., int.):  8.65 (d, 4H), 8.13 (dd, 4H), 7.62 (s, 4H), 7.54 (dd, 
4H). 
Synthesis of cis-Rh2(µ-HNCOCF3)2(phen)2(Cl)2 (19) 
  A brown solution of [Rh2(µ-O2CO)2(phen)2(H2O)2 (0.103 g, 0.14 mmol)  in 
H2O/CH3OH (3/7, 60 ml), was heated with trifluoroacetamide (0.130 g, 1.15 mmol) 
under nitrogen. It was stirred for 15 minutes, and 0.1 M HCl (2.8 ml) was added 
dropwise. The mixture was refluxed for 24 h, after which time the solution was 
concentrated to ~20 mL and the dark red product recovered by vacuum filtration and 
recrystallized from methanol. Yield: 89.2 mg (74%). Anal. Calc. for 
Rh2C28N6O2H18F6Cl2: C, 39.05; H, 2.11; N, 9.76. Found: C, 39.27; H, 2.43; N, 9.51 
%. 1H NMR (300 MHz) in CD3OD, δ / ppm (mult., int.):  8.78 (d, 2H), 8.65 (d, 2H), 
8.45 (m, 4H), 7.96 (s, 2H), 7.88 (s, 2H), 7.74 (m, 4H), 6.57 (br, 2H). 
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Synthesis of cis-Rh2(µ-O2CO)2(dppz)2(H2O)2 (20) 
  A red slurry of [Rh2(µ-O2CCH3)2(dppz)2][O2CCH3]2 (0.163 g, 0.16 mmol) in 
100 mL of H2O/CH3OH (4/1) was added to a 1 M solution (35 ml) of Na2CO3 in H2O 
and the mixture refluxed under nitrogen for 1 h, during which time the color of the 
reaction mixture changed from red to brown. The volume was reduced to c.a. 30 mL 
and the product was recovered by filtration as a brown powder. The compound was 
recrystallized from a H2O/MeOH (1/2) solution. Yield: 108.2 mg (73%). ESI-MS: 
m/z 891.0 ([Rh2(µ-O2CO)2(dppz)2] + H+). Anal. Calc. for Rh2(µ-
O2CO)2(dppz)2(H2O)2·2.5H2O: C, 46.98; H, 3.01; N, 11.53. Found: C, 47.04; H, 2.79; 
N, 11.71 %. 1H NMR (300 MHz) in CD3OD, δ / ppm (mult., int.): 8.15 (m, 4H), 8.41 
(m, 4H), 8.65 (m, 4H), 9.24 (d, 4H), 9.95 (d, 4H). 
Synthesis of cis-Rh2(µ-HNCOCF3)2(dppz)2(Cl)2 (21) 
  A brown solution of [Rh2(µ-O2CO)2(dppz)2(H2O)2 (0.083 g, 0.09 mmol)  in 
H2O/CH3OH (3/7, 60 ml) was reacted with trifluoroacetamide (0.085 g, 0.75 mmol) 
under nitrogen and stirred for 15 minutes, after which time 0.1 M HCl (1.8 mL) was 
added dropwise. The mixture was refluxed for 24 h, the solution was concentrated to 
~20 mL and the red product was collected by filtration and finally recrystallized from 
methanol. Yield: 74.8 mg (78%). Anal. Calc. for [Rh2(µ-HNCOCF3)2(dppz)2(Cl)2]: 
C, 45.09; H, 2.08; N, 13.15. Found: C, 44.94; H, 2.11; N, 13.10 %. 1H NMR (300 
MHz) in CD3OD, δ / ppm (mult., int.): 9.13 (d, 2H), 9.06 (d, 2H), 8.90 (m, 4H), 8.55 
(m, 4H), 8.28 (m, 4H), 8.14 (m, 4H), 6.65 (br, 2H). 
 
 139
Synthesis of cis-Rh2(pyro)2(dppz)2(Cl)2 (22) 
  A brown solution of Rh2(µ-O2CO)2(dppz)2(H2O)2 (82.2 mg, 0.09 mmol) in 
H2O/CH3OH (3/7, 60 mL), was reacted with 2-pyrrolidinone (62.1 mg, 0.72 mmol), 
and the reaction mixture was stirred for 15 minutes, followed by the dropwise 
addition of 0.1 M HCl (1.8 mL). The mixture was refluxed under nitrogen for 36 h, 
after which the solution was concentrated to ~40 mL and the red product was 
collected by filtration. Yield: 49.1 mg (54%). 1H NMR (300 MHz) in CDCl3/CD3OD 
(1:1 v:v), δ / ppm (mult., int., assignment):  2.68 (m, 4H, pyrro), 2.75 (t, 4H, pyrro), 
4.21 (t, 4H, pyrro), 7.24 (m, 4H, dppz), 8.77 (d, 2H, dppz), 9.02 (d, 2H, dppz), 9.25 
(t, 2H, dppz), 8.41 (m, 4H, dppz), 9.72 (t, 2H, dppz), 9.99 (m, 4H, dppz). 
Synthesis of cis-[Rh2(µ-O2CCF3)2(phen)2](O2CCF3)2 (4) 
  Rh2(µ-O2CO)2(phen)2(H2O)2 (0.075 g, 0.11 mmol)  was treated with 
trifluoroacetic acid (10 mL) and the mixture stirred at r.t. under nitrogen for 15 
minutes. The solvent was evaporated under vacuum and the product dissolved in 
acetonitrile. The red microcrystalline product was recovered after the addition of 
hexanes. Yield: 101.9 mg (91%). 1H NMR (300 MHz) in CD3OD, δ / ppm (mult., 
int.): 8.29 (d, 4H), 8.06 (dd, 4H), 7.44 (s, 4H), 7.32 (dd, 4H). 
Synthesis of cis-[Rh2(µ-O2CCF3)2(dppz)2](O2CCF3)2 (8) 
  Rh2(µ-O2CO)2(dppz)2(H2O)2 (118.3 mg, 0.14 mmol)  was treated with 
trifluoroacetic acid (15 mL) and the mixture was stirred at r.t. under nitrogen for 15 
minutes. The solvent was evaporated under vacuum and the product was dissolved in 
acetonitrile. A red microcrystalline product was recovered after the addition of 
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hexanes. Yield: 159.2 mg (93%). 1H NMR (300 MHz) in CD3OD, δ / ppm (mult., 
int.): 9.35 (m, 4H), 8.95 (m, 4H), 8.45 (m, 4H), 8.25 (d, 4H), 8.10 (d, 4H). 
Methods 
X-ray Crystallographic Studies 
X-ray Structural Study of cis-Rh2(µ-HNCOCF3)2(phen)2(Cl)2 (19).  For the X-
ray crystallographic analysis, a red prismatic crystal of 19 (approximate dimensions:  
0.24 x 0.22 x 0.18 mm3) was selected. The crystal was grown from a solution of 19 in 
CH3CN/CH3OH layered with diethyl ether. The crystal was coated with Paratone oil, 
transferred to a nylon loop, and placed in a cold N2 stream at 110(2) K.  An indexing of 
the preliminary diffraction patterns indicated that the crystal was monoclinic. A total of 
12,871 reflections were collected in the range 1.82 ≤ θ  ≤ 28.29°. The data collection 
covered approximately a hemisphere of reciprocal space, by a combination of three sets 
of exposures; each set had a different φ  angle for the crystal and each exposure covered 
0.3º in Ω.  Crystal decay, which was monitored by analyzing duplicate reflections, was 
found to be less than 1%, therefore, no decay correction was applied.  During the final 
cycles of refinement, all atoms with the exception of hydrogen were refined 
anisotropically. The structure of 19 was solved and refined in the space group C 1 2/c1.  
X-ray Structural Study of cis-Rh2(pyro)2(dppz)2(Cl)2 (22).  For the X-ray 
crystallographic analysis, a red plate crystal of 22 (approximate dimensions:  0.20 x 0.15 
x 0.08 mm3) was selected.  The crystal was grown from a solution of 19 in 
CH3CN/benzene layered with diethyl ether in the presence of NaBF4. The crystal was 
coated with Paratone oil, transferred to a nylon loop, and placed in a cold N2 stream at 
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110(2) K.  An indexing of the preliminary diffraction patterns indicated that the crystal 
was monoclinic. A total of 18,539 reflections were collected in the range 1.50 ≤ θ  ≤ 
23.32°.  Hydrogen atoms belonging to methylene groups were placed in regions of 
maximum electron density around the methylene C atoms. The structure was solved and 
refined in the space group P-1. The final refinement cycle was based on 18,539 unique 
reflections (6,247 with Fσ2 > 2σ( Fσ2)), 588 parameters, and 0 restraints (R1 = 0.0561, 
wR2 = 0.1362).  The maximum and minimum peaks in the final difference Fourier map 
corresponded to 2.712 and –0.813 e/Å3, respectively, with a goodness-of-fit value of 
1.038. 
X-ray Structural Study of cis-[Rh2(µ-O2CCF3)2(dppz)2](O2CCF3)2 (8).  For the 
X-ray crystallographic analysis, a red block crystal of 8 (approximate dimensions:  0.34 
x 0.23 x 0.14 mm3) was selected.  The crystal was coated with Paratone oil, transferred 
to a nylon loop, and placed in a cold N2 stream at 110(2) K.  An indexing of the 
preliminary diffraction patterns indicated that the crystal was monoclinic. A total of 
39,468 reflections were collected in the range 1.78 ≤ θ  ≤ 27.61°.  The structure was 
solved and refined in the space group P-1. The final refinement cycle was based on 
10,042 unique reflections (5,151 with Fσ2 > 2σ( Fσ2)), 684 parameters, and 24 
restraints (R1 = 0.0871, wR2 = 0.2040).  The maximum and minimum peaks in the final 
difference Fourier map corresponded to 0.993 and –1.017 e/Å3, respectively, with a 
goodness-of-fit value of 1.017. 
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Instrumentation 
The 1H NMR spectra of the complexes were recorded on a Unity-300 NMR 
spectrometer.  Absorption measurements were performed on a Schimadzu UVPC-3001 
spectrophotometer. X-ray diffraction data were collected on a Bruker APEX CCD 
diffractometer with graphite monochromated Mo-Kα radiation (λ = 0.71073 Å).  The 
frames were integrated with the Bruker SAINT software,110 and a semi-empirical 
absorption correction using multiple-measured reflections was applied using 
SADABS.111 The structures were solved and refined using X-SEED,112 a graphical 
interface to SHELX97.113
Results and Discussion 
Synthesis 
The synthetic routes for the newly synthesized dirhodium(II,II) complexes 8, and 
18-22 are outlined (Schemes V.1 and V.2). When [Rh2(µ-O2CCH3)2(phen)2][O2CCH3]2 
in distilled water is added to an aqueous solution of Na2CO3 and refluxed for 1 h, the 
complex Rh2(µ-O2CO)2(phen)2(H2O)2 (18) is formed. Compound 18 is soluble in H2O 
and CH3OH, sparingly soluble in CH3CN and C2H5OH and insoluble in CHCl3 and 
CH2Cl2. The ESI mass spectrum of 18 exhibits a parent ion peak, [Rh2(µ-
O2CO)2(phen)2] + H+ , at m/z =  687.3, and the 1H-NMR (300 MHz) spectrum in 
CD3OD shows resonances at δ / ppm (mult., int.) 8.65 (dd, 4H), 8.13 (dd, 4H), 7.62 (s, 
4H), 7.54 (dd, 4H) with no features in the aliphatic region. The observed 1H-NMR 
aromatic peaks resemble that of the parent dirhodium complex containing two 
phenanthroline ligands, although they are shifted downfield by ~1 ppm. 
 143
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Scheme V.1. Synthetic routes for the syntheses of compounds 4, 18, and 19
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Scheme V.2. Synthetic routes for the syntheses of compounds 8, 20 - 22.  
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  In the case of [Rh2(µ-O2CCH3)2(dppz)2][O2CCH3]2, the reaction with 
Na2CO3(aq) under conditions used for the bis-phenanthroline analogue produces the 
expected complex in low yields,  a result that is most likely due to the low solubility 
of the starting material in H2O. The addition of methanol to the reaction mixture 
increases the yield of Rh2(µ-O2CO)2(dppz)2(H2O)2 (20) to 73%. The 1H NMR (300 
MHz) spectrum in CD3OD contains resonances peaks at δ / ppm (mult., int.) 9.95 (d, 
4H), 9.24 (d, 4H), 8.65 (m, 4H), 8.41 (m, 4H), and 8.15 (m, 4H). The spectrum is 
very similar to that of  [Rh2(µ-O2CCH3)2(dppz)2][O2CCH3]2 (6), with the difference 
being that in the case of 20 the resonances appear at lower fields. These results 
indicate that the structure of 20 must be similar to that of 6, and that the dirhodium 
core remains intact in the product. 
  The presence of two carbonato ligands bound to the bis-diimine dirhodium 
unit offers the possibility of facile access to other similar complexes. Roos et al., 
have shown that the tetracarbonato complex quickly reacts within 20-40 minutes with 
8 equivalents of the desired carboxylic acid in water at 80-90° C.191 Based on this 
information, a reasonable course of action is to react the bis-carbonato bis-diimine 
dirhodium species with an excess of acetamido ligand. 
  Reactions of Rh2(µ-O2CO)2(phen)2(H2O)2 (18) with an excess of 
trifluoroacetamide (8 eq.) in a H2O/MeOH (3/7) mixture under nitrogen produces the 
amidato derivative Rh2(µ-HNCOCF3)2(phen)2(Cl)2 (19) in a good yield. During the 
reaction, an intensely colored blue product is formed in both cases. Attempts to 
isolate this compound proved to be unsuccessful since, upon cooling, the reactions 
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turn red and 19 is the only product recovered. This color has been previously 
observed in reactions involving the preparation of related bis-diimine dirhodium 
derivatives in the presence of methanol and it has been determined that is due to the 
formation of reduced Rh2(I,II) species that form chains in the solid state.156-158 
  Similarly, 20 was treated with trifluoroacetamide to produce Rh2(µ-
HNCOCF3)2(dppz)2(Cl)2 (21) in good yield (78%). As mentioned above, a blue color 
appears during the reaction that turns red-brown when the reaction is exposed to air 
or when the solution is cooled. When 20 is treated with 2-pyrrolidinone in 
water/methanol (3/7), the compound Rh2(pyro)2(dppz)2(Cl)2, (22), is recovered in 
moderate yield (54%).     
  It is possible to convert the carbonato ligands into better leaving groups by 
protonation. By treating both 18 and 20 with neat trifluoroacetic acid, it is possible to 
isolate [Rh2(µ-O2CCF3)2(phen)2](O2CCF3)2 (4), and [Rh2(µ-
O2CCF3)2(dppz)2](O2CCF3)2 (8). The reaction proceeds to near completion at room 
temperature and the red products are obtained in approximately 15 minutes.  
 
 
 
 
 
 
 
 147
X-Ray crystallography  
  The molecular structure of 19, as revealed by X-ray crystallography, consists 
of a central Rh2 core coordinated to two trifluoroamidato ligands in a cis disposition 
and two chelating phen molecules in the remaining equatorial positions. The rhodium 
atoms are further coordinated to two chloride anions at the axial sites. The structure 
of 19 is shown in Figure V.1. The Rh-Rh distance of 2.614(1) Å is comparable to the 
analogous distance obtained for the closely related compound Rh2(µ-
HNCOCF3)2(phen)2(C5H5N)2, 2.612(1) Å,189 but longer than the Rh-Rh distances in 
acetato counterparts.44 The Rh-Cl bonds deviate slightly from the axis formed by the 
rhodium-rhodium bond at an angle of 172.2°.   
  The bonds to the oxygen atoms of the bridging amidato ligands are longer 
than those to the nitrogen atoms (2.059(4) and 2.024(4) Å respectively). The lengths 
of the Rh-Nphen bonds are affected by the different trans influence of the nitrogen and 
oxygen atoms on the bridging ligands; those trans to oxygen have a mean distance of 
2.003(4) Å, while those trans to nitrogen are at an average distance of 2.031(4) Å. 
These distances are shorter than the those reported for the related complex Rh2(µ-
HNCOCF3)2(phen)2(C5H5N)2 (Rh-Nphen trans to O, 2.020(6); Rh-Nphen trans to NH, 
2.040(5) Å).186 The two phen moieties are found in a staggered arrangement about the 
Rh-Rh bond with a torsion angle of 13.8°, similar to the one observed for the 
aforementioned di-cation which exhibits an angle of  15.8°.189   Selected crystal crystal 
parameters, bond distances and angles for compound 19 are listed in Tables V.1, V.2, 
and V.3. 
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 Figure V.1. Thermal ellipsoid plot at the 50% probability level of compound 19. 
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  The structure of Rh2(pyro)2(dppz)2(Cl)2 (22), is shown in Figure V.2. The 
molecular structure consists of a dinuclear Rh2(II,II) core with two chelating dppz 
ligands coordinated to each Rh atom, and two bridging pyrrolidinonato ligands 
occupying the remaining equatorial sites. The complex exhibits a head-to-tail 
arrangement of the bridging ligands, similar to that observed for compound 19. The 
octahedral coordination around the rhodium atoms is completed by a pair of Cl- ions 
bound to the axial positions. The Rh-Rh bond distance is 2.612(12) Å, which is 
longer than the Rh-Rh bond observed for the Rh2(pyro)4(Hpyro)2 complex (2.445(1) 
Å).192 This increase in the metal-metal bond distance may be related to the presence 
of the Cl- ligands in the axial positions which are known to cause such an increase, 
the ocurrence of the two dppz ligands that push the two rhodium atoms further apart 
in order to avoid repulsive π interactions, or more likely a combination of both 
factors.189,193 The Rh-Cl interactions are slightly off the axis formed by the two metal 
atoms and form angles of 175.93(5)° and 176.05(6)° with the dirhodium axis, 
respectively. Selected crystal parameters, bond distances and angles for compound 
19 are listed in Tables V.4, V.5, and V.6. 
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Table V.1. Crystal data and structural refinement parameters for compound 19. 
 
Empirical formula  C28H18Cl2F6N6O2Rh2
Formula weight  861.20 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21 
a  19.310(4) Å 
b  14.880(3) Å 
C 14.690(3) Å 
α 90° 
β 118.00(3)° 
γ 90° 
Volume 3726.8(13) Å3
Z 4 
Density (calculated) 1.535 Mg/m3
Crystal size 0.24 x 0.22 x 0.18 mm3
Theta range for data collection 1.82 to 28.29°. 
Reflections collected 12871 
Independent reflections 4302 [R(int) = 0.0500] 
Data / restraints / parameters 4302 / 208 / 0 
Goodness-of-fit on F2 0.927 
Final R indices [I>2sigma(I)] R1 = 0.0647, wR2 = 0.1496 
R indices (all data) R1 = 0.0983, wR2 = 0.1634 
 
R1 = Σ⎪⎪Fo⎪ - ⎪Fc⎪⎪/Σ⎪Fo⎪; wR2 = [Σ[w(F02-Fc2)2]/Σ[w(F02)2]]1/2
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Table V.2.   Selected bond distances (Å) for  compound 19. 
 
 Bond Distances (Å)
Rh(1)-Rh(2)  2.614(1)
Rh(1)-N(1)  2.031(4)
Rh(1)-N(2)  2.003(4)
Rh(1)-N(3)  2.024(4)
Rh(1)-O(1)  2.058(4)
Rh(1)-Cl(1)  2.540(2)
 
 
  
 
Table V.3.   Selected bond angles (°) for  compound 19. 
 
 Bond Angles (°)
N(1)-Rh(1)-N(2) 82.1(2)
N(2)-Rh(1)-N(3) 94.9(2)
N(3)-Rh(1)-O(1) 90.9(2)
O(1)-Rh(1)-N(1) 92.1(2)
Cl(1)-Rh(1)-Rh(1a) 172.24(4)
N(1)-Rh(1)-Cl(1) 88.4(1)
N(2)-Rh(1)-Cl(1) 91.1(1)
N(3)-Rh(1)-Cl(1) 90.5(1)
O(1)-Rh(1)-Cl(1) 88.9(1)
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Figure V.2. Thermal ellipsoid plot at the 50% probability level of compound 22. 
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Table V.4. Crystal data and structural refinement parameters for compound 22. 
 
Empirical formula  C47H38Cl2N11O3Rh2
Formula weight  1081.60 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
a  12.45(3) Å 
b  13.16(6) Å 
C 14.32(6) Å 
α 98.2(1)° 
β 105.0(1)° 
γ 100.1(1)° 
Volume 2186(15) Å3
Z 2 
Density (calculated) 1.643 Mg/m3
Crystal size 0.20 x 0.15 x 0.08 mm3
Theta range for data collection 1.50 to 23.32°. 
Reflections collected 18539 
Independent reflections 6247 [R(int) = 0.0500] 
Data / restraints / parameters 6247 / 588 / 0 
Goodness-of-fit on F2 1.038 
Final R indices [I>2sigma(I)] R1 = 0.0561, wR2 = 0.1362 
R indices (all data) R1 = 0.0778, wR2 = 0.1480 
 
R1 = Σ⎪⎪Fo⎪ - ⎪Fc⎪⎪/Σ⎪Fo⎪; wR2 = [Σ[w(F02-Fc2)2]/Σ[w(F02)2]]1/2
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Table V.5.   Selected bond distances (Å) for  compound 22. 
 
 Bond Distances (Å)
Rh(1)-Rh(2)  2.612(12)
Rh(1)-N(2)  2.027(10)
Rh(1)-O(1)  2.059(7)
Rh(1)-N(7)  2.032(9)
Rh(1)-N(8)  2.001(7)
Rh(1)-Cl(1)  2.557(12)
Rh(2)-N(1)  2.023(8)
Rh(2)-O(2)  2.056(10)
Rh(2)-N(3)  1.995(10)
Rh(2)-N(4)  2.044(8)
Rh(2)-Cl(2)  2.561(12)
 
 
  
 
Table V.6.   Selected bond angles (°) for  compound 22. 
 
 Bond Angles (°)
O(1)-Rh(1)-N(2) 88.0(3)
N(2)-Rh(1)-N(8) 94.4(3)
N(8)-Rh(1)-N(7) 80.9(3)
Cl(1)-Rh(1)-N(8) 88.8(2)
O(2)-Rh(2)-N(1) 86.9(2)
N(1)-Rh(2)-N(3) 95.0(3)
N(3)-Rh(2)-N(4) 80.8(2)
Cl(2)-Rh(2)-N(3) 89.8(2)
Rh(1)-Rh(2)-Cl(2) 176.06(6)
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  The molecular structure of 8, determined by X-ray crystallographic methods, 
consists of a dinuclear Rh2(II,II) core with a chelating dppz ligands coordinated to 
each Rh atom in a syn disposition, and two bridging trifluoroacetato groups 
occupying the remaining equatorial sites.  A trifluoroacetate ligand and a CH3CN 
group coordinated at the axial positions completes an irregular octahedral 
coordination sphere about each Rh atom. The structure of 8 is shown in Figure V.3. 
The Rh-Rh distance in 8, 2.567(1) Å, is comparable to the one reported for 
[Rh2(O2CCF3)2(bpy)2]2+, 2.570(6) Å. When compared to the analogous bis-acetato 
complex, a lengthening of the metal-metal bond (2.5519(6) Å) is observed, a 
situation that also occurs with other acetate-trifluoroacetate pairs. The lengths of the 
Rh-Oeq bonds in 8, which range from 2.056(6) to 2.063(6) Å, are also longer than the 
analogous acetato complex (2.009(4)-2.051(3) Å). The Rh-Ndppz bonds, 1.988(7) to 
2.011(7) Å, are shorter (2.005(4) to 2.016(4) Å). The internal twist angle from the 
eclipsed geometry of 10.6° in 8 is smaller than that observed for the bis-acetate 
analogue (13°). Selected crystal parameters, bond distances and angles for compound 
19 are listed in Tables V.7, V.8, and V.9. 
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 Figure V.3. Thermal ellipsoid plot at the 50% probability level of compound 8.  
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Table V.7. Crystal data and structural refinement parameters for compound 8. 
 
Empirical formula  C47H26BF13N9O6Rh2
Formula weight  1276.40 
Temperature  100(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
a  51.678(10) Å 
b  11.735(2)Å 
C 15.943(3) Å 
α 90.00 ° 
β 106.32(3)° 
γ 90.00° 
Volume 9279(3) Å3
Z 8 
Density (calculated) 1.827 Mg/m3
Crystal size 0.34 x 0.23 x 0.14 mm3
Theta range for data collection 1.78 to 27.61°. 
Reflections collected 39468 
Independent reflections 10042 [R(int) = 0.0500] 
Data / restraints / parameters 10042 / 684 / 28 
Goodness-of-fit on F2 1.017 
Final R indices [I>2sigma(I)] R1 = 0.0871, wR2 = 0.2040 
R indices (all data) R1 = 0.1710, wR2 = 0.2534 
 
R1 = Σ⎪⎪Fo⎪ - ⎪Fc⎪⎪/Σ⎪Fo⎪; wR2 = [Σ[w(F02-Fc2)2]/Σ[w(F02)2]]1/2
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Table V.8.   Selected bond distances (Å) for  compound 8. 
 
 Bond Distances (Å)
Rh(1)-Rh(2)  2.567(1)
Rh(1)-N(1a)  2.006(7)
Rh(1)-N(2a)  1.988(7)
Rh(1)-O(4)  2.058(5)
Rh(1)-O(6)  2.063(6)
Rh(1)-O(1)  2.249(5)
Rh(2)-N(1b)  2.011(7)
Rh(2)-N(2b)  2.008(7)
Rh(2)-O(3)  2.056(6)
Rh(2)-O(5)  2.063(6)
Rh(2)-N(1)  2.279(7)
 
 
  
 
Table V.9.   Selected bond angles (°) for  compound 8. 
 
 Bond Angles (°)
Rh(1)-Rh(2)-N(1) 176.6(2)
Rh(2)-Rh(1)-O(1) 170.1(2)
O(6)-Rh(1)-O(4) 87.3(2)
O(6)-Rh(1)-N(1a) 94.5(3)
O(4)-Rh(1)-N(2a) 96.4(3)
O(5)-Rh(2)-O(3) 87.8(2)
O(5)-Rh(2)-N(1b) 96.0(3)
O(3)-Rh(2)-N(2b) 94.3(3)
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Concluding Remarks 
The results of this study demonstrate that the carbonato-bridged complexes of the 
Rh2(µ-O2CO)2(diimine)2(H2O)2-type are useful precursors for the preparation of 
dirhodium-diimine compounds. The reactions of Rh2(µ-O2CO)2(diimine)2(H2O)2 
(diimine = dppz, phen) with trifluoroacetamide, 2-pyrrolidinone, and trifluoroacetic acid 
lead to products in which the carbonato ligands have been displaced from the dirhodium 
core. The compounds described in this chapter lay the synthetic groundwork for a new 
series of dirhodium complexes that contain the interesting dppz ligand and bridging 
ligands other than acetate. 
 160
CHAPTER VI 
CONCLUSIONS  
The discovery of new molecules for the treatment of diseases is obviously of 
tantamount importance in the field of medicinal chemistry. Once the activity of a 
particular compound is noted, however, it is also important to understand the 
structure/activity relationship of the new molecules, so they can be modified to obtain 
molecules with improved pharmacological properties as compared to the parent 
compound(s). In this dissertation, a new family of dirhodium complexes containing the 
electron acceptor ligand dipyrido[3,2-a:2´,3´-c]phenazine (dppz) was reported along 
with their chemical, physical and biological properties. Of particular interest is the 
understanding of the relationship between the reactivity of the metal complexes and their 
cytotoxicity in the dark as well as after irradiation.  
In Chapter II, the synthesis and characterization of the new dirhodium complexes 
cis-[Rh2(µ-O2CCH3)2(η1-O2CCH3)(dppz)(MeOH)]+ (5), [Rh2(µ-O2CCH3)2(dppz)2]2+  
(6), [Rh2(µ-O2CCH3)2(dppz)(bpy)]2+ (7), and  [Rh2(µ-O2CCF3)2(dppz)2]2+ (8) was 
reported. All of these complexes photocleave pUC18 plasmid DNA in vitro under 
irradiation with visible light, resulting in the nicked, circular form. A comparison of the 
phοtotocleavage properties of ds-DNA of 5 and 6 revealed that 5 is more reactive, a fact 
that is attributed to the intercalative ability of the former compound. The presence of the 
dppz ligand is important for the photocleavage activity of these complexes, since other 
dirhodium caraboxylate compounds that do not contain this ligand are not able to cleave 
DNA after irradiation. 
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The toxicity of dirhodium dppz complexes ligand towards human skin cells 
increases when the cell cultures are irradiated with visible light. In contrast, the 
photocytotoxicity of those complexes that do not contain the dppz ligand do not differ 
from their cytotoxicity properties in the dark. The mono-substituted compound, 5, does 
not significantly increase its cytotoxicity upon irradiation., whereas greater differences 
were observed for compounds 6, 7 and 8 which increase their cytotoxicity from two to 
five times when irradiated with visible light. In particular, compound 7 shows an 
increase in its cytotoxicity upon irradiation similar to that of the clinically used 
photodynamic therapy drug hematoporphyrin. 
An interesting fact encountered in these studies is that dirhodium complexes 
containing the dppz ligand can photocleave DNA in the absence of oxygen as well as in 
the presence of oxygen. Although less photocleavage is observed under anaerobic 
conditions, it is apparent that there are two pathways that are operative. It is plausible 
that the role of molecular oxygen in the reactivity of these molecules is the reoxidation 
of the dirhodium-dppz molecules, thereby rendering the photocleavage of DNA 
catalytic. As reported in Chapter III, compounds 6 and 7 are reduced in the presence of 
ethanol to form a blue compound which reverts to the original complex upon exposure to 
air. If one considers the photocleavage mechanism proposed by Turro et al.,194 for 
dirhodium tetraacetate in the presence of an external electron acceptor (Figure VI.1), it is 
obvious that if a similar mechanism is invoked for the dirhodium-dppz complexes, the 
cycle cannot be closed without the assistance of an oxidizing agent (Figure VI.2). From  
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Figure VI.1. Proposed mechanism for the photocatalytic generation of 
hydroxyl radical from dirhodium tetraacetate (ref. 194). 
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Figure VI.2. Proposed mechanism for the photocatalytic generation of 
hydroxyl radical from a dirhodium-dppz complex. 
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the reactions of these complexes with ethanol it can be concluded that oxygen will lead 
to the re-oxidation of species V into I (Figure VI.2). 
The work described in Chapter III describes reactivity studies of dirhodium-dppz 
complexes with glutathione, an important molecule in the deactivation of metal-based 
drugs due to its high concentration (millimolar) in the cellular milieu.  Compounds 6 and 
7 are reacte with glutathione to produce a blue compound that is reminiscent of the blue 
color obtained in the reduction reactions with alcohols. The product formed in the 
reaction with glutathione also reoxidizes to the original complex. An EPR spectrum of 
the product formed in the reaction of complex 7 with glutathione consists of a broad 
isotropic signal similar to the spectra obtained for one-electron reduced dirhodium 
complexes containing polypyridyl ligands, where the added electron is found delocalized 
on the aromatic ligands.  DFT calculations indicate that the LUMO and LUMO + 1 
orbitals in compound 7 are ligand-based π* orbitals, a fact that corroborates the 
conclusion that the extra electron is located on the ligands as in the case of the 
aforementioned dirhodium complexes. 
In addition, Chapter III also reports results from single-cell electrophoresis 
experiments of cells treated with compound 7. As depicted in Figure III.6a, in the 
absence of light, 7 does not damage nuclear DNA. If the cell culture containing 7 is 
irradiated, however, a comet tail appears which accounts for cellular DNA damage 
(Figure III.6b). Hematoporphyrin, the key ingredient of Photofrin®, does not damage 
DNA, as observed previously in a similar experiment. This implies that, despite the 
abundance of other reactive compounds in the cell, compound 7 (or the species 
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generated after activation), is capable of reaching the cellular nucleus and causes damage 
to nuclear DNA.  
Chapter IV discusses the molecular characteristics that affect the in vitro activity 
of dirhodium complexes. It was observed that the lability of the groups coordinated to 
the dirhodium complexes is a significant factor that influences the toxicity of the 
complexes. In the case of acetate and trifluoroacetate derivatives, the reactivity ratios for 
ligand displacement in compounds 1 and 2 (2:1 ratio) correlate well with the LC50 values 
of the acetate derivatives with 1, 3, and 6 being half as cytotoxic as the trifluoroacetate 
derivatives 2, 4, and 8. In addition, the presence of labile solvent molecules and the 
monodentate acetate groups in 5, 10, 13 and 14 provide potential “open sites” accessible 
for nucleophilic substitution, as opposed to these sites being occupied by non-labile 
groups such as bpy that reduce the reactivity of the complexes. Clearly, the labile 
equatorial groups play a critical role in the toxicity of dirhodium(II,II) complexes in 
vitro.  
A large cytotoxicity/photocytotoxicity ratio is an important property in 
compounds for PDT applications. From the data in Chapter IV, it is plausible to suggest 
that in order to decrease the cytotoxicity of the dirhodium-dppz complexes in the dark, 
the acetato bridging ligands should be replaced by less labile groups. The results of 
Chapter V demonstrate that the carbonato-bridged complexes of the [Rh2(µ-
O2CO)2(diimine)2(H2O)2 ]2+ type are useful precursors to access new dirhodium-diimine 
compounds. These compounds react with trifluoroacetamide, 2-pyrrolidinone, and 
trifluoroacetic acid to form products in which the carbonato ligands have been displaced 
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from the dirhodium core. Chapter V lays the synthetic groundwork for a new series of 
dirhodium complexes that contain the interesting dppz ligand and bridging ligands other 
than acetate. 
  
 167
REFERENCES 
 
1. Chabner, B. A.; Roberts, T. G. Nature Rev. Cancer 2005, 5, 65-72. 
 
2.    Futreal, P. A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; 
Rahman, N.; Stratton, M. R. Nature Rev. Cancer 2004, 4, 177-183. 
 
3.    Suarez, H. G. Anticancer Res. 1989, 9, 1331-1343. 
 
4.    Povirk, L. F.; Shuker, D. E. Mutation Research-Rev. Gen. Toxicol. 1994, 318, 205-
226. 
 
5. Souhami, R. L. Quarterly J. Med. 1994, 87, 195-197. 
 
6. (a) Hurley, L. H. Nature Rev. Cancer 2002, 2, 188-200. (b) Jordan, M. A.; Wilson, 
L. Nature Rev. Cancer 2004, 4, 253-265. 
 
7. Neidle, S.; Thurston, D. E. Nature Reviews Cancer 2005, 5, 285-296. 
 
8. Thurston, D. E. British J. Cancer 1999, 80, 65-85. 
 
9. Schultz, E. M.; Sprague, J. M. J. Am. Chem. Soc. 1948, 70, 48-52. 
 
10. Suggitt, M.; Bibby, M. C. Clin. Cancer Res. 2005, 11, 971-981. 
 
11. Holbeck, S. L. Eur. J. Cancer 2004, 40, 785-793. 
 
12. Monga, M.; Sausville, E. A. Leukemia 2002, 16, 520-526. 
 
13. Brown, J. M. Oncology Res. 1997, 9, 213-215. 
 
14. Anderson, A. C. Chem. Biol. 2003, 10, 787-797. 
 
15. Suggitt, M.; Bibby, M. C. Clin. Cancer Res. 2005, 11, 971-981. 
 
16. Pizzorno, G.; Davis, S. J.; Hartigan, D. J.; Russello, O. Biochem. Pharmacol. 1994, 
47(11),  1981-1988. 
 
17. Agrawal, K. C.; Booth, B. A.; Michaud, R. L.; Moore, E. C.; Sartorelli, A. C. 
Biochem. Pharmacol. 1974, 23(17), 2421-2429. 
 
18. Rosenberg, B.; Vancamp, L.; Krigas, T. Nature 1965, 205, 698-699. 
 168
 
19. Rosenberg, B.; Vancamp, L.; Trosko, J. E.; Mansour, V. H. Nature 1969, 222, 385-
386. 
 
20. McKeage, M. J.; Higgins, J. D.; Kelland, L. R. British J. Cancer 1991, 64, 788-
792. 
 
21. McKeage, M. J. Exp. Opin. Invest. Drugs 2005, 14, 1033-1046. 
 
22. Ang, W. H.; Khalaila, I.; Allardyce, C. S.; Juillerat-Jeanneret, L.; Dyson, P. J. J. 
Am. Chem. Soc. 2005, 127, 1382-1383. 
 
23. Farrell, N.; Ha, T. T. B.; Souchard, J. P.; Wimmer, F. L.; Cros, S.; Johnson, N. P. J. 
Med. Chem. 1989, 32, 2240-2241. 
 
24. Farrell, N. Cancer Invest. 1993, 11, 578-589. 
 
25. Farrell, N. J. Inorg. Biochem. 2001, 86, 45-51. 
 
26. Farrell, N. Met. Ions Biol. Syst. 2004, 42, 251-296. 
 
27. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Curr. Top. Med. Chem. 2004, 4, 
1525-1535. 
 
28. Clarke, M. J. Coord. Chem. Rev. 2002, 232, 69-93. 
 
29. Kratz, F.; Schutte, M. T. Cancer J. - France 1998, 11, 176-182. 
 
30. Iwamoto, M.; Mukundan, S.; Marzilli, L. G. J. Am. Chem. Soc. 1994, 116, 6238-
6244. 
 
31. Takahara, P. M.; Frederick, C. A.; Lippard, S. J. J. Am. Chem. Soc. 1996, 118, 
12309-12321. 
 
32. Guo, M. L.; Sun, H. Z.; McArdle, H. J.; Gambling, L.; Sadler, P. J. Biochemistry 
2000, 39, 10023-10033. 
 
33. Guo, M. L.; Guo, Z. J.; Sadler, P. J. J. Biol. Inorg. Chem. 2001, 6, 698-707. 
 
34. Caruso, F.; Rossi, M. Met. Ions Biol. Syst. 2004, 42, 353-384. 
 
35. Chifotides, H. T.; Dunbar, K. R. Acc. Chem. Res. 2005, 38, 146-156. 
 
 169
36. Bear, J. L.; Gray, H. B.; Rainen, L.; Chang, I. M.; Howard, R.; Serio, G.; Kimball, 
A. P. Cancer Chem. Rep. Part 1 1975, 59, 611-620. 
 
37. Erck, A.; Rainen, L.; Whileyman, J.; Chang, I. M.; Kimball, A. P.; Bear, J. Proc. 
Soc. Exp. Biol. Med. 1974, 145, 1278-1283. 
 
38. Fimiani, V.; Ainis, T.; Cavallaro, A.; Piraino, P. J. Chemother. 1990, 2, 319-326. 
 
39. Pruchnik, F.; Dus, D. J. Inorg. Biochem. 1996, 61, 55-61. 
 
40. Esposito, B. P.; Zyngier, S. B.; De Souza, A. R.; Najjar, R. Metal-Based Drugs 
1997, 4, 333-338. 
 
41. Esposito, B. P.; Zyngier, S. B.; Najjar, R.; Paes, R. P.; Ueda, S. M. Y.; Barros, J. C. 
Metal-Based Drugs 1999, 6, 17-18. 
 
42. Howard, R. A.; Sherwood, E.; Erck, A.; Kimball, A. P.; Bear, J. L. J. Med. Chem. 
1977, 20, 943-946. 
 
43. Crawford, C. A.; Matonic, J. H.; Streib, W. E.; Huffman, J. C.; Dunbar, K. R.; 
Christou, G. Inorg. Chem. 1993, 32, 3125-3133. 
 
44. Crawford, C. A.; Matonic, J. H.; Huffman, J. C.; Folting, K.; Dunbar, K. R.; 
Christou, G. Inorg. Chem. 1997, 36, 2361-2371. 
 
45. Perlepes, S. P.; Huffman, J. C.; Matonic, J. H.; Dunbar, K. R.; Christou, G. J. Am. 
Chem. Soc. 1991, 113, 2770-2771. 
 
46. Aoki, K.; Salam, M. A. Inorg. Chim. Acta 2002, 339, 427-437. 
 
47. Farrell, N. J. Inorg. Biochem. 1981, 14, 261-265. 
 
48. Crawford, C. A.; Day, E. F.; Saharan, V. P.; Folting, K.; Huffman, J. C.; Dunbar, 
K. R.; Christou, G. Chem. Comm. 1996, 1113-1114. 
 
49. Catalan, K. V.; Mindiola, D. J.; Ward, D. L.; Dunbar, K. R. Inorg. Chem. 1997, 36, 
2458-2460. 
 
50. Catalan, K. V.; Hess, J. S.; Maloney, M. M.; Mindiola, D. J.; Ward, D. L.; Dunbar, 
K. R. Inorg. Chem. 1999, 38, 3904-3913. 
 
51. Chifotides, H. T.; Koshlap, K. M.; Perez, L. M.; Dunbar, K. R. J. Am. Chem. Soc. 
2003, 125, 10703-10713. 
 
 170
52. Chifotides, H. T.; Koshlap, K. M.; Perez, L. M.; Dunbar, K. R. J. Am. Chem. Soc. 
2003, 125, 10714-10724. 
 
53. Chifotides, H. T.; Dunbar, K. R. Chem.-Eur. J. 2006, 12, 6458-6468. 
 
54. Asara, J. M.; Hess, J. S.; Lozada, E.; Dunbar, K. R.; Allison, J. J. Am. Chem. Soc. 
2000, 122, 8-13. 
 
55. Chifotides, H. T.; Koomen, J. M.; Kang, M. J.; Tichy, S. E.; Dunbar, K. R.; 
Russell, D. H. Inorg. Chem. 2004, 43, 6177-6187. 
 
56. Dunham, S. U.; Chifotides, H. T.; Mikulski, S.; Burr, A. E.; Dunbar, K. R. 
Biochemistry 2005, 44, 996-1003. 
 
57. Sorasaenee, K.; Fu, P. K. L.; Angeles-Boza, A. M.; Dunbar, K. R.; Turro, C. Inorg. 
Chem. 2003, 42, 1267-1271. 
 
58. Chifotides, H. T.; Fu, P. K. L.; Dunbar, K. R.; Turro, C. Inorg. Chem. 2004, 43, 
1175-1183. 
 
59. Bradley, P. M.; Bursten, B. E.; Turro, C. Inorg. Chem. 2001, 40, 1376-1379. 
 
60. Fu, P. K. L.; Bradley, P. M.; Turro, C. Inorg. Chem. 2001, 40, 2476-2477. 
 
61. Lutterman, D. L.; Turro, C. Personnal communication. Department of Chemistry, 
Ohio State University, Columbus, Ohio. 
 
62. Broxterman, H. J.; Georgopapadakou, N. Drug Resist. Upd. 2001, 4, 197-209. 
 
63. Goldie, J. H. Cancer Metast. Rev. 2001, 20, 63-68. 
 
64. Heringova, P.; Woods, J.; Mackay, F. S.; Kasparkova, J.; Sadler, P. J.; Brabec, V. 
J. Med. Chem. 2006, 49, 7792-7798. 
 
65. Karukstis, K. K.; Perelman, L. A.; Wong, W. K. Langmuir 2002, 18, 10363-10371. 
 
66. Fuertes, M. A.; Alonso, C.; Perez, J. M. Chem. Rev. 2003, 103, 645-662. 
 
67. Cohen, S. M.; Lippard, S. J. Prog. Nucleic Acid Res. Mol. Biol., Vol 67 2001, 67, 
93-130. 
 
68. Dougherty, T. J. Proc. Am. Assoc. Cancer Res. 1984, 25, 408-410. 
 
69. Dougherty, T. J. Adv. Exp. Med. Biol. 1985, 193, 313-328. 
 
 171
70. Dougherty, T. J. Lasers Surg. Med. 1985, 5, 140. 
 
71. Dougherty, T. J. Lasers Surg. Med. 1988, 8, 177. 
 
72. Young, S. W.; Woodburn, K. W.; Wright, M.; Mody, T. D.; Fan, Q.; Sessler, J. L.; 
Dow, W. C.; Miller, R. A. Photochem. Photobiol. 1996, 63, 892-897. 
 
73. Stilts, C. E.; Nelen, M. I.; Hilmey, D. G.; Davies, S. R.; Gollnick, S. O.; Oseroff, A. 
R.; Gibson, S. L.; Hilf, R.; Detty, M. R. J. Med. Chem. 2000, 43, 2403-2410. 
 
74. Sessler, J. L.; Mallouk, T. E.; Maiya, B. G.; Hemmi, G.; Harriman, A. Abstracts of 
Papers of the American Chemical Society 1989, 197, 248-ORGN. 
 
75. Kessel, D.; Dougherty, T. J. Rev. Cont. Pharm. 1999, 10, 19-24. 
 
76. Ho, Y. K.; Missert, J. R.; Dougherty, T. J. Photochem. Photobiol. 1991, 54, 83-87. 
 
77. Dougherty, T. J. Clin. Chest Med. 1985, 6, 219-236. 
 
78. Dougherty, T. J. Sem. Surg. Onc. 1989, 5, 6-16. 
 
79. Derosa, M. C.; Crutchley, R. J. Coord. Chem. Rev. 2002, 233, 351-371. 
 
80. Friedman, A. E.; Chambron, J. C.; Sauvage, J. P.; Turro, N. J.; Barton, J. K. J. Am. 
Chem. Soc. 1990, 112, 4960-4962. 
 
81. Holmlin, R. E.; Dandliker, P. J.; Barton, J. K. Angew. Chem.-Int. Ed. 1997, 36, 
2715-2730. 
 
82. Mcmillin, D. R.; Liu, F.; Meadows, K. A.; Aldridge, T. K.; Hudson, B. P. Coord. 
Chem. Rev. 1994, 132, 105-112. 
 
83. Olson, E. J. C.; Hu, D.; Hormann, A.; Jonkman, A. M.; Arkin, M. R.; Stemp, E. D. 
A.; Barton, J. K.; Barbara, P. F. J. Am. Chem. Soc. 1997, 119, 11458-11467. 
 
84. Stoeffler, H. D.; Thornton, N. B.; Temkin, S. L.; Schanze, K. S. J. Am. Chem. Soc. 
1995, 117, 7119-7128. 
 
85. Turro, C.; Bossmann, S. H.; Jenkins, Y.; Barton, J. K.; Turro, N. J. J. Am. Chem. 
Soc. 1995, 117, 9026-9032. 
 
86. Copeland, K. D.; Lueras, A. M. K.; Stemp, E. D. A.; Barton, J. K. Biochemistry 
2002, 41, 12785-12797. 
 
87. Peyratout, C. S.; Aldridge, T. K.; Crites, D. K.; Mcmillin, D. R. Inorg. Chem. 1995, 
34, 4484-4489. 
 
88. Turro, N. J.; Barton, J. K. J. Biol. Inorg. Chem. 1998, 3, 201-209. 
 
89. Lewis, F. D.; Wu, T. F.; Zhang, Y. F.; Letsinger, R. L.; Greenfield, S. R.; 
Wasielewski, M. R. Science 1997, 277, 673-676. 
 172
 
90. Delaney, S.; Pascaly, M.; Bhattacharya, P. K.; Han, K.; Barton, J. K. Inorg. Chem. 
2002, 41, 1966-1974. 
 
91. Brauns, E. B.; Murphy, C. J.; Berg, M. A. J. Am. Chem. Soc. 1998, 120, 2449-
2456. 
 
92. Brauns, E. B.; Madaras, M. L.; Coleman, R. S.; Murphy, C. J.; Berg, M. A. Phys. 
Rev. Lett. 2002, 88, 158101-158104. 
 
93. Gearheart, L. A.; Somoza, M. M.; Rivers, W. E.; Murphy, C. J.; Coleman, R. S.; 
Berg, M. A. J. Am. Chem. Soc. 2003, 125, 11812-11813. 
 
94. Kang, J. S.; Lakowicz, J. R.; Piszczek, G. Arch. Pharm. Res. 2002, 25, 143-150. 
 
95. Fu, P. K. L.; Bradley, P. M.; van Loyen, D.; Durr, H.; Bossmann, S. H.; Turro, C. 
Inorg. Chem. 2002, 41, 3808-3810. 
 
96. Thomas, A. M.; Neelakanta, G.; Mahadevan, S.; Nethaji, M.; Chakravarty, A. R. 
Eur. J. Inorg. Chem. 2002, 2720-2726. 
 
97. Dhar, S.; Reddy, P. A. N.; Nethaji, M.; Mahadevan, S.; Saha, M. K.; Chakravarty, 
A. R. Inorg. Chem. 2002, 41, 3469-3476. 
 
98. Collins, J. G.; Aldrich-Wright, J. R.; Greguric, I. D.; Pellegrini, P. A. Inorg. Chem. 
1999, 38, 5502-5509. 
 
99. Arounaguiri, S.; Maiya, B. G. Inorg. Chem. 1996, 35, 4267-4272. 
 
100. Mcfadyen, W. D.; Wakelin, L. P. G.; Roos, I. A. G.; Hillcoat, B. L. Biochem. J. 
1987, 242, 177-183. 
 
101. Onfelt, B.; Lincoln, P.; Norden, B. J. Am. Chem. Soc. 1999, 121, 10846-10847. 
 
102. Breiner, K. M.; Daugherty, M. A.; Oas, T. G.; Thorp, H. H. J. Am. Chem. Soc. 
1995, 117, 11673-11679. 
 
103. Kalsbeck, W. A.; Gingell, D. M.; Malinsky, J. E.; Thorp, H. H. Inorg. Chem. 1994, 
33, 3313-3316. 
 
104. Carter, P. J.; Breiner, K. M.; Thorp, H. H. Biochemistry 1998, 37, 13736-13743. 
 
105. Winkhaus, G.; Ziegler, P. Z. Anorg. Allg. Chem. 1967, 350, 51-57. 
 
106. Dickeson, J. E.; Summers, L. A. Aust. J. Chem. 1970, 23, 1023-1027. 
 
107. Nair, R. B.; Cullum, B. M.; Murphy, C. J. Inorg. Chem. 1997, 36, 962-965. 
 
108. Pyle, A. M.; Rehmann, J. P.; Meshoyrer, R.; Kumar, C. V.; Turro, N. J.; Barton, J. 
K. J. Am. Chem. Soc. 1989, 111, 3051-3058. 
 
 173
109. Peterson, G. L. Anal. Biochem. 1977, 83, 346-356. 
 
110. SAINT, version 6.34; Bruker AXS Inc.: Madison, WI, 2001. 
 
111. SADABS, version 2.03; Bruker AXS Inc.: Madison, WI, 2002. 
 
112. Barbour, L. J. J. Supra. Chem. 2007, 1, 189-191. 
 
113. Sheldrik, G. M. SHELX, Programs for Solving and Refining Crystal Structures; 
University of Göttingen: Göttingen, Germany, 2007. 
 
114. Kornhauser, A.; Wamer, W. G.; Lambert, L. A. In Dermatotoxicology; Marzulli, F. 
N.; Maibach, H. I., Eds.; Taylor and Francis: Washington, DC, 2002; pp 189-230.  
 
115. Chambron, J. C.; Sauvage, J. P.; Amouyal, E.; Koffi, P. Nouveau Journal de 
Chimie-New Journal of Chemistry 1985, 9, 527-529. 
 
116. Liu, J. G.; Zhang, Q. L.; Shi, X. F.; Ji, L. N. Inorg. Chem. 2001, 40, 5045. 
 
117. Calligaris, M.; Campana, L.; Mestroni, G.; Tornatore, M.; Alessio, E. Inorg Chim 
Acta 1987, 127, 103-112. 
 
118. Hunter, C. A.; Sanders, J. K. M. J. Am. Chem. Soc. 1990, 112, 5525-5534. 
 
119. Nair, R. B.; Teng, E. S.; Kirkland, S. L.; Murphy, C. J. Inorg. Chem. 1998, 37, 139-
141. 
 
120. Felthouse, T. R. Prog. Inorg. Chem. 1982, 29, 73-166. 
 
121. Miskowski, V. M.; Dallinger, R. F.; Christoph, G. G.; Morris, D. E.; Spies, G. H.; 
Woodruff, W. H. Inorg. Chem. 1987, 26, 2127-2132. 
 
122. Jones, G.; Vullev, V. I. J. Phys. Chem. A 2001, 105, 6402-6406. 
 
123. Bilakhiya, A. K.; Tyagi, B.; Paul, P.; Natarajan, P. Inorg. Chem. 2002, 41, 3830-
3842. 
 
124. Jockusch, S.; Turro, N. J.; Tomalia, D. A. Macromol. 1995, 28, 7416-7418. 
 
125. Slavnova, T. D.; Chibisov, A. K.; Gorner, H. J. Phys. Chem. A 2002, 106, 10985-
10990. 
 
126. Wang, M. M.; Dilek, I.; Armitage, B. A. Langmuir 2003, 19, 6449-6455. 
 
127. Wang, M. M.; Silva, G. L.; Armitage, B. A. J. Am. Chem. Soc. 2000, 122, 9977-
9986. 
 
128. Kang, M.; Chouai, A.; Chifotides, H. T.; Dunbar, K. R. Angew. Chem.-Int. Ed. 
2006, 45, 6148-6151. 
 
129. Fu, P. K. L.; Bradley, P. M.; Turro, C. Inorg. Chem. 2003, 42, 878-884. 
 174
 
130. Suh, D.; Oh, Y. K.; Chaires, J. B. Proc. Biochem. 2001, 37, 521-525. 
 
131. Paoletti, C.; Lepecq, J. B.; Lehman, I. R. J. Mol. Biol. 1971, 55, 75-84. 
 
132. Tang, T. C.; Huang, H. J. Electroanal. 1999, 11, 1185-1190. 
 
133. Sitlani, A.; Long, E. C.; Pyle, A. M.; Barton, J. K. J. Am. Chem. Soc. 1992, 114, 
2303-2312. 
 
134. Brennaman, M. K.; Alstrum-Acevedo, J. H.; Fleming, C. N.; Jang, P.; Meyer, T. J.; 
Papanikolas, J. M. J. Am. Chem. Soc. 2002, 124, 15094-15098. 
 
135. Dyer, J.; Blau, W. J.; Coates, C. G.; Creely, C. M.; Gavey, J. D.; George, M. W.; 
Grills, D. C.; Hudson, S.; Kelly, J. M.; Matousek, P.; McGarvey, J. J.; McMaster, 
J.; Parker, A. W.; Towrie, M.; Weinstein, J. A. Photochem. Photobiol. Sc. 2003, 2, 
542-554. 
 
136. Pourtois, G.; Beljonne, D.; Moucheron, C.; Schumm, S.; Kirsch-De Mesmaeker, 
A.; Lazzaroni, R.; Bredas, J. L. J. Am. Chem. Soc. 2004, 126, 683-692. 
 
137. Cervantes, G.; Marchal, S.; Prieto, M. J.; Perez, J. M.; Gonzalez, V. M.; Alonso, 
C.; Moreno, V. J. Inorg. Biochem. 1999, 77, 197-203. 
 
138. Featherstone, J.; Dykes, P. J.; Marks, R. Skin Pharm. 1991, 4, 169-174. 
 
139. Sandman, K. E.; Fuhrmann, P.; Lippard, S. J. J. Biol. Inorg. Chem. 1998, 3, 74-80. 
 
140. Gharehbaghi, K.; Szekeres, T.; Yalowitz, J. A.; Fritzer-Szekeres, M.; Pommier, Y. 
G.; Jayaram, H. N. Life Sc. 2000, 68, 1-11. 
 
141. Quiroga, A. G.; Ranninger, C. N. Coord. Chem. Rev. 2004, 248, 119-133. 
 
142. Bear, J. L.; Gray, H. B., Jr.; Rainen, L.; Chang, I. M.; Howard, R. A.; Serio, G.; 
Kimball, A. P.   Cancer Chem. Rep., Part 1  1975,  59(3),  611-20. 
 
143. Howard, R. A.; Spring, T. G.; Bear, J. L. Cancer Res. 1976, 36(12), 4402-4405. 
 
144. Das, K.; Bear, J. L. Inorg. Chem. 1976, 15(9), 2093-2095.  
 
145. Sorasaenee, K.; Galan-Mascaros, J. R.; Dunbar, K. R. Inorg. Chem.  2002, 41(2),  
433-436. 
 
146. Sorasaenee, K.; Galan-Mascaros, J. R.; Dunbar, K. R. Inorg. Chem.  2003, 42(3),  
661-663.  
 
147. Chin T. A.; Templeton D. M.  Toxicol. 1993, 77(1-2),  145-156. 
 
148. Reedijk, J. Chem. Rev. 1999, 99, 2511. 
 
 175
149. Zak F.; Turanek J.; Kroutil A.; Sova P.; Mistr A; Poulova A.; Mikolin P.; Zak Z.; 
Kasna A.; Zaluska D.; Neca J.; Sindlerova L.; Kozubik A. J. Med. Chem. 2004,  
47(3),  761-763. 
 
150. Christoph G. G.; Tolbert, M. ACA 1980, Ser. 2, 7, 39. 
 
151. Hess, J. H. M. Sc. Thesis, Michigan State University, 1998.  
 
152. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; 
Cheeseman, J. R.; Zakrzewski, V. G.; Montgomery, J. A.; Stratmann, R. E.; Burant, 
J. C.; Dapprich, S.; Millam, J. M.; Daniels, A. D.; Kudin, K. N.; Strain, M. C.; 
Farkas, O.; Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, 
C.; Adamo, C.; Clifford, S.; Ochterski, J.; Petersson, G. A.; Ayala, P. Y.; Cui, Q.; 
Morokuma, K.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; 
Cioslowski, J.; Ortiz, J. V.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; 
Komaromi, I.; Gomperts, R.; Martin, R. L.; Fox, D. J.; Keith, T.; Al-Laham, M. A.; 
Peng, C. Y.; Nanayakkara, A.; Gonzalez, C.; Challacombe, M.; Gill, P. M. W.; 
Johnson, B. G.; Chen, W.; Wong, M. W.; Andres, J. L.; Head-Gordon, M.; 
Replogle, E. S.; Pople J. A. Gaussian 98, revision A.7; Gaussian, Inc.: Pittsburgh, 
PA, 1998. 
 
153. Becke, A. D. J. Chem. Phys. 1993, 98, 5648-5652.  
 
154. Lee, C.; Yang, W.; Parr, R. G. Phys. Rev. B 1988, 37, 785. 
 
155. Andrae, D.; Häussermann, U.; Dolg, M.; Stoll, H.; Preuss, H. Theor. Chim. Acta 
1990, 77, 123-141. 
 
156. Cossi, M.; Barone, V.; Cammi, R.; Tomasi, J. Chem. Phys. Lett. 1996, 255, 327-
335. 
 
157. Miertus, S.; Scrocco, E.; Tomasi, J. Chem. Phys. 1981, 55, 117-129. 
 
158. Speit, G.; Hartmann, A. In Methods Molecular Biology; DNA Repairs Protocols; 
Henderson, D. S., Ed.; Humana Press: New York, 1999;Vol. 113, pp 203-212.  
 
159. Pruchnik, F. P.; Jakimowicz, P.; Ciunik, Z.; Stanislawek, K.; Oro, L. A.; Tejel, C.; 
Ciriano, M. A. Inorg. Chem. Comm. 2001, 4(1),  19-22. 
 
160. Pruchnik, F. P.; Jakimowicz, P.; Ciunik, Z. Inorg. Chem. Comm. 2001, 4(12),  726-
729. 
 
161. Pruchnik, Florian P.; Jutarska, Anna; Ciunik, Zbigniew; Pruchnik, Miroslaw. Inorg. 
Chim. Acta 2004, 357(10), 3019-3026. 
 
162. Bear, J. L.; Chau, L. K.; Chavan, M. Y.; Lefoulon, F.; Thummel, R. P.; Kadish, K. 
M. Inorg. Chem.  1986,  25(10), 1516-1518. 
 
163. Norman, J. G. Jr.; Kolari, H. J. J. Am. Chem. Soc. 1978, 100, 791. 
 
 176
164. Cotton, F. A.; Walton, R. A. In Multiple Bonds Between Metal Atoms; Wiley-
Interscience: New York, 1982.  
 
165. Natkaniec, Leszek; Pruchnik, Florian P. J. Chem. Soc., Dalton Trans. 1994, (22), 
3261-3266. 
 
166. Fairbairn, D. W.; Olive, P. L.; O’Neill, K. L. Mutat. Res. 1995, 339, 37. 
 
167. Rojas, E.; Lopez, M. C.; Valverde, M. J. Chromatogr., B: Biomed. Sci. Appl. 1999, 
722, 225. 
 
168. Chiba, K.; Yoshizawa, K.; Makino, I.; Kawakami, K.; Onoue, M. J. Biochem. Mol. 
Tox. 2001, 15, 150-158. 
 
169. Egyeki, M.; Tóth, K.; Waldeck, W.; Schmezer, P.; Langowski, J.; Csík, G. J. 
Photochem. Photobiol.: B Biology 2006, 84, 119-127.  
 
170. Barnes, K. R.; Lippard, S. J. Metal Ions in Biological Systems 2004, 42, 143-177. 
 
171. Wang, D.; Lippard, S. J. Nature Rev. Drug Discovery 2005, 4(4), 307-320. 
 
172. Torchilin, V. P.; Trubetskoy, V. S.; Wolf, G. L. Handbook of Targeted Delivery of 
Imaging Agents 1995, 403-413.  
 
173. Arbab, A. S.; Liu, W.; Frank, J. A. Exp. Rev. Med. Dev. 2006, 3(4), 427-439.  
 
174. Bottrill, Melanie; Kwok, Lilian; Long, Nicholas J. Chem. Soc. Rev. 2006, 35(6), 
557-571. 
 
175. Caravan, Peter. Chem. Soc. Rev. 2006, 35(6), 512-523. 
 
176. Zhang, C. X.; Lippard, S. J. Curr. Opin. Chem. Biol. 2003, 7(4), 481-489. 
 
177. Lippard, S. J. Nature Chem. Biol.2006, 2(10), 504-507. 
 
178. Farver, O. In Textbook of Drug Design and Discovery (3rd Edition); Taylor & 
Francis Ltd.: London, 2002; pp. 364-409.  
 
179. Guo, Z.; Sadler, P. J. Angew. Chem., Int. Ed. 1999, 38(11), 1512-1531. 
 
180. Yam, V. W.-W.; Lo, K. K.-W.; Cheung, K.-K.; Kong, R. Y.-C. J. Chem. Soc., 
Chem. Comm. 1995, 11, 1191-1193. 
 
181. CRC Handbook of Chemistry and Physics, 81st ed.; Lide, D. R., Ed.; CRC Press: 
New York, 2001; Chapter 8, pp 46-47. 
 
182. Reedijk, J. Proc. Natl. Acad. Sci. U.S.A. 2003, 100(7), 3611-3616.  
 
183. McAuliffe, C. A.; Sharma, H. L.; Tinker, N. D. Cancer Chemotherapy Involving 
Platinum and Other Platinum Group Complexes; 1991; Chapter 16, pp 546-593. 
 
 177
184. Monti, E.; Gariboldi, M.; Maiocchi, A.; Marengo, E.; Cassino, C.; Gabano, E.; 
Osella, D. J. Med. Chem. 2005, 48(3), 857-866. 
 
185. Macquet, J. P.; Butour, J. L. J. Natl. Cancer Inst. 1983, 70(5), 899-905. 
 
186. Cleare, M. J.; Hoeschele, J. D. Bioinorg. Chem. 1973, 2(3), 187-210. 
 
187. Farrell, N.; Kiley, D. M.; Schmidt, W.; Hacker, M. P. Inorg. Chem. 1990, 29(3), 
397-403. 
 
188. Chifotides, H. T.; Hess, J. S.; Angeles-Boza, A. M.; Galán-Mascarós, J. R.; 
Sorasaenee, K.; Dunbar, K. R. Dalton Transactions 2003, 4426-4430. 
 
189. Daniels, M. A. M.; Mehmet, N.; Tocher, D. A. J. Chem. Soc. Dalton Trans. 1991, 
2601-2606. 
 
190. Wilson, C.R.; Taube, H. Inorg. Chem. 1975, 14, 405-411.  
 
191. Roos, G. H. P.; McKervey, M. A. Synth. Comm. 1992, 22(12), 1751-1756. 
 
192. Bear, J. L.; Lifsey, R. S.; Chau, L. K.; Ahsan, M. Q.; Korp, J. D.; Chavan, M.; 
Kadish, K. M. J. Chem. Soc., Dalton Trans. 1989, 93-100. 
 
193. Pasternak, H.; Pruchnik, F. P. Inorg. Nucl. Chem. Lett. 1976, 12, 591-598. 
 
194. Turro, C. personal communication. Department of Chemistry, Ohio State 
University, Columbus, Ohio. 
 
 178
VITA 
 
Alfredo Milton Angeles Boza received his Bachelor of Sciences degree in 
chemistry from the Pontificia Universidad Católica del Perú in 2000. He took a position 
as an Inorganic Chemistry Instructor at the Universidad Peruana Cayetano Heredia, 
where he lectured for two semesters. He entered the Ph. D. program at Texas A&M 
University, where he joined the group directed by Prof. Dunbar, in January 2002. His 
research interests include the medicinal uses of compounds, in particular metal 
complexes as well as the photochemistry of molecules.  
Mr. Angeles Boza may be reached at Matute Chalet 40-I, La Victoria (Lima13), 
Lima, Peru. His e-mail address is alfredo.angeles@gmail.com. 
 
 
 
 
 
 
 
